Characterization of the Degradation of Shape Memory Polymers by Weems, Andrew Christopher
CHARACTERIZATION OF THE DEGRADATION OF SHAPE MEMORY 
POLYMERS 
 
 
A Dissertation 
by 
ANDREW CHRISTOPHER WEEMS 
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
Chair of Committee,  Duncan J. Maitland 
Committee Members, Elizabeth Cosgriff-Hernandez 
 Balakrishna Haridas 
 Karen L. Wooley 
Head of Department, Anthony Guiseppi-Elie 
 
May 2017 
 
Major Subject: Biomedical Engineering 
 
Copyright 2017 Andrew Christopher Weems
 ii 
 
ABSTRACT 
Shape memory polymer (SMP) polyurethanes have been proposed for a variety of 
vascular devices due to their biocompatibility, stimuli-responsiveness, and tunable 
properties. While this technology shows promise, a primary limitation for translation of 
these SMPs into the clinic is a lack of understanding of the degradation behavior and 
stability.  
Characterization of the degradation of these SMPs revealed excellent hydrolytic 
stability although the presence of tertiary amines results in a rapid oxidatively-induced mass 
loss over time. The mechanism of degradation was found to be the scission of the tertiary 
amines, producing secondary amines, primary amines, aldehydes and carboxylic acids. This 
understanding of degradation was then used to assess the toxicity risks for SMP implants, 
and it was found that despite degradation these SMPs may possess minimal risks as vascular 
implants. 
One of the goals in medical devices is biostability, or relatively minimal mass loss 
over time. One method of tailoring oxidative mass loss was the use of antioxidants. Bulk 
inclusion of antioxidants resulted in tunability of pore size, mechanical properties, shape 
recovery kinetics, and oxidative resistance. A limitation of this method was the retention of 
antioxidants in the SMP matrix after cleaning the material post-synthesis, as determined 
from gas-chromatography mass spectrometry (GCMS). Synthesis and incorporation of 
polyurethane microparticles was used to improve the retention of antioxidants, determined 
by gravimetric comparisons. Additionally, while the inclusion of antioxidants resulted in 
various property changes, SMP composites containing the particles possessed similar 
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scaffold pore size, shape recovery kinetics, and mechanical properties while displaying 
improved oxidative stability. 
Further increase of the SMPs’ biostability was achieved through chemical 
modification of the polymer structure, with glycerol and isocyanurate groups examined. 
Glycerol was found to improve the oxidative resistance, resulting in SMPs with lifespans 
of ca 5 years when sufficient concentrations of glycerol were used. Isocyanurate-based 
SMPs are predicted to have lifespans extending potentially to nearly 20 years. 
The presented work demonstrates the degradation behavior, toxicity risks, and 
mechanism for SMPs containing tertiary amines. This work is then applied for further 
tuning oxidation by the biostability through chemical and physical means, including new 
covalently added monomers and macromers, as well as composite synthesis. This work 
supports the concept of SMP-based vascular occlusion materials, and it is hoped that these 
studies will aid in the translation of such devices into clinics in the near future. 
 iv 
 
ACKNOWLEDGEMENTS 
I am exceptionally grateful to my committee chair, Dr. Duncan Maitland, for his 
guidance and support throughout my graduate career.  
I would also like to thank my committee members, Dr. Elizabeth Cosgriff-
Hernandez, Dr. Balakrishna Haridas, Dr. Karen L Wooley, and Dr. William Wustenberg 
for their continual support and guidance in my research and professional development.  
I have been fortunate to have collaborated with many researchers across multiple 
disciplines, all of whom have been crucial to the work that is presented here. I would also 
like to expressly thank my Biomedical Device Laboratory peers that have supported me 
throughout the course of my research, specifically Dr. Tony Boyle, Mark Wierzbicki, Jason 
Szafron, Alexandra Easley and Scott Herting have provided invaluable assistance for this 
work. Kevin T Wacker was instrumental in numerous projects, and without his help this 
work would not have been completed. Without the support of my friends and colleagues at 
the Biomedical Device Laboratory and Texas A&M University, completion of this work 
would not have been possible. 
Also, I would like to thank my parents. They funded and enabled my passion and 
curiosity. They taught me the value of hard work, patience, and perseverance.  
v 
CONTRIBUTORS AND FUNDING SOURCES 
Contributors Section 
I would like to acknowledge my committee chair, Dr. Duncan Maitland and 
committee members, Dr. Elizabeth Cosgriff-Hernandez, Dr. Balakrishna Haridas, Dr. 
Karen L Wooley, and Dr. William Wustenberg, and to thank them for their continual 
support and guidance in my research and professional development. 
I would also like to thank Dr. Luz M Calle and Dr. Wenyan Li of Kennedy Space 
Center, NASA, who contributed to the experimental design of Chapter V, and Dr. Lawrence 
Dangott of the Protein Characterization Lab, TAMU, who trained me in using LCMS 
analysis. I am especially grateful to Dr. Jeffery Raymond and his expertise across both 
chemistry and engineering fields. Kevin T Wacker was instrumental in chemical analysis 
and experimental preparation (Chapter II, Chapter VI, Chapter VII), and without his help 
this work would not have been completed. 
Funding Section 
I would like to acknowledge the National Institute of Biomedical Imaging and 
Bioengineering and National Institute of Neurological Disorders and Stroke, both part of 
the National Institute of Health, and the NASA H Jenkins Fellowship for their support of 
the Biomedical Device Laboratory and my research. I would also like to acknowledge 
Shape Memory Medical, Inc. for their support of the laboratory and this work. 
 vi 
 
NOMENCLATURE 
Accel Accelerated 
Amino Amino-3-propanol 
ATR Attenuated total reflectance 
BHT Butylated hydoxytoluene 
Bis Bis(2-hydroxyethyl)propylamine 
Boc Boc protecting group 
13C Carbon 
CaCl2 Calcium chloride 
CoCl2 Cobalt chloride 
CO2 Carbon dioxide 
COOH Carboxylic acid 
CDCl3 deuterated chloroform 
CP Cross polarization 
DEA Diethanolamine 
DCTB trans-2-[3-(4-tert-Butylphenyl)-2-methyl-2- 
 propenylidene]malonoitrile 
DI H2O Deionized water 
DMA Dynamic mechanical analysis 
DMSO Dimethyl sulfoxide 
DSA Digital subtraction angiography 
DSC Differential scanning calorimetry 
 vii 
 
DMF Dimethylformamide 
E’ Storage modulus 
E’’ Loss modulus 
EA Ethanolamine 
EtOH Ethyl alcohol 
ESI Electrospray 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FTIR Fourier Transform Infrared Spectroscopy 
GC Gas chromatography 
GFP Green fluorescent protein 
Gly Glycerol 
Glyco Glycolic acid 
GPC Gel permeation chromatography 
HCl Hhydrochloric acid 
HDI Hexamethylene Diisocyanate 
HDA Hexamethylene diamine 
HPED N,N,N’,N’-Tetrakis(2-hydroxypropyl)ethylenediamine 
H2O2 hydrogen peroxide 
HP High performance 
IC30 30% cell viability reduction 
ID Inner diameter 
 viii 
 
Iso Isocyanurate Triol 
IPA Isopropyl alcohol 
IPDI Isophorone diisocyanate 
KOH Potassium hydroxide 
KTFA Potassium trifluoroacetate 
Lac Lactic acid 
LC Liquid chromatography 
MALDI Matrix assisted laser desorption/ionization 
MDI Methylene diisocyanate 
Methyl 2,2’-methylenebis(6-tert-butyl-methylphenol) 
MS Mass spectrometry 
NaOH Sodium hydroxide 
NCO Isocyanate 
Nile Nile blue chloride 
NMR Nuclear magnetic resonance 
NR Natural red dye 
OD Optical density 
OH Alcohol 
PBS Phosphate buffered saline 
PCL Poly(ε-caprolactone) 
PDMS Poly(dimethylsiloxane) 
PhB Phloxine B 
 ix 
 
Piper 1,2,2,6,6-tetramethyl piperidinol 
RO Water Reverse osmosis water 
r.t. Real time 
SEM Scanning electron microscopy 
SMP Shape memory polymer 
TEA Triethanolamine 
THF Tetrahydrofuran 
Tg Glass transition temperature 
TMHDI Trimethyl hexamethylene diisocyanate 
TOF Time of flight 
TriPhen Triphenyl phosphite 
Vit C L-ascorbic acid (vitamin C) 
XPS X-ray photospectroscopy 
  
 x 
 
TABLE OF CONTENTS 
 Page 
ABSTRACT ....................................................................................................................... ii 
ACKNOWLEDGEMENTS .............................................................................................. iv 
CONTRIBUTORS AND FUNDING SOURCES .............................................................. v 
NOMENCLATURE .......................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................... x 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF TABLES ......................................................................................................... xvii 
CHAPTER I  INTRODUCTION AND LITERATURE REVIEW ................................... 1 
1.1 Polyurethane Medical Devices ......................................................................... 1 
1.2 Shape Memory Polymers in Vascular Applications ........................................ 3 
1.3 Characterizing the Degradation of Shape Memory Polymers .......................... 4 
1.4 Rationale for Increasing the Biostability of Shape Memory Polymers ............ 7 
CHAPTER II  CHARACTERIZATION OF THE DEGRADATION BEHAVIOR 
OF SHAPE MEMORY POLY(AMINO URETHANE UREAS) INTENDED FOR 
VASCULAR OCCLUSION APPLICATIONS ................................................................. 9 
2.1 Introduction ...................................................................................................... 9 
2.2 Materials and Methods ................................................................................... 12 
2.3 Results and Discussion ................................................................................... 19 
2.4 Conclusions .................................................................................................... 37 
CHAPTER III  CYTOCOMPATIBILITY OF DEGRADATION PRODUCTS 
PRODUCED BY AMINO-ALCOHOL BASED ALIPHATIC, THERMOSET 
SHAPE MEMORY POLYURETHANES INTENDED FOR VASCULAR 
TISSUE ENGINEERING ................................................................................................ 38 
3.1 Introduction .................................................................................................... 38 
3.2 Methods and Materials ................................................................................... 42 
3.3 Results and Discussion ................................................................................... 50 
3.4 Conclusions .................................................................................................... 61 
CHAPTER IV  OXIDATION-RESISTANT SHAPE MEMORY 
POLYURETHANES CONTAINING ANTIOXIDANTS ............................................... 63 
 xi 
 
4.1 Introduction .................................................................................................... 63 
4.2 Methods and Materials ................................................................................... 67 
4.3 Results ............................................................................................................ 72 
4.4 Discussion ...................................................................................................... 81 
4.5 Conclusions .................................................................................................... 84 
CHAPTER V  POLYURETHANE MICROPARTICLE COMPOSITE SHAPE 
MEMORY POLYMER POROUS SCAFFOLDS CONTAINING 
ANTIOXIDANTS FRO ENHANCED OXIDATIVE BIOSTABILITY ......................... 85 
5.1 Introduction .................................................................................................... 85 
5.2 Experimental .................................................................................................. 88 
5.3 Results and Discussion ................................................................................... 92 
5.4 Conclusions .................................................................................................. 104 
CHAPTER VI  HIGHLY POROUS THERMOSET SHAPE MEMORY 
POLYURETHANE TISSUE SCAFFOLD FROM THE RENEWABLE 
RESOURCE GLYCEROL, AND ITS OXIDATIVE DEGRADATION 
PATHWAY .................................................................................................................... 107 
6.1 Introduction .................................................................................................. 107 
6.2 Conclusions .................................................................................................. 112 
CHAPTER VII  ISOCYANURATE TRIOL AS A MORE OXIDATIVELY 
STABLE STARTING MATERIAL FOR SHAPE MEMORY POLYMERS 
BASED UPON ALIPHATIC, SYMMETRIC DIISOCYANATES AND AMINO 
ALCOHOLS ................................................................................................................... 118 
7.1 Introduction .................................................................................................. 118 
7.2 Methods and Materials ................................................................................. 120 
7.3 Results and Discussion ................................................................................. 126 
7.4 Conclusions .................................................................................................. 138 
CHAPTER VIII CONCLUSIONS ................................................................................. 140 
8.1 Summary ...................................................................................................... 140 
REFERENCES ............................................................................................................... 143 
 
 
 xii 
 
LIST OF FIGURES 
 Page 
Figure 2.1. Starting materials used for the synthesis of SMPs and a representative 
porous scaffold (top), along with representative SEM images for the 
original pores, after 250 days in accelerated base solution, and 45 days in 
real time oxidative solution. 3-D pore structures demonstrating the 
material collapse are displayed (bottom). ......................................................... 21 
Figure 2.2. Gravimetric results for SMPs displaying the effect of varied hydrogen 
peroxide concentration (left) on mass loss rate and the effect of porosity 
(right). H2O2 concentration dependency is demonstrated for HDI based 
porous SMPs (TEA: HPED 40: 60), and the porosity dependency 
displays results for the three diisocyanates used with alcohol ratios of 
TEA:HPED 40:60. All experiments were conducted at 37°C. ......................... 24 
Figure 2.3. Abundances of major degradation products for the model study, 
determined from LCMS, displaying abundance of degradation products 
for HPED-hexyl (left) and TEA-hexyl (right). All experiments were 
conducted at 37°C. ............................................................................................ 25 
Figure 2.4.   Proposed degradation pathway for TEA in an oxidative environment.  
The observed species are the TEA-hexyl starting material (1), which 
oxidizes to the N-oxide (amine oxide, 2). Fragmentation combined with 
oxidation and reduction will lead to the formation of the secondary 
amine (3), and an aldehyde (4), which further oxidizes to a carboxylic 
acid (5). The secondary amine fragments to form the primary amine (6), 
which will also lead to carboxylic acid (5); the byproduct of the primary 
amine fragmentation is ammonia. ..................................................................... 26 
Figure 2.5.    Proposed degradation pathway for HPED in an oxidative 
environment. The starting compound (7) can oxidize to the N-oxide (8). 
Fragmentation will lead to a secondary amine (9), or an N-oxide and a 
primary amine (10) which will further degrade to a single N-oxide (13). 
The formation of (9) also yields an aldehyde (11), which further oxidizes 
to a common final degradation product, (12). The degradation of (13) 
with competing asymmetric C-N fragmentation pathways is governed by 
sterics and electronics e.g. product (17) versus (18) from (13). 
Degradation to form (18) will yield a small molecule glyoxylic acid (15) 
that oxidizes to oxalic acid (16). Analagous competitive cleavage is also 
possible with other degradation intermediates such as (9). The byproduct 
of the primary amine (19) degradation is ammonia. ......................................... 28 
 xiii 
 
Figure 2.6.  Spectroscopic analysis of implanted, porous, HDI SMPs (HDI with an 
alcohol composition of 60% HPED and 40% TEA). (A) displays FTIR 
comparison (between 2200 and 800 cm-1) for an untreated sample (day 
0), a sample degraded in 3% H2O2 for 90 days (90 day in vitro), and a 
sample explanted from the porcine sidewall aneurysm after 90 days (90 
day implant). (B) displays the C1s peak XPS comparison of the same 
samples, as well as a 1 day implant (Day 1 implant), a 30 day implant 
(Day 30 implant), a sample degraded in 0.1 M NaOH for 90 days (Day 
90 NaOH). SEM images of day 0 (C), day 30 (D), and day 90 (E) are 
presented as well. Using SEM, it is apparent that the membranes are 
degraded over the course of the implantation, with residual membranes 
shown in (D) compared with (C) (complete membranes are present) and 
(E) (no membranes remain). Further, the struts are more pitted and 
marked in (E) (90 day implant), compared with day 0 and day 30 
implant surfaces. ............................................................................................... 30 
Figure 2.7. (A)The relationship between mass loss over this same time and the gel 
fraction is overlayed on the theoretical accumulation degradation 
products based upon relative size, and the rate of change of product 
accumulation (B). The cytocompatibility of films incubated in 
degradation solutions is presented, displaying no changes between the 
original and materials degraded for 12 weeks (C). Selected molecular 
species are displayed, demonstrating the relative sizes of the degradation 
products. ............................................................................................................ 33 
Figure 3.1. Proposed general pathways of oxidation of shape memory polymers 
containing amino alcohols triethanolamine (TEA) and hydroxypropyl 
ethylenediamine (HPED), where R denotes a proton or the continuation 
of the chain. ...................................................................................................... 40 
Figure 3.2. Synthetic scheme of HDI diethanolamine 1-amino-2-propanol (HDI 
DEA Amino). .................................................................................................... 46 
Figure 3.3. Basic characterization of porous SMPs. SEM images before (A) and 
after (B) 90 days of real time oxidation (3% H2O2 at 37°C), shape 
recovery testing of the original materials at two relevant in vivo 
temperatures (37°C and 50°C) (C), and FTIR spectra of the before and 
after oxidized materials. .................................................................................... 51 
Figure 3.4. Mass loss profiles based upon the concentration of H2O2 (left), and 
fitted linear approximations of degradation displaying the maximum rate 
of change and the fitted rate of change for both mass loss and gel 
fraction measurements of SMPs degraded in 3% H2O2 (right). All 
experiments were conducted at 37°C. .............................................................. 53 
 xiv 
 
Figure 3.5. Cell viability curves for HPED degradation products (top left), TEA 
degradation products (top right), and bulk SMP foam (bottom) after 
complete degradation. All experiments were conducted at 37°C. .................... 56 
Figure 3.6. Brightfield microscopy images of cells exposed to HDI DEA Gly with 
concentrations at 0.15 mg/mL (top), 0.1 mg/mL (middle), and 0.05 
mg/mL (bottom), displaying an increasing compatibility trend that 
increases from top to bottom. ........................................................................... 57 
Figure 4.1. Antioxidant structures used to produce oxidatively stable porous 
SMPs. (A) butylated hydroxytoluene, (B) 1,2,2,6,6 tetramethyl 
piperidinol, (C) 2,2’-methylenebis(6-tert-butyl-methylphenol), (D) 
didodecyl 3,3 thiodipropionate, (E) triphenyl phosphite. ................................. 68 
Figure 4.2.  Spectroscopic analysis of the antioxidant reactions with isocyanates 
using model compounds BHT, Methyl and Piper, and FTIR-ATR of the 
antioxidant-containing SMPs. ........................................................................... 74 
Figure 4.3. Shape memory behavior of porous SMPs (HH40) containing 10% 
antioxidants (left) and mechanical behavior for HH40 SMPs containing 
10% antioxidants. ............................................................................................. 76 
Figure 4.4. 10% antioxidant in HH40 (left) and 5% antioxidant in HH40 (right) 
degraded in 20% H2O2 with 0.1M CoCl2, at 37°C. .......................................... 78 
Figure 4.5. Control SEM and 12 Piper at day 0 (A,D), day 3 (B,E), and  day 7 
(C,F). ................................................................................................................. 78 
Figure 4.6.  GCMS chromatographs for extracted antioxidants from SMPs. .................. 79 
Figure 4.7. Predicted real time oxidative mass loss of antioxidant (Piper) 
containing HDI-based SMPs. (equivalent of 2% H2O2 at 37°C) ...................... 80 
Figure 5.1. Synthesis of polyurethane particles, as first thermoplastic chains that 
are the core of the crosslinked shell. The particles are then cleaned, the 
thermoplastic core extracted, and then loaded with antioxidants. The 
particles are then combined with the displayed monomers to synthesize 
shape memory polymer foam (SMP). ............................................................... 93 
Figure 5.2. Size distribution of IPDI TEA particles synthesized at varied 
temperatures. ..................................................................................................... 95 
Figure 5.3. Particles synthesized from IPDI and TEA at 20°C. ....................................... 96 
 xv 
 
Figure 5.4. A comparison of the areas of the original microspheres (PU with core) 
and those that have undergone extraction reveals a relative crystallinity 
of 3.3% for the starting material, which can be attributed to the 
thermoplastic polyurea core. ............................................................................. 97 
Figure 5.5. SMP foam with TEA-hollow microparticles (A), BHT loaded with 
BHT-hollow microparticles (B). The agglomeration of microparticles 
can be seen to occur along the edges of pore membranes (C, D). 
Aggregate diameters (E) and pore sizes (F) determined using 
microscopy. ..................................................................................................... 100 
Figure 5.6. Shape recovery characterization over 15 minutes in 37°C RO H2O 
displaying the various compositions and their shape recovery behavior. ...... 101 
Figure 5.7. Degradation of composite SMPs compared to control and selected 
small molecule antioxidant containing SMPs over the course of 20 days 
in accelerated conditions (left, 20% H2O2 with 0.1 M CoCl2 at 37°C), 
and the predicted real time degradation behavior of the SMP composites 
(right, equivalent of 2% H2O2 at 37°C). ......................................................... 104 
Figure 5.8. Comparison of the predicted mass loss profiles for antioxidant-
containing SMPs, with Piper incorporated as both a small molecule 
antioxidant as well as in the microparticles. The predictions are for 2% 
H2O2, or the equivalent of real time for the HH60 composition being 
examined. ........................................................................................................ 106 
Figure 6.1. Accelerated mass loss (left, 20% H2O2 with 0.1 M CoCl2) examined 
over 35 days, and real time mass loss (right, 2% H2O2) examined over 
the course of real time oxidation out to eight months. All experiments 
were conducted at 37°C. ................................................................................. 108 
Figure 6.2. Representative stress-strain curve for 20 Gly SMPs at each examined 
degradation time point in 2% H2O2 at 37°C. .................................................. 111 
Figure 6.3. Proposed oxidative degradation pathway of the 2G molecule, 
examined at 37°C in 50% H2O2 using LCMS. ............................................... 114 
Figure 6.4. Proposed oxidative pathway for the 3G molecular segments. ..................... 115 
Figure 6.5. Relative rate of product formation from 2G model compounds (top). 
3G relative abundances of products are displayed (right). Model 
compounds were degraded in 50% H2O2 at 37°C. ......................................... 115 
 xvi 
 
Figure 6.6. Comparison of the predicted real time (2% H2O2, 37°C) mass loss 
profiles for TMHDI-based SMPs, comparing control samples, 5% BHT 
(antioxidant) SMPs, and various concentrations of glycerol. ......................... 117 
Figure 7.1. Thermomechanical properties of Iso films, displaying tan δ vs temp 
(left) and E’ (storage moduli) vs temp (right). ............................................... 127 
Figure 7.2. Stress-strain behavior of non-porous SMPs, comparing the role of 
diisocyanate, amino alcohol monomers, and isocyanurate triol on 
mechanical properties under ambient conditions. .......................................... 128 
Figure 7.3. Fluorescent 3T3 fibroblasts seeded on films at 7 days incubation. ............. 129 
Figure 7.4. SEM images of 10% (left), 20% (middle) and 30% (right) Iso SMPs. ....... 130 
Figure 7.5. Shape recovery behavior of porous SMPs. .................................................. 132 
Figure 7.6. (Left) Water uptake studies is gravimetric analysis and (right) plots of 
elastic modulus and strain to failure for 30 Iso SMPs allowed to 
equilibrate with the room over the course of 2.5 hrs (n=2 at each time 
point for tensile testing). ................................................................................. 133 
Figure 7.7. Oxidative degradation of non-porous SMP containing isocyanurate 
(left) and of porous SMPs (HDI TEA Iso) containing (right). Samples 
were degraded in 20% H2O2 catalyzed by 0.1 M CoCl2 at 37°C. .................. 134 
Figure 7.8. Proposed main hydrolysis steps for isocyanurate-urethane linkages as 
determined using model compound studies and MS, determined from 
model compounds in 2M NaOH at 37°C. ....................................................... 134 
Figure 7.9. Proposed main oxidative step for isocyanurate-urethane linkages as 
determined using model compound studies and MS over 5 weeks in 50% 
H2O2 at 37°C. .................................................................................................. 135 
Figure 7.10. Mass loss profiles of SMPs in real time oxidative solution (2% H2O2), 
predicted from real time data and accelerated testing (20% H2O2 in 0.1 
M CoCl2). ........................................................................................................ 139 
 
xvii 
LIST OF TABLES 
Page 
Table 2.1. The calculated degradation times relative to the in vivo samples. .................. 31 
Table 3.1. Cytotoxicity threshold established for degradation products and 
degraded bulk material. .................................................................................... 54 
Table 3.2. Factors of Safety use in analysis of toxicity risks for SMP degradation. ....... 58 
Table 3.3. Cytocompatibility thresholds and approximated rates of production for 
select degradation products. A theoretical calculation is denoted by *. ........... 60 
Table 4.1. Thermal characterizations of antioxidant SMPs. ............................................ 75 
Table 4.2. Mechanical properties of antioxidant-SMPs. .................................................. 77 
Table 4.3. Mass and concentration of antioxidants added during synthesis and 
extracted during cleaning, determined using GC/MS. ...................................... 79 
Table 5.1. Morphological properties of IPDI microparticles synthesized from three 
alcohol monomers. ............................................................................................ 94 
Table 5.2. Morphological properties of IPDI-TEA microparticles. ................................. 94 
Table 5.3. Morphological properties of IPDI-TEA microparticles synthesized 
using varied concentrations of acetone and water. ........................................... 95 
Table 5.4. XPS determined elemental composition of selected particles and 
composite SMPs. .............................................................................................. 98 
Table 5.5. Mechanical properties of microparticle composite SMPs............................. 101 
Table 5.6. Released concentrations of antioxidants determined from GCMS. .............. 103 
Table 7.1. Tg determined by DMA and maximum complex modulus value. ................. 127 
Table 7.2. Mechanical properties of SMP films at ambient conditions, 
incorporating isocyanurates and varied diisocyanate and amino alcohol 
monomer units. ............................................................................................... 129 
Table 7.3. Physical and thermal properties of porous Iso SMPs (HDI TEA Iso). ......... 131 
Table 7.4. Mechanical properties of control and HDI TEA Iso 30 porous SMPs at 
      ambient conditions and submerged in 37⁰C water. ...................................... 131 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
1.1 Polyurethane Medical Devices 
Polyurethane-based medical devices have been a gold-standard of care for decades, 
and have been utilized in a range of products including pacemaker leads, aneurysm 
occlusion devices, and implant coatings.1-5 In many commercial applications, linear 
polyurethanes are used due to the ease of processing, mechanical properties and excellent 
biocompatibility.1,5-9 These are commonly consisting of a hard segment with urethane 
linkages and well-packing structures, connected by a chain extending soft segment, 
typically esters, ethers, or siloxanes.1,5-8 The degradation of the carbamate and urea 
linkages occurs via hydrolysis, but this occurs over the course of years in vivo.1,5-8 For this 
reason, polyurethanes seemed ideal for long-term implant applications.  
Two well-known failures have been the cause of substantial research into toxicity 
risks and degradation susceptibility of these materials: pacemaker lead wire failure (non-
porous polyurethanes) and the degradation of polyurethane foam coatings.9-22 In non-
porous polyurethanes, failures that have occurred include surface cracking, erosion, and 
chain scission.1,5,13-15 The mechanisms of degradation in these cases are varied, with the 
polyester soft segments undergoing hydrolysis; proximity to the hard segment was found 
to impact this rate.1,5 Polyether segments were found to be susceptible to oxidative 
degradation mediated by neutrophils and monocyte-derived macrophages and catalyzed by 
the presence of metal ions; both erosion and surface cracking have been attributed to these 
 2 
 
factors.1,5 The presence of stress cracking has also been attributed to the residual stresses 
caused in part by phase separation of the segmented polyurethanes.13-15  
In the case of porous polyurethanes, similar failure mechanisms were reported but 
analysis and toxicological concerns were handled differently.5-8,12,16-22 For polyurethanes 
intended to be biostable, aromatic diisocyanates were typically used during synthesis; 
hydrolytic by-products of methylene diisocyanates (MDI) and toluene diisocyanates, two 
traditionally used aromatic diisocyanates, are carcinogenic in animal models and thus 
would be unsuitable in biodegradable applications.1,23-25 For the intended applications, 
biostability was the goal, but in vivo studies found that degradation was occurring, in some 
cases rapidly (months to years for porous polyurethanes).18-21 Early analytical studies of 
this degradation reported high risks of toxic byproducts, but reviews of these studies have 
since indicated that many of the techniques utilized were not appropriated models of in 
vivo degradation.18 While the authors reported that they had found these carcinogenic 
hydrolysis products, little focus was made to understand how the degradation that was 
found in vivo could be related to the in vitro data to gain an understanding the degradation 
process and toxicological risk.18 In fact, the carcinogenic diamines that were found during 
testing were more likely present in the body as part of polyurethane chains with acid or 
hydroxyl end groups as a result of polyester hydrolysis, rather than are carcinogenic 
diamines.18 The polyurethane chains were being cleared through the kidneys as urine, and 
only through post-treatment did the products become a carcinogenic risk.18 As a result of 
the initial toxicity concerns, and in spite of the flaws in the research, the use of 
polyurethane foam coatings was dramatically decreased in the United States afterward, and 
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it is only recently that such materials are again considered relevant in biomedical 
applications.15-17,19-20 
1.2 Shape Memory Polymers in Vascular Applications 
While there were long-term toxicity concerns of polyurethane porous materials, short 
term performance was generally positive.26-34 Immune response seemed to be mediated with 
the presence of the porous coating around implanted devices compared with the uncoated, 
non-porous surfaces.34-35 First proposed by Sokolowski et al, aneurysm occlusion using 
shape memory polymer (SMPs) polyurethane foams offered a novel approach for 
treatment.30,32 SMPs can be compressed into a temporary, secondary shape and stored in this 
shape until an external stimulus is applied, which allows for the material to recover its 
original geometry.35-48 In these cases, the mechanism of recovery would be a combination 
of thermal and solvent actuation.28-30,39-42 The use of SMPs allowed for minimally invasive 
devices to be employed for the occlusion of large void spaces, a procedure which had 
previously required the packing of coils into the aneurysm space in the hopes of occluding 
it without rupturing or having a recanalization post-procedure.30,32,49 However, SMPs are not 
just limited to neurovascular aneurysm occlusion devices.28-30,39-42 Other occlusion devices 
could be improved through the incorporation of SMPs, such as venous occlusions.  
Previous studies on the biocompatibility and thrombus formation of these SMPs 
indicates that within an hour of implantation in the aneurysm space, a stable blood clot will 
form.33-34 Compared with bare metal coils which may never fully develop a complete 
thrombus or fully heal, these materials hold substantial promise in terms of performance.33-
34 In regards to biocompatibility, initial studies demonstrated that both the thermoplastic and 
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thermoset versions of SMPs synthesized from aromatic diisocyanates (MDI and 
carbodiimide modified MDI) as well as aliphatic diisocyanates (hexamethylene diisocyanate 
(HDI)) possessed good biocompatibility.26-27 Over the course of 90 days in porcine 
aneurysms, the porous SMPs allowed for transition from fibrin to order collagen connective 
tissue throughout the aneurysm. Inflammatory scoring of the aneurysm was performed by 
counting the presence of macrophages and leukocytes in the aneurysm; SMPs had reduced 
local inflammatory cells compared with the suturing materials, as well as neovascular buds 
present, indicating that these SMPs are promising for long-term in vivo applicaitons.33  
1.3 Characterizing the Degradation of Shape Memory Polymers 
While the SMPs present with good biocompatibility out to 90 days in a porcine 
aneurysm, it is unknown how the long-term degradation behavior of these materials will 
occur. Wilson et al presumed that these SMPs would be biodurable, with degradation 
occurring at the carbamate linkage due to hydrolysis; the use of aliphatic diisocyanates was 
intended to improve the biocompatibility of the hydrolysis products.36 Regardless of theory, 
however, translation of a medical device into the clinic requires extensive testing of 
degradation and toxic risk associated with it, with materials unknown to the Food and Drug 
Administration (FDA) often requiring more extensive testing.50  
Degradation studies of polyurethanes, as mentioned previously, have identified a 
variety of failure mechanisms.1,5 Primarily, these mechanisms can be related to oxidative or 
hydrolytic chain scission, although enzymatic degradation may occur.1,5-8,50 Hydrolytic 
conditions that are appropriate for testing medical devices are phosphate buffered saline 
(PBS, pH=7.4) and 0.1 M sodium hydroxide (NaOH), and oxidative conditions are usually 
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3% H2O2 (real time) and 20% H2O2 catalyzed by 0.1 M CoCl2.1,5-11,50 While accelerated 
testing through elevated temperatures is suggested by some, including the International 
Starndards Organization (ISO) standard 10993-13, it appears that there are discrepancies 
between in vivo and in vitro results.1,5-11,50 It has been suggested that while the Arrhenius 
equation may be used to predict acceleration, the role of the glass transition temperature (Tg) 
is not taken into account in this way.9 Due to this, testing performed with more aggressive 
(but still reasonable) environmental conditions at body temperature may provide more 
accurate modeling of long-term behavior.9  
While the degradation rates are more readily available using in vitro testing, the 
mechanism by which degradation occurs is less easily attainable in some cases. Predictions 
of the degradation pathway are usually accomplished using surface characterization (FTIR), 
along with scanning electron microscopy (SEM), thermal characterizations such as 
differential scanning calorimetry (DSC) or dynamic mechanical analysis (DMA), and 
examinations of the polymer chains using mechanical testing, gel permeation 
chromatography (GPC) or light scattering to examine chain length, and possible nuclear 
magnetic resonance (NMR) to examine changes in the chemical groups present. 1,5-11,50 
However, in thermoset materials, analysis is hindered by the lack of solubility and the 
crosslinked nature of the polymer. Many conventional techniques recommended by ISO are 
not appropriate to perform on the bulk material, or will not produce the complete 
understanding of the degradation pathway. In this case, it is necessary to more closely 
examine the components individually, using model compounds, to determine their 
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susceptibility to the degradation environment if preliminary bulk testing reveals concerning 
behavior.50 
While determining the mechanism of degradation is necessary, the other component 
of long-term risk assessment for medical devices is determining the toxicity of the 
degradation products.23-25,51-56 Toxicological studies may be referenced for many starting 
materials, depending on their industrial uses, but degradation products may be more difficult 
to assess with accuracy.55-60 In the case of SMPs, the fully degraded started material can be 
used to determine the risks of the bulk material through cell exposed to varying dilutions of 
the products. While this does not give detail on the individual products, it does allow for 
understanding overall toxicity levels that are tolerable, and for examining any synergistic 
effects of the products. Synthesis of select products may be used to gain further 
understanding of toxicity risks and be used for predicting limitations on the use of the 
biomaterial (maximum device size, etc). 
The long-term degradation behavior and toxicity risks of the SMP foams has not yet 
been fully understood. Therefore, this research is aimed at investigating the degradation of 
polyurethane SMPs intended for vascular applications. The degradation mechanisms, rates, 
and toxicity risks will be studied to provide an understanding of the long-term utility and 
safety of these materials in endovascular devices, although the presented process is 
applicable for many implantable polymer systems. 
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1.4 Rationale for Increasing the Biostability of Shape Memory Polymers 
 Even with the cytotoxicity testing, degradation mechanism understanding, and the 
toxicological risk assessment that will accompany FDA submissions, reducing the rate of 
degradation (and thus the rate of degradation product formation) may be a useful tactic to 
assuage concerns of toxic risk associated with a device. A device that is considered biostable 
will be subjected to different regulatory considerations than one that is degradable.50 
 The desire to decrease the rate of oxidation in the SMPs was counterpoint to 
maintaining the biocompatibility and functionality of the current SMP formulations. Tuning 
the composition while maintaining the polyurethane linkages, high crosslinks, aliphatic 
monomers, and tertiary amines still offers avenues for increasing the biodurability. Previous 
work into reducing oxidation has indicated that the presence of antioxidants in the polymer 
bulk will reduce the mass loss rate.7,73 EM Christenson incorporated Santowhite® into 
poly(ether urethane) and poly(carbonate urethane) films, which were shown to inhibit in vivo 
degradation in subcutaneous implants over a year.7  Many other medical implants also utilize 
antioxidants to reduce oxidation of materials, with butylated hydroxy toluene (BHT) and its 
derivatives being common choices.74-93 BHT and similar derivatives, as well as a hindered 
amine light stabilizer, vitamin C, and triphenyl phosphite were examined for their utility in 
reducing the oxidative mass loss of porous SMPs. 
 A limitation of this approach was the retention of antioxidants in the SMP throughout 
both the cleaning process as well as the time that the material is implanted. Unlike films, 
porous SMPs possess very high surface area, which increased the diffusion of physically 
incorporated antioxidants out of the bulk; covalently bound antioxidants may have altered 
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performance or may impact the properties of the polymer. The use of microparticles was 
investigated as an alternative to direct incorporation of the antioxidants.  
While the incorporation of antioxidants may allow reduction in the rate of oxidation 
and mass loss due to tertiary amine fragmentation, a more stable chemistry could be useful 
for long-term stability. Glycerol, as well as isocyanurate triol, were examined as alternative 
starting materials to the amino alcohols, as these monomers may be less susceptible to 
oxidative fragmentation compared with the tertiary amines. 
The characterization of degradation and assessment of toxicity risk of SMP is 
discussed in Chapter 2 and 3, respectively. Chapter 4 discusses the use of antioxidants for 
increasing biostability, and Chapter 5 expands upon this through the use of antioxidant-
containing microparticles. Chapter 6 discusses the use of glycerol for producing more 
biostable SMPs, and Chapter 7 examines isocyanurate triols.  
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CHAPTER II  
CHARACTERIZATION OF THE DEGRADATION BEHAVIOR OF SHAPE 
MEMORY POLY(AMINO URETHANE UREAS) INTENDED FOR VASCULAR 
OCCLUSION APPLICATIONS 
2.1 Introduction 
Polyurethanes have been in use for over fifty years as medical materials.1-5,12,11-13 
During this time, several widespread failures of these materials have been reported in both 
literature and the clinic, with two of the most notable being polyurethane coatings for 
pacemaker wire leads, and porous polyurethane coatings. 1-5,12,11-13,17-20,114 A recent 2016 
study found that for pacemaker/defibrillator lead damage within the first year of device 
implantation has resulted in ca $1.1 billion costs, with damage to the leads occurring 0.47% 
to 1.94% of implanted devices, depending on specific application.14 In a smaller case study, 
27 pacemaker leads were returned to the manufacturer and analyzed, with 8 of the devices 
having undergone material failure that lead to 4 high voltage failures and one death, with an 
average implantation time of ca of 25.5 months. 15 Based upon the study being performed 
and the device selected for analysis, these failure rates may range from 0.19 %/year to 2.71 
%/year or higher.14-15 Failures for commercially available medical devices result in patient 
morbidity and mortality, and a major cause of these failures is the lack of analysis performed 
prior to implantation of the devices, which ultimately results in decreased understanding of 
the in vivo behavior.1-5,12-15,113 Correlations between the in vivo and in vitro responses for the 
selected materials must be performed to not only characterize the rates of degradation, but 
also to determine the possible mechanisms, products, and associated patient risks.  
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Some of the analysis performed on the porous polyurethane systems has led to 
contradictory results; lab methodology used for testing was not supported by in vivo data.17-
20,114 The urethane coatings were reported to undergo hydrolysis in the body, resulting in the 
presence of aromatic amines formed during hydrolysis of the carbamate, but the amine 
formation was a result of testing conditions that did not align with what the material would 
have experienced in vivo, ultimately resulting in data that does not accurately predict 
stability, and therefore toxicity risks, overtime.5-8,18-22,38 Additional long term studies of these 
polyurethane foams have further indicated a reduced rate of tumorogenesis, no association 
with cancer and the use of the aromatic diisocyanates, and no long term risk of cancer in 
studies ranging from animal to human studies, although a few studies still point to possible 
risks within the first few years after implantation.17-21,114 These conflicting outcomes present 
the need for better analyses of degradation and toxicity. 1,37 
For many polyurethane systems, oxidation is also known to occur in addition to 
hydrolysis, but is typically limited to the chain extenders in the soft segment, such as ether 
linkages.1,4,5-8] Despite these degradation concerns, tissue engineered scaffolds, drug 
delivery therapeutics, and devices continue to utilize poly(urethane urea) chemistries due to 
the versatility of the compositions and the ease with which traditional polymerization yields 
the final products.1-3,113 However, there are still a lack of studies that provide adequate 
correlations between in vivo and in vitro behaviors as well as degradation mechanisms and 
toxicity assessments. 
In fact, polyurethanes have gained even greater interest as medical materials due to 
inherent shape memory properties.26-27,36-37,71,115 Ideal vascular materials will incorporate 
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stimuli-responsive polymers (for minimally invasive procedures) with a controlled 
biostability that do not suffer from the limitations of thermoplastic systems.36 An example 
of a series of stimuli-responsive polyurethanes intended for minimally-invasive medical 
devices was initially developed by Wilson et al., with the intent to overcome toxicity 
limitations while also improving on the shape-responsiveness of the polymers.36 The 
developed shape memory polymers (SMPs) are amorphous, highly crosslinked, and have 
ultra-low density.26-27,36-37,71 These SMPs were derived from monomers that are symmetric, 
multi-functional, and aliphatic, based upon the use of polyaddition reactions between 
diisocyanates and amino tri- or tetra-ols.36  This approach was used to produce highly 
crosslinked networks that possess high-strain-low-stress shape recovery, Tgs tunable around 
body temperature, and excellent biocompatibility, confirmed using both in vitro cellular 
studies as well as histological analysis of implants.26-27,36-37,71 However, given that the 
alcohols used in the synthesis of these SMPs are also polyamines, it was important to 
consider their ultimate fate, and to conduct material degradation studies. Similar amino 
alcohol species have also found use in carbon dioxide remediation, where fragmentation is 
common, although environmental conditions are varied; other applications of polyamines 
include gene and drug delivery.115-123  
Here we present the comparison of in vivo and in vitro degraded SMP samples. We 
utilize commonly available laboratory techniques to demonstrate methodology for 
determining rates of degradation based upon morphology, composition, and thermal 
properties in thermosets. The mechanism of degradation and the rate of specific degradation 
product formation are also determined through the use of model compound studies and 
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analytical techniques. The relationship between the benchtop studies and the in vivo 
materials were further characterized using spectroscopic and morphological techniques, 
allowing for the determination of conditions to accurately model the degradation of the 
materials. The determination of the concentration of hydrogen peroxide (H2O2), the main 
oxidative source for degradation, as well as the degradation products, was used to determine 
the toxicological risk associated with treating the largest plausible aneurysm. 
2.2 Materials and Methods 
N,N,N’,N’-Tetrakis(2-hydroxypropyl)ethylenediamine (HPED, 99%, Sigma 
Aldrich), triethanolamine (TEA, 98%, Sigma Aldrich), hexamethylene diisocyanate (HDI, 
TCI America, >98%), 2,2,4-trimethyl hexamethylene diisocyanate (TMHDI, TCI America, 
a mixture of 2,2,4 and 2,4,4 monomers, > 97%), isophorone diisocyanate (IPDI, Sigma 
Aldrich, 98%) were the monomers used in the synthesis of bulk SMPs. Hexyl isocyanate 
(TCI America, >98%) was used without purification. H2O2 (50%), sodium hydroxide (NaOH 
pellets, Sigma, >97%), phosphate buffered saline (PBS, Sigma, pH=7.4), cobalt chloride 
(CoCl2, anhydrous, Alfa Aesar, 98%) were used for degradation solutions, in reverse 
osmosis (RO) water. Ethanol (EtOH, 195 proof, Sigma), isopropyl alcohol (99%, IPA, 
Sigma Aldrich), acetone (99%, Sigma) were used for cleaning. Phloxine B (PhB, 99%, 
Sigma) was used for confocal microscopy. 
Bis(2-hydroxypropyl)amine (>98%), 3-amino-1-propanol (>99%), ethanolamine 
(>99%), diethanolamine (>99%), oxalic acid (>99%), glycolic acid (99%), glyoxal (40% in 
H2O), and allyl alcohol (>99%) were purchased from Sigma Aldrich, and were used without 
further modification. Di-tert-butyl dicarbonate (99%), molecular iodine (99.99%, trace 
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metals basis), sodium thiosulfate (99%), and hydrogen chloride solution (4 M in dioxane) 
were obtained from Sigma Aldrich, as well. 
Acetonitrile (99.93%, HPLC grade, Sigma), methanol (50% in H20 with 0.1% v/v 
formic acid, LCMS grade, Sigma), methanol (99.9%, LCMS grade, Sigma), and water 
solution (0.5 % v/v formic acid, HPLC grade, Sigma) were used with liquid chromatography. 
Pancreatin, collagenase, and trypsin were purchased from Sigma, and used without 
modification.  
Porous SMP foams were synthesized using a two-step method, composed of an 
isocyanate premix and an alcohol premix. The isocyanate premix was made by dissolving 
stoichiometric amounts of alcohols in diisocyanates, and curing the premix. The 
stoichiometry is the isocyanate index (NCO index, ratio of [NCO]:[OH]); the NCO index of 
the premix is 2.5-3.0, adjusted to achieve a variety of pore sizes and densities. The premix 
was heated in a 36-hour cycle to 50 °C (room temperature for 6 hours, 20 °C/hr to 50 °C, 
isothermal for 18 hrs) before returning to room temperature. The alcohol premix was made 
prior to the foaming process, and contained the remaining alcohol moieties (HPED and 
TEA), surfactants (Siloxanes, industrially named DC 5943 and DC 198), catalysts (tin (II) 
2-ethylhexanoate and triethylamine), and blowing agents (Enovate) to achieve a final NCO 
index of 1.05. The two components are mixed in a high speed speedmixer before being 
placed in a 90°C oven for 20 minutes, followed by an overnight cold cure in the fume hood. 
Figure 1 shows the final product in bulk, and SEM images of pores. 
Non-porous SMP films were synthesized using the same polyaddition, with 
stoichiometric amounts of diisocyanates added to an alcohol mixture of HPED and TEA. 
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Alcohol ratios were varied, as were diisocyanate species. The NCO index was ca 1.05 for 
films. The polymer mixture was heated to 120 °C at 30 °C/hr, isothermal at 120 °C for 2 hrs, 
and then allowed to cool to room temperature.  
Samples were cleaned using water and IPA rinses at 35 °C (2x water for 15 minutes 
under sonication, followed by 2x IPA for 15 minutes under sonication, with tumbling steps 
in between sonication, followed by 4x water for 15 minutes with sonication and 30 second 
tumbling in between) and dried at 50 °C under vacuum overnight. 
Samples were characterized using differential scanning calorimetry (DSC) and 
dynamic mechanical analysis (DMA). For DSC (Q-200 DSC, TA Instruments, Inc., New 
Castle, DE), ca 5 mg samples were examined from -40°C to 120°C at a rate of 10°C/min, 
with the glass transition temperature (Tg) determined from the third heating cycle. For DMA, 
a Q800 TA DMA (TA Instruments, New Castle, DE) was used for a single temperature 
sweep from 0°C to 100°C at 2°C/min was used, with the peak tan δ value being taken as the 
Tg. 
SMP foam cell structure and film surfaces were examined using scanning electron 
microscopy (SEM). Foams and films for SEM imaging were sputter-coated prior to imaging 
at 10 kV with 11x and 110x magnifications.  
Degradation solutions were made on a 1 L scale. Phosphate buffered saline(PBS, 
pH=7.4) was made by adding RO water to packets of PBS solution, mixed well, and stored 
at 4 °C. 0.1 M NaOH solutions were made by adding 12 g of NaOH to 3 L of RO water, 
mixed well, and stored at 4 °C. 3% H2O2 solution was made by diluting 180 mL of 50% 
H2O2 with 2820 mL of RO water, mixed well, and stored at 4 °C. 20% H2O2 with CoCl2 was 
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made by first weighing 7.77 g of CoCl2 into a beaker, which was dissolved in 400 mL of RO 
water. 400 mL of 50% H2O2 was diluted with 200 mL of RO water, which was then poured 
into the CoCl2 solution. The H2O2 solution was kept cold prior to dilution and addition. It 
sat for 10 min to warm to room temperature prior to use. The 20% H2O2 (accelerated) 
solution and 3% H2O2 (real time) were used for oxidative solutions. PBS was the real time 
hydrolytic and NaOH solution was the accelerated hydrolytic condition. 
Sample cubes were then cut (2 cm x 2 cm x 2 cm) from the dried blocks using a hot 
wire cutter. Sections were taken from the center of the blocks to ensure that minimal changes 
to the foam pores had occurred due to cleaning. Masses were then recorded for each cube, 
and each cube was placed in a labeled, sealed vial. 
SMP cubes were submerged in 30 mL of solution in a sealed vial. The vials were 
placed in a 37 °C oven (± 0.1 °C, measured with a thermocouple over 3 days). Samples were 
incubated for 3 days before replenishing the solution, checked daily to monitor solution 
levels, and were weighed every week for real time testing, and every 3 days for accelerated 
testing. Samples were then removed, rinsed thoroughly in ethanol, blotted with a Kim Wipe 
and placed on a second Kim Wipe in a 50 °C oven. Vacuum was pulled overnight, at 30 mm 
Hg. After removal from the oven, samples were weighed and returned to the vials, with 
freshly replenished solution. Sample analysis is detailed below. Films were tested using the 
same protocol, but were cut into DMA bars with thicknesses of ~3 mm. 
The mass was converted to remaining mass percentage, and the average change and 
standard deviation was recorded and plotted. 
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Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
spectroscopy was used to determine any spectroscopic changes to the bulk material, although 
no significant changes were expected. ATR-FTIR spectra were taken using a Bruker ALPHA 
infrared spectrometer (Bruker, Billerica, MA) using 32 scans per spectra for both 
background and samples. Spectra data was collected in absorption mode with a resolution 
of 4 cm-1. OPUS software was used to examine spectra, identify peaks, and perform baseline 
and atmospheric corrections. Examinations were performed in triplicate to confirm results.  
Solution state nuclear magnetic resonance (13C 125 MHz and 1H 500 MHz) was 
performed on an INOVA 500 spectrometer and spectra were referenced to solvent, CDCl3 
or DMSO-d6 . Solid state CP (cross-polarization) MAS NMR (13C 100 MHz) was performed 
using a 4.0 mm 13C probe on an Avance-400 Solids spectrometer (Bruker). A frequency of 
123.63 MHz was used, with a spin speed of 5 kHz and 90° pulse lengths of 4.5 µs. A recycle 
delay of 5 s and a contact time of 1.6 ms were the used measurement parameters. Edited CP 
MAS NMR experiments were performed as well, to observe positively-phased signals for C 
and CH carbons, negatively-phased CH2, and zero-intensity signals for CH carbons to assist 
in peak assignments, with an external TMS standard. 
X-ray photoelectron spectroscopy (XPS) was performed on dry samples using an 
Omicron XPS/UPS system with Argus detector. A magnesium x-ray source, a 124 mm 
electrostatic hemisphere dispersive energy analyzer and a 128 channel micro-channel plate 
Argus detector with 0.8 eV resolution. A CN10 charge neutralizer was used to reduce surface 
charging. Experimental parameters were a X-ray emission current of 5 mA and an anode 
voltage of 15 kV, and 10 µA with a beam energy of 5 eV for the CN10 neutralizer; a 
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rectangular aperture (0.311 mm x 3.22 mm was used. Survey scans from 1100 eV to -10 eV 
were performed with a step of 1 eV and a dwell time of 0.05 s.  High resolution scans for 
C1S (305-282 eV), N1S (408-396 eV) and O1 (516-503 eV) peaks were selected, with steps 
of 0.05 eV, a CAE of 20 and dwell time of 0.1 s. 
 Stoichiometric amounts of TEA and HPED were added to respective, and sealed, 20 
mL round bottom flasks equipped with stir bars. The flasks were charged with a slight excess 
of hexyl isocyanate, and nitrogen was purged into the flask. The reactions were allowed to 
continue overnight at 50°C. TEA-hexyl produced a waxy solid, and HPED-hexyl produced 
a viscous liquid. Both products were purified using silica column chromatography. 
 Standards were synthesized to confirm degradation products and species. Bis(2-
hydroxypropyl) amine, 3-amino-1-propanol, ethanolamine, diethanolamine, oxalic acid, 
glycolic acid, glyoxal, and allyl alcohol were found to be representative end groups of the 
main degradation products. Di-tert-butyl dicarbonate was added in stoichiometric amounts 
to each solution of amines (10 mmol) in a 10 mL round bottom flask with a stir bar, along 
with 1 mmol molecular iodine, as a catalyst, and was allowed to react over night at 50 °C. 
Stoichiometric amounts of hexyl isocyanate were then added to the solution and allowed to 
react for 24 hours, under nitrogen at 50 °C. Characterization confirmed the presence of 
carbamates, and deprotection was performed using 4 M HCl in dioxane for 3 hours. LCMS 
standards were washed with sodium thiosulfate (aq.) to remove iodine, and then the organic 
phase was collected and dried at 50 °C under vacuum (30 in Hg). Samples were diluted to 
0.1 mg/mL, and then diluted by 50x 6 additional times to produce 6 calibration standards. 
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Samples were dissolved in 50% methanol with 0.5% formic acid, the same solvent used for 
LCMS characterization. 
Samples were incubated at 37 °C with 50% hydrogen peroxide (uncatalyzed). 
Aliquots were separated, filtered through activated carbon, and characterized; the remainder 
of the sample was left in solution. Degradation rates and products were characterized using 
NMR (1H, 13C), LC-MS, and FTIR characterization. 
LCMS was performed using a ThermoFisher Orbitrap with a Hewlett Packard LC 
attachment, and a C18 normal phase silica gel column. The chromatography profile was 23 
minutes long, altering from 95% methanol to 90% acetonitrile over 18 minutes with a linear 
gradient, with the remaining time at 95% acetonitrile to remove contaminants.123 A blank of 
50% methanol with 0.5% formic acid was used to clean the column. 
Green fluorescent protein (GFP)-expressing fibroblasts (NIH3T3/GFP, Cell Biolabs 
Inc., USA) were expanded then seeded onto control (unmodified) and degraded films at a 
density of 20,000 cells/film in normal growth media, which contained high glucose 
Dulbecco’s Modified Eagle Medium (DMEM, GE Biosciences, USA) with 10% fetal bovine 
serum (FBS) (Atlanta Biologicals, USA), and 1% penicillin/streptomycin (100 U/µg/mL, 
Invitrogen, USA). For foam studies, foams were soaked overnight in cell-binding media, 
which contained normal growth media with 1% dissolved gelatin, prior to cell seeding. After 
initial cell seeding, films and foams were transferred to new well-plates to ensure cell growth 
was limited to the polymeric biomaterial.  
To investigate cell proliferation, an Alamar Blue assay (Thermo Fisher, USA) was 
utilized per the manufacturer’s instructions to calculate percent reduction of reszurin (blue) 
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to resorufin (pink). Proliferation within foam samples was normalized to accessible surface 
area via considerations of foam volume and percent porosity. At the respective time points 
(Day 0, Day 1, Day 3, and Day 7), cell morphology was evaluated using fluorescence 
microscopy with an excitation of 488 nm (Nikon Ti-U Inverted Microscope, USA); for Day 
0 time point, cells were allowed to adhere for three hours prior to imaging. Representative 
images were selected over the course of imaging three replicates for each film or foam. 
2.3 Results and Discussion  
 Porosity of the SMPs can be controlled through a combination of NCO index, 
premix viscosity, catalyst concentrations, and concentration of physical blowing agents that 
are used. By removing the catalysts and blowing agents, non-porous films were produced; 
decreasing premix visocisty and NCO indexed results in larger pore sizes and reduced 
densities of the SMPs.  
The reactions of the alcohols with the diisocyanates produces the urethane linkage 
that dominates throughout the bulk material, although other linkages will be present in small 
concentrations. Urea will from as a result of water reacting with an isocyanate to produce a 
primary amine, which then may react to form a urea linkage; the primary amine may also be 
a chain end. It is known that allophanate and biuret linkages may form (tri-branching 
urethane and urea, respectively) due to catalyst presence. Substitution of the diisocyanates 
or alcohols does not affect gel fraction of the materials (all greater than 99%), or the physical 
attributes of the material. The end result is a highly crosslinked, amorphous polymer with 
controllable pore size, density, and composition. 
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 By increasing TEA concentration, the Tg of the material decreases, and increasing 
HPED results in increased Tg. The increasing HPED also results in greater crosslink density, 
higher elastic modulus, and greater hydrophobicity. As the diisocyanate is substituted from 
HDI to THMDI to IPDI, modulus, thermal transition, and hydrophobicity will increase as 
well.  
 For porous SMPs incubated in accelerated hydrolytic solution, no changes in the 
pore structure were found (no strut erosion, membrane rupture, pore collapse) after 36 
weeks. This result contrasted with the behavior in real time oxidation: pore collapse and 
membrane rupture/erosion were found to occur within 4-6 weeks (Figure 2.1). For non-
porous materials, surface erosion appeared as pitting and the formation of surface rippling, 
culminating in total material collapse. This behavior was found, qualitatively, to be 
dependent on both pore size and Tg.  
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Figure 2.1. Starting materials used for the synthesis of SMPs and a representative 
porous scaffold (top), along with representative SEM images for the original pores, 
after 250 days in accelerated base solution, and 45 days in real time oxidative 
solution. 3-D pore structures demonstrating the material collapse are displayed 
(bottom). 
 
 
 
SEM of non-porous SMP displayed no significant changes for hydrolytically 
degraded films. For oxidative films, the hydrophobicity (and thermal transition) had distinct 
differences on the degradation and the topology of the film after incubation. For higher 
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thermal transitions/more hydrophobic samples, films displayed more significant surface 
cracking and surface rippling over time. Cracking did not occur across the entire surface, 
and while presenting rapidly (within a few days of incubation) did not dominate the surface 
over the testing period. Surface rippling occurred across the majority of the surfaces, after 
significant time passed, and was more predominantly seen in real time oxidative solutions. 
Conversely, the more hydrophilic/lower Tg films displayed significantly greater surface 
pitting and bubbling. This occurred for both accelerated and real time oxidative testing. 
The surface area for the porous scaffolds was determined microscopically, and 
comparisons between the rates of degradation between the porous and non-porous materials 
was performed. The larger pores (lower surface area) result in a slower mass loss rate 
compared with smaller pores. The non-porous films have lower Tgs, but slower degradation 
rates. This behavior may be due to the presence of membranes in the porous materials, which 
allows for the formation of concentration gradients prior to the membrane perforation and 
removal as well as providing increased surface area. Simultaneously, the hydroxyl radicals 
are also degrading the struts, which eventually results in the complete material collapse as 
well as surface pitting and cracking. 
A lack of mass loss over the examined period of 250 days in accelerated hydrolytic 
solution was observed, in agreement with SEM results. Accelerated oxidative testing (20% 
H2O2, 0.1 M CoCl2) resulted in rapid oxidation and total mass loss within days for materials 
with Tgs ranging from 20 °C to 130 °C; degradation rate was Tg dependent, as well as 
concentration and surface-area dependent (Figure 2.2). SMPs in accelerated oxidative 
solution underwent complete mass loss in less than 30 days, with HDI degrading in 9 days, 
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TMHDI in 20 days, and 50% IPDI/50% TMHDI in ca 28 days. These results are supported 
by gravimetric analysis in 3% H2O2 solution. Porous SMPs incubated in this solution 
displayed similar trends based on Tg and diisocyanate species. The time to 50% mass loss of 
the porous SMPs in 3% H2O2 is ca 100 days for HDI, and 150 days for TMHDI using 
extrapolation. 
Gravimetric analysis of the non-porous SMPs revealed rapid mass loss over the 
course of the study when incubated in oxidative solutions. With the TMHDI non-porous 
SMPs, the rate of degradation was distinctly dependent on the Tg, as the HPED: TEA 0:100 
(TEA as the alcohol monomer) films degraded significantly faster compared to the 
HPED:TEA 100:0 (HPED as the alcohol monomer). This dependence on Tg is demonstrated 
by the substitution of the diisocyanate species in films containing only HPED as the alcohol 
monomer. In these gravimetric studies using 3% H2O2, HDI films degraded more rapidly, 
and IPDI films were found to be extremely oxidatively resistant. These behaviors agree with 
examinations of the porous SMPs, such as with the delay in the onset of mass loss found in 
real time oxidative testing. 
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Figure 2.2. Gravimetric results for SMPs displaying the effect of varied hydrogen 
peroxide concentration (left) on mass loss rate and the effect of porosity (right). H2O2 
concentration dependency is demonstrated for HDI based porous SMPs (TEA: HPED 
40: 60), and the porosity dependency displays results for the three diisocyanates used 
with alcohol ratios of TEA:HPED 40:60. All experiments were conducted at 37°C. 
 
 
 
Figure 2.3 indicates the major amine degradation products observed by LCMS. Both 
alcohols will oxidize to form the respective amine oxides (N-oxides) or aminium radical 
cations (Figure 2.4 and 2.5).29,30,36,38 The tetra-ol (HPED, starting material 7) will have steps 
analogous to the triol TEA to form N-oxide(s) or radical cation(s) (product 8), prior to any 
fragmentation occurring. One of the N-oxides fragments by C-N cleavage to form an 
aldehyde (eventually a carboxylic acid) and a secondary amine, which may further fragment 
to form a primary amine endgroup (product 10).  Further fragmentation at this amine (C-N), 
could produce either an aldehyde and subsequent acid end group after concomitant release 
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of ammonia (product 13). Alternatively, the N-oxide (product 9) may fragment to form 
another secondary amine (product 14). Internal C-N fragmentation (product 1318 or 
1719) would result in the formation of small molecule aldehydes (glyoxal), glycolic acid, 
and carboxylic acids (oxalic acid) from cleavage of the ethylene chain linking the amine 
groups. These small molecules will form through a glyoxylic acid intermediate (product 15) 
before formation of oxalic acid (product 16). Oxalic acid formation appears more likely than 
dialdehyde (glyoxal) due to consumption of aldehyde in the highly oxidative environment.  
 
 
 
 
Figure 2.3. Abundances of major degradation products for the model study, 
determined from LCMS, displaying abundance of degradation products for HPED-
hexyl (left) and TEA-hexyl (right). All experiments were conducted at 37°C. 
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Figure 2.4.   Proposed degradation pathway for TEA in an oxidative environment.  
The observed species are the TEA-hexyl starting material (1), which oxidizes to the 
N-oxide (amine oxide, 2). Fragmentation combined with oxidation and reduction will 
lead to the formation of the secondary amine (3), and an aldehyde (4), which further 
oxidizes to a carboxylic acid (5). The secondary amine fragments to form the primary 
amine (6), which will also lead to carboxylic acid (5); the byproduct of the primary 
amine fragmentation is ammonia. 
 
 
 
Spectroscopic analysis of in vivo samples indicates that oxidation occurs, but at a 
slower rate than what is indicated as real time by previous (in vitro) studies.[1,5,12,13] Surface 
analysis was performed using FTIR, X-ray photoelectron spectroscopy (XPS) and SEM 
(Figure 2.6).[1,5] SEM images reveal that the material underwent collapse similar to what is 
found for in vitro samples: membranes are completely destroyed by 90 days, with some 
fragments still seen at 30 days. Surface pitting is also greater over time. Spectroscopic 
comparison indicates similar changes in peak location and relative height compared with in 
vitro testing, albeit at a slower rate. This is supported by C1s analysis via XPS, confirming 
oxidation of the material surface. Based upon the relationship between the mass loss and the 
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gel fraction and the determined mechanisms, a release rate of degradation products was 
determined. (Figure 2.7).  The size of products was determined by MS and used to further 
characterize the types of products that would accumulate over time, with the smallest, most 
soluble products being the most prominent. The carbamic acid products, which are a result 
of the long term oxidation of the urethanes, were found to have the lowest concentration 
over time, with little change in the generation of carbamic acids over the course of the study. 
Low molecular weight products containing acid and aldehyde end groups were the most 
common products, followed by low molecular products with amine end groups.  
The variation in Tg associated with moisture is due to the plasticization of the 
urethane bonds via interruption of the hydrogen bonding by water molecules. Without a 
solvent, sufficient temperature is required for movement of the polymer backbone, which 
allows for shape change associated with the return the entropic maximum that determines 
the primary shape of the material. In the presence of a solvent that can interrupt the hydrogen 
bonding, such as water or ethanol, the required temperature for the shape to change to occur 
is dramatically reduced, and shape recovery can be achieved at lower temperatures through 
the use of solvent as opposed to a purely thermally-driven recovery mechanism.132-133 
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Figure 2.5.    Proposed degradation pathway for HPED in an oxidative environment. 
The starting compound (7) can oxidize to the N-oxide (8). Fragmentation will lead to 
a secondary amine (9), or an N-oxide and a primary amine (10) which will further 
degrade to a single N-oxide (13). The formation of (9) also yields an aldehyde (11), 
which further oxidizes to a common final degradation product, (12). The degradation 
of (13) with competing asymmetric C-N fragmentation pathways is governed by 
sterics and electronics e.g. product (17) versus (18) from (13). Degradation to form 
(18) will yield a small molecule glyoxylic acid (15) that oxidizes to oxalic acid (16). 
Analagous competitive cleavage is also possible with other degradation intermediates 
such as (9). The byproduct of the primary amine (19) degradation is ammonia. 
 
 
 
Surface area calculations revealed a relationship with pore size: with increasing pore 
size, surface area decreases. Pore size is defined as the average diameter of the pore. As this 
diameter decreases, and porosity of the material increases, surface area increases. For non-
porous materials, however, the surface area is smaller, and this relates to a slower rate of 
degradation. The behaviors of the pores and the degradation were determined via confocal 
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microscopy, allowing for 3D representation of the pore. As mentioned previously, during 
oxidation the pores of the material are eroded away rapidly. This is followed by a reduction 
in strut diameter. The membrane removal occurs over the initial three days (accelerated 
oxidative solution, 20% H2O2 with 0.1 M CoCl2), confirmed by SEM. Towards the end of 
the process, the struts begin to erode and reduce in diameter. 
Gravimetric analysis was related to the morphological changes and the network 
behavior through examination of spectroscopic changes (Fourier transform infrared 
spectroscopic analysis (FTIR), solid state 13C nuclear magnetic resonance (13C NMR). The 
scission of the C-N bond in the tertiary amine was indicated through both the shift in the 
urethane peak (1688 cm-1 to 1702 cm-1) relative to the urea peak (at 1640 cm-1) in FTIR, as 
well as the formation of new peaks in the 13C NMR spectra within the amine region (60 
ppm and 67 ppm converging into a single peak at 65 ppm that shifts to 68 ppm) indicative 
of primary amine formation. Solid state 13C NMR showed no change in the urethane peak 
resonance (155 ppm); and any potential formation of an aldehyde may be obscured by a 
spinning side band. Neither FTIR nor solid state 13C NMR spectroscopic signals indicated 
distinct change during the more mild hydrolytic testing, under both real time and 
accelerated conditions.  
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Figure 2.6.  Spectroscopic analysis of implanted, porous, HDI SMPs (HDI with an 
alcohol composition of 60% HPED and 40% TEA). (A) displays FTIR comparison 
(between 2200 and 800 cm-1) for an untreated sample (day 0), a sample degraded in 
3% H2O2 for 90 days (90 day in vitro), and a sample explanted from the porcine 
sidewall aneurysm after 90 days (90 day implant). (B) displays the C1s peak XPS 
comparison of the same samples, as well as a 1 day implant (Day 1 implant), a 30 day 
implant (Day 30 implant), a sample degraded in 0.1 M NaOH for 90 days (Day 90 
NaOH). SEM images of day 0 (C), day 30 (D), and day 90 (E) are presented as well. 
Using SEM, it is apparent that the membranes are degraded over the course of the 
implantation, with residual membranes shown in (D) compared with (C) (complete 
membranes are present) and (E) (no membranes remain). Further, the struts are 
more pitted and marked in (E) (90 day implant), compared with day 0 and day 30 
implant surfaces. 
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Table 2.1. The calculated degradation times relative to the in vivo samples. 
Species FTIR (days) XPS (days) Strut thickness (days) 
In vivo Day 30 30 30 30 
In vivo  Day 90 90 90 90 
H
2
O
2
 (30 day) 20 ± 1 14 ± 1 16 ± 3 
H
2
O
2
 (90 day) 48 ± 2 42 ± 1 46 ± 4 
 
 
Due to the observations of material breakdown macroscopically and gravimetrically, 
yet the limited solid-state FTIR and 13C NMR evidence for the chemistry occurring during 
degradation of the thermosets, model studies were undertaken.  Although the harsh 
conditions of the oxidatively-degraded samples showed distinct spectroscopic changes to the 
amine (C-N bond), indicating the scission of the tertiary amine, limitations in the detailed 
analysis of the thermoset networks (limited analysis via NMR, mass spectrometry, etc., as a 
result of insolubility), required the examination of degradation products using small 
molecule analogs and LC-MS.29  The small molecule structures include urethane and amino 
linkages to simulate the chemical moieties in the SMP thermosets. 
As demonstrated by the solution NMR spectra, carboxylic acids are formed rapidly 
during the degradation process in 50% H2O2. 1H NMR indicates the formation of carboxylic 
acid with significant presence of aldehyde (relative to the carboxylic acid peak). 13C also 
confirms presence of aldehyde and acid resonances at ca. δ 207 and 173 ppm. LCMS also 
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quantified the degradation products. The NMR spectra support the degradation products as 
presented in Figure 2.4 and 2.5 (aldehyde and carboxylic acid formation). At any time 
during the degradation of the bulk material, sufficiently small network fragments may be 
solubilized and interact directly with or be taken up by cells present at the material interface. 
Other products are indicated by literature and were found, but accounted for less than 0.05% 
(by mass) of the total. It is important to note that in the degradation of small molecule 
urethanes, ethyl carbamate, which is a known mutagen, is a product of concern to the Food 
and Drug Administration (FDA). However, this product, which would require the 
deoxygenation of the carboxylic acid endgroup followed by oxidative fragmentation of the 
hydrocarbon backbone at the beta position to the urethane. This would need to occur 
preferential to the more favored decarboxylation and occur either in sequence or 
simultaneously to the hydrocarbon oxidation, all of which are unlikely as singular events. 
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Figure 2.7. (A)The relationship between mass loss over this same time and the gel 
fraction is overlayed on the theoretical accumulation degradation products based 
upon relative size, and the rate of change of product accumulation (B). The 
cytocompatibility of films incubated in degradation solutions is presented, displaying 
no changes between the original and materials degraded for 12 weeks (C). Selected 
molecular species are displayed, demonstrating the relative sizes of the degradation 
products.  
 
 
 
The rate of mass loss at 50% H2O2 is the equivalent of the 20% H2O2 catalyzed by 
CoCl2 (Figure 3). This indicates that mass loss of the polymer, which occurs by 2 weeks at 
these conditions, happens after the consumption of the tertiary amines and the initial 
formations of the secondary and primary amines, respectively. Additionally, the delay in 
mass loss found over the initial few days and concomitant mass increase is most likely due 
to the formation of amine oxides from the available amines. Only after remaining amines 
A B C 
n=3 
n=2 
n=1 
carbamic 
acid 
small 
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have been oxidized will significant chain scission begin to occur, and subsequent mass loss 
observed. The oxidized SMP will not crystallize at any point in the degradation product, 
further indicating that the majority of the oxidation results in the generation of small 
molecule degradation products (primary amine end groups rather than longer chains 
containing repeating secondary amines). 
Surface analysis indicates that the time implanted at the aneurysm site differs from 
the literature standard 3% H2O2 solution as a real-time approximation. This difference is 
such that 45 ± 3 days in vitro is the equivalent of 90 days in vivo. The urethane peak shift in 
FTIR (1689 to 1694 cm-1) and change in the percentage of C1s determined by XPS indicated 
a surface aged to the equivalent of 48 ± 2 days and 42 ± 1 days, respectively (Table 2.1). 
This suggests that a 1% or 2% H2O2 solution would be a more appropriate solution for 
modeling degradation for these highly porous SMP scaffolds when they are used in 
endovascular applications, with the comparison between the H2O2 concentration-dependent 
rates displayed in Figure 2.2; the lower-than-anticipated degradation rate is most likely due 
to the combination of surface chemistry, high surface area, and the porosity.[5.32,33] As 
compared to the silk and polypropylene present at the aneurysm sites, these SMPs display 
reduced inflammatory response and higher neovascularization, resulting in lower numbers 
of macrophages and neutrophils at the implant site, which in turn results in lower levels of 
peroxides  and superoxides, and will ultimately decrease the oxidation rate at the material 
surface.119-121 
Comparison of the in vivo and in vitro surfaces indicates, again, the loss of 
membranes over the course of degradation. Additionally, the struts of the SMP are thinner, 
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with surface pits forming and residue being clearly visible. The initial SMPs do not contain 
these issues. Cytocompatibility of the degraded SMPs was confirmed via examination of 
cellular proliferation. The change in cytocompatibility between the original SMPs and those 
incubated in degradation solutions was examined using direct contact studies, with no 
differences between surfaces found. Cell morphology and proliferation were found to be 
equivalent across the control, oxidative, and hydrolytically treated surfaces.  
Analysis of the degradation products and interpolation of the concentration vs 
degradation rate allowed for determination of the concentration and species of degradation 
products (Figure 2.6) based upon the now determined rate of material degradation (Figure 
2.2). This analysis allows for the identification of molecular species that are known to be 
toxic, carcinogenic, or have other risks associated with them, as well as to determine the 
formation rate of these products. Through this analysis, it is possible to further understand 
the long-term behavior of these implants and the toxicological risks associated with potential 
exposure to degradation products. While a complete toxicological risk assessment is 
ultimately necessary prior to commercialization, the most immediately concerning products 
of SMP fragmentation are glycolic acid and oxalic acid, which could limit the maximum 
mass of implanted materials if the daily dose rate exceeded the human safe exposure limit 
of 0.54 mg/kg body weight/day, determined from reproductive effects in animal studies; for 
an average 70 kg human this threshold is 37.8 mg/day for oxalic acid, which has a lower 
threshold compared with glycolic acid.130-131 The analysis of SMP degradation indicates that 
the levels of exposure for a SMP foam that has a total mass of ca 400 mg (ca 32.0 to 36.6 
mg total dose of oxalic acid, a daily dose of 0.7 to 0.8 mg/day, which is 1.1µg/kg/day) are 
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well below what would be considered a patient protective safe exposure limit per day. 130-131 
An actual SMP device may be up to 100 mg, but most devices will in fact be less massive 
than this. 
These degradation products may not completely oxidize, as well. The roles of 
primary amines and aldehydes in the adhesion of biomaterials with tissue has been the 
subject of recent study, with aldehydes in particular being of interest; increasing 
concentration of aldehydes increased the adhesion of the biomaterial to the tissue.132-133 In 
the case of the presented SMPs, oxidation of the material produces aldehydes along with 
lower amines. This increased adhesion, in addition to the high porosity of the SMP, may 
explain previous results that demonstrate excellent biocompatibility of the SMP out to 90 
days.33,127-129,132-133 
While these results indicate the promise of such materials for use in vascular 
occlusion applications, further work is needed to definitively conclude that there are minimal 
cytotoxic concerns from degradation products. Based upon the mechanism and relative sizes 
of degradation products presented here, cytotoxicity testing of individual degradation 
product species is needed to determine the concentration thresholds and relationship with 
the rates of exposure. These experiments should also include mutagenicity testing, to 
determine that no adverse events will occur as a result of long term exposure over the life of 
the biomaterial. 
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2.4 Conclusions 
In conclusion, we have demonstrated the degradation analysis of porous and non-
porous SMPs intended for implantable vascular medical devices, and correlated the in vivo 
and in vitro behaviors. The use of amino-alcohols allows for degradation of the SMPs via an 
oxidative mechanism that results in the formation of lower amines and aldehydes, 
determined through model compound studies and analytical characterization. The degraded 
materials still possess excellent cytocompatibility, indicating their utility for long-term 
usage. Characterization of in vivo SMP samples was used to determine the rate of 
degradation and the relationship of the macrophage presence to the oxidation that is 
displayed. The in vitro degradation was used to confirm the mechanism of degradation in 
the bulk SMP, as well as to assess the rate of degradation product formation and examine 
the potential toxic risk these products pose to the host. 
It is our belief that while many applications propose the use of amine-containing 
materials and similar structures, there is insufficient information currently available to 
accurately and appropriately assess the risks associated with using such materials for medical 
applications. The presented work provides results that support the use of these SMPs for 
vascular device, specifically for cerebrovascular aneurysm occlusions, and introduces the 
methodology required for accurate assessment of long-term stability and safety. Wide-
spread use of such methods will allow for more accurate, safer modeling of implantable 
biomaterials and increase the translation of more reliable devices with fewer patient risks. 
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CHAPTER III  
CYTOCOMPATIBILITY OF DEGRADATION PRODUCTS PRODUCED BY AMINO-
ALCOHOL BASED ALIPHATIC, THERMOSET SHAPE MEMORY 
POLYURETHANES INTENDED FOR VASCULAR TISSUE ENGINEERING 
3.1 Introduction 
Shape memory polymers (SMPs) have been proposed for a variety of minimally-
invasive medical devices due to the material’s ability to change its geometry from one shape 
to another upon the application of a stimulus.28,31,49 Medical devices that made from SMPs 
would be responsive to an external thermal or thermal-solvent stimuli, allowing for delivery 
of small device volumes before they recover their expanded, original form to be utilized in 
a variety of applications, such as for void-space filling applications.29,40 An example of this 
is cerebral aneurysm occlusion, originally proposed by Sokolowski et al as a possible 
application for highly porous, polyurethane SMPs.30,32 Material limitations of the SMPs used 
by Sokolowski led to the development of alternative porous, polyurethane-based SMPs with 
varied molecular architecture, such as the highly crosslinked aliphatic SMPs developed by 
Wilson et al.27,36 
Polyurethanes were selected for these and other blood contacting applications due to 
their typically good bio- and cytocompatibility.51-53 However, previous studies have 
indicated possibilities of toxicity and carcinogenicity as a result of urethane hydrolysis and 
by-products of the starting materials.18 While this is typically associated with aromatic 
polyurethanes and diisocyanates, stability and toxicity risks are of concern for all 
biomaterials designed intended for long-term in vivo applications.1,9-11,18 For this reason, 
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studies that characterize the degradation behavior, the degradation products, the rates of 
product formation, and the compatibility of such products are crucial before the translation 
of biomaterials from the lab into the clinic.  
Previous studies have indicated that the symmetric, aliphatic, thermoset polyurethane 
SMPs developed by Wilson et al and utilized by Boyle et al and others, undergo mass loss 
as a result of an oxidatively-induced polymer scission mechanism (Figure 3.1).36,39-40,134 
This degradation is the result of tertiary amine oxidation to a N-oxide, followed by oxidation-
reduction reactions that ultimately form secondary and primary amines, as well as aldehydes, 
carboxylic acids and possibly ammonia.134 Further studies also revealed only minimal 
oxidation of the urethane linkage (carbamate) and the backbone of the diisocyanate starting 
monomers, indicating that the mass loss is primarily occurring due to tertiary amine 
fragmentation.134  
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Figure 3.1. Proposed general pathways of oxidation of shape memory polymers 
containing amino alcohols triethanolamine (TEA) and hydroxypropyl 
ethylenediamine (HPED), where R denotes a proton or the continuation of the chain. 
  
 
 
 
There are a number of concerns about toxic side effects from the degradation 
products produced by these SMPs; polymeric amines as well as acidic by products have been 
linked to cytotoxic effects.55-56 Carboxylic acids may result in increased local pH, which 
ultimately can damage host tissues or the device, and some aldehydes are also known to be 
toxic.55-56 Metabolism of amines and polyamines is known to result in a variety of outcomes, 
with some products being extremely toxic and others simply acting as antioxidants.55 This 
indicates that there are many biocompatibility considerations for in vivo applications of 
materials, not just the initial bulk compatibility but the degradation products and leachable 
components, as well.23-27,54-56,123 
HDI-TEA unit HDI-HPED unit 
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These thermoset SMPs are synthesized from polyaddition reactions of aliphatic 
diisocyanates such as hexamethylene diisocyanate (HDI), trimethyl hexamethylene 
diisocyanate (TMHDI), or isophorone diisocyanate (IPDI), with poly functional amino 
alcohols such as triethanolamine (TEA) and hydroxypropyl ethylenediamine (HPED).36,49,134 
Hexamethylene diamine (HDA), which may occur as a synthesis by-product (hydrolysis of 
residual diisocyanate) or hydrolysis of the urethane bond, has been demonstrated to have 
cytocompatibility, resulting in improved cellular proliferation and adhesion when tested as 
a surface treatment.59 In the body, HDI may be hydrolyzed to the diamine, react with tissue 
prior to hydrolysis to yield a diamine product, form a diacetylated product or a derivative 
containing an amine and an acetyl group.23 The product is then excreted, although this is 
assuming it can enter the body from the material, but as a result of both the synthesis and 
cleaning processes for implantable biomaterials, the concentration of HDI should be 
negligent, although there is a possibility of HDA present.23-25 It is expected that the behavior 
of IPDI and TMHDI is similar to that of HDI.23-25 TEA is known to be cleared from the body 
rapidly, with ca 50-90% cleared in the first hour and the majority of the remainder in the 
following ten hours following intravenous injections.57-58 Degradation products include 
those identified by previous studies, such as diethanolamine, monoethanolamine, and the 
corresponding aldehydes and carboxylic acids.134 HPED is not known to be cytotoxic, but 
the in vivo behavior is expected to be excreted similarly to the TEA, but more slowly, and 
metal-diamine complexes have been proposed for antithrombogenic applications.59 The 
HPED that is not passively excreted through the kidneys may chelate with metals present in 
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the body and/or oxidize to N-oxides followed by excretion or fragmentation during cellular 
metabolism.60  
While a review of literature indicates that the leachable compounds are 
cytocompatible in sufficiently low concentrations, the toxicities of degradation products are 
not known and are difficult to accurately assess accurately. In this study, we characterized 
the size of degradation products from porous HDI-based SMPs, and synthesized selected 
products for cytocompatibility testing. These synthesized products were tested for 
cytocompatibility, and were then compared to the cytocompatibility of SMPs that had been 
exposed to degradation environments, as well as those that had been completely degraded in 
order to confirm our results and examine any synergistic effects of the products. The toxic 
levels were used to determine parameters for dosing of degradation products and maximum 
implantable material mass. These levels and parameters were finally compared to in vivo 
behavior, to access toxicity risks for these SMPs in vascular applications. 
3.2 Methods and Materials 
 N,N,N’,N’-Tetrakis(2-hydroxypropyl)ethylenediamine (HPED, 99%, Sigma 
Aldrich), triethanolamine (TEA, 98%, Sigma Aldrich), hexamethylene diisocyanate (HDI, 
TCI America, >98) were the monomers used in the synthesis of bulk SMPs. Hexyl 
isocyanate (TCI America, >98%) was used without purification. Hydrogen peroxide (50%, 
H2O2), sodium hydroxide (NaOH pellets, Sigma, >97%), phosphate buffered saline (PBS, 
Sigma, pH=7.4), cobalt chloride (CoCl2, anhydrous, Alfa Aesar, 98%) were used for 
degradation solutions, in reverse osmosis (RO) water. Ethanol (EtOH, 195 proof, Sigma), 
isopropyl alcohol (99%, IPA, Sigma Aldrich), acetone (99%, Sigma) were used for cleaning. 
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Catalase (from bovine liver, 2000 to 5000 units/mg, suitable for cell culture) was obtained 
from Sigma Aldrich. 
Bis(2-hydroxypropyl) amine (>98%), 1-amino-2-propanol (>93%), ethanolamine 
(>99%), diethanolamine (>99%), oxalic acid (>99%), glycolic acid (99%), lactic acid (80% 
in H2O) were purchased from Sigma Aldrich, and were used without further modification. 
Glyoxal (40% in H2O) was purchased from Sigma Aldrich and recrystallized prior to use. 
Di-tert-butyl dicarbonate (99%), dimethyl sulfoxide (99%), tetrahydrofuran (99%, THF). 
and hydrogen chloride solution (4 M in dioxane) were obtained from Sigma Aldrich, as well.  
Acetonitrile (99.93%, LCMS grade, Sigma), methanol (50% in H20 with 0.1% v/v 
formic acid, LCMS grade, Sigma), methanol (99.99%, LCMS grade, Sigma), and water 
solution (0.5 % v/v formic acid, LCMS grade, Sigma) were with mass spectrometry (MS).  
MS was performed using a ThermoFisher Orbitrap in positive mode, with injection 
and column temperatures at 50°C. A blank of 50% methanol with 0.5% formic acid was used 
between samples to clean the column. MALDI mass spec with a 4800 Plus MALDI/ 
TOF/TOF Analyzer (Applied Biosystems, MSD Sciex, ThermoFischer Scientific) was used 
to examine bulk SMP degradation. Solution state nuclear magnetic resonance (13C 75.4 MHz 
and 1H 300 MHz) was performed on a Mercury 300 spectrometer and spectra were 
referenced to solvent, CDCl3 or d6-DMSO. Fourier Transform Infrared Spectroscopy (FTIR) 
attenuated total reflectance (ATR) was performed using a Bruker ALPHA FTIR-ATR 
(Bruker, Billerica, MA).  An Omicron XPS system (Mg/Al x-ray source) with an Argus 
detector was used for elemental analysis of the final SMPs prior to degradation. 
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 Typical procedures for the protection of amino alcohols is described for 1-amino-2-
propanol. A slight excess of glacial tert-butyl carbonate (3 g, 0.014 moles) was added 1 g 
amino-2-propanol in 20 mL vials (0.013 moles) with 1 mL of THF. The reaction was allowed 
to take place at room temperature while stirring. After one hour, the vial was heated to 50 
°C for 24 hours and held under vacuum for an additional 12 hours, yielding a viscous clear 
liquid (yield 98%, Boc-Amino).135-136 
1HNMR (d6-DMSO): δ 3.5 (p, 1H, OHCHCH3CH2NH-), 3.5 (d, 2H, 
OHCHCH3CH2NH-), 1.4 (s, 9H, -NHCOOC(CH3)3), 1.1 (d, 3H, OHCHCH3CH2NH-). 
13CNMR (d6-DMSO): δ 156.3, 77.9, 67.4 (THF), 65.9, 48.2, 28.6, 28.6, 21.4 (THF). MS 
theory: 175.1209, MS experimental: 176.1246 (m+H+). The protected forms of ethanolamine 
(Boc-Ea), diethanolamine (Boc-DEA), and bis (2-hydroxypropyl) amine (Boc-Bis) were 
synthesized in the manner described above. 
 HDI (0.85 g, 0.005 moles) in DMSO (2 mL) was added dropwise to the Boc-Amino 
(1.84 g, 0.011 moles) over the course of five minutes at room temperature. The reaction was 
allowed to proceed overnight while stirring in a sealed flask at 50 °C, followed by another 
12 hours at 60 °C. 4M HCl in dioxane (4 mL) was added to the product, and allowed to react 
overnight, and the same volume of 4M NaOH (4 mL) was used to wash the product, followed 
by two washed with DI H2O. The aqueous layer was discarded and the organic layer was 
characterized (yield 76%). 1HNMR (d6-DMSO): δ 4.8 (h, 1H, NH2CH2CHCH3O-), 3.2 (t, 
2H, NH2CH2CHCH3O-), 2.8 (d, 2H, NH2CH2CHCH3O-), 1.6 (q, 2H, -
OCONHCH2CH2CH2), 1.4 (d, 3H, NH2CH2CHCH3O-), 1.3(q, 2H, -OCONHCH2CH2CH2-
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). 13CNMR (d6-DMSO): δ 156.4, 67.8, 46.5, 40.9, 30.1, 27.1, 18.6. Theoretical mass: 
318.2267. Experimental mass: 319.2301 (m+H+). 
Synthesis of HDI-ethanolamine (HDI EA), HDI-lactic acid (HDI Lac), and HDI-
glycolic acid (HDI Gly) were performed in the same manner described above. 
A typical procedure for the synthesis of amino alcohol carbamates containing 
secondary amines is described for HDI diethanolamine 1-amino-2-propanol (HDI DEA 
Amino) (Figure 3.2). HDI (0.89g, 0.005 mol) was added to a reaction flask containing Boc-
DEA (0.75g, 0.004 mol) and DMSO (2 mL), and was allowed to react for 10 minutes at 
room temperature. Boc-amino-2-propanol (0.6g, 0.003 mol) was added dropwise over 5 
minutes to the solution before sealing the vial, purging with nitrogen, and allowing the 
reaction to proceed over the course of 24 hours at room temperature, followed by 8 hrs at 
50°C while stirring. The crude product was deprotected in 4M HCl (4 mL) for 12 hours 
while stirring, followed by 4M NaOH (4 mL) for an additional 4 hours. The product was 
washed twice in DI H2O, and the organic layer collected. Yield (54%). 1HNMR (d6-DMSO): 
4.9 (s, 1H, NH2CH2CHCH3O-), 4.3 (t, 2H, -NHCH2CH2OCONH-), 3.3 (t, 2H, 
NHCH2CH2CH2-), 2.9 (t, 2H, -NHCH2CH2OCONH-) 2.8 (d, 2H, NH2CH2CHCH3O-), 1.6 
(5, 2H, -NHCH2CH2CH2-), 1.5 (d, 3H, NH2CH2CHCH3O-), 1.4 (t, 2H, -NHCH2CH2CH2-). 
13CNMR (d6-DMSO): 157.1, 156.3, 68.3, 63.4, 48.9, 41.2, 30.3, 27.3, 18.8. Characterization 
of the product using MS revealed 74% HDI DEA amino propanol (Theoretical MS: 
591.3956, 864.5664. Experimental MS: 592.4003 (m+H), 296.6995 (M/2+2H)), and 26% 
with two HDI-DEA repeat units (Theoretical MS: 864.5664 (311.1780, M/3 +3Na). 
Experimental MS: 311.1709 (M/3+3Na)).  
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Figure 3.2. Synthetic scheme of HDI diethanolamine 1-amino-2-propanol (HDI DEA 
Amino). 
 
 
 
The products HDI diethanolamine ethanolamine (HDI DEA EA), HDI 
bis(hydroxypropyl)amine ethanolamine (HDI Bis EA), HDI bis(hydroxypropyl)amine 1-
amino-2-propanol (HDI Bis Amino), HDI diethanolamine lactic acid (HDI DEA Lac), HDI 
diethanolamine glycolic acid (HDI DEA Gly), HDI bis(hydroxypropyl)amine lactic acid 
(HDI Bis Lac), HDI bis(hydroxypropyl)amine glycolic acid (HDI Bis Gly) were synthesized 
in the same manner. 
 Porous SMP foams were synthesized using a two-step method, composed of an 
isocyanate premix and an alcohol premix, described in detail elsewhere.20,35 The isocyanate 
premix was made by dissolving stoichiometric amounts of alcohol moieties (TEA, HPED) 
in diisocyanates (HDI). The stoichiometry is described by the isocyanate index (NCO index, 
ratio of [NCO]:[OH]); the NCO index of the premix is 0.35, and the remaining alcohols were 
mixed into the alcohol premix to produce a NCO index for the SMP of 1.05. The premix 
was heated in a 36-hour cycle to 50 °C (room temperature for 6 hours, 20 °C/hr to 50 °C, 
 47 
 
isothermal for 18 hrs) before returning to room temperature. The alcohol premix was made 
prior to the foaming process, and contained the remaining alcohols (HPED and TEA), 
surfactants (Siloxanes industrially named DC 5943 and DC 198), catalysts (tin (II) 2-
ethylhexanoate and triethylamine, industrially named T131 and BL-22, respectively), and 
blowing agents (Enovate, Honeywell Products, Inc).20,35 The two components were mixed 
in a high speed speedmixer before being placed in a 90°C oven for 20 minutes, followed by 
an overnight cold cure in the fume hood. Compositions were with alcohol compositions of 
80% HPED and 20% TEA (HH80) and 20% HPED with 80% TEA (HH20) were degraded 
for testing. The percentages denote the ratio of the alcohol composition. SMPs were cleaned 
using alternating washed of IPA and RO H2O while sonicating (three times each) at 50°C. 
Characterization of the SMP foam was performed using XPS and FTIR, as well as 
confirming shape memory using volume recovery in RO H2O and SEM analysis of pores 
(Figure 3). Theoretical elemental composition: C: 57.52%, O: 27.35%, N: 15.13%.36 
Experimental elemental composition: 57.25%, O: 27.92%, N:14.38%, Sn: 0.45% (Si was 
present as well, due to the surfactants used. Compositions were adjusted to exclude 
surfactant components). 
Degradation product structures were determined in previous studies, where the end 
groups were identified and quantified over time, and related to the in vivo rate of oxidation.134 
This rate was then correlated to the mass loss found in vitro, and further used to determine 
the in vivo concentration of H2O2.50,134 This allowed for extrapolation of the rate of 
degradation product formation in vivo. SMPs were degraded using similar protocols, with 
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3% H2O2 solution, and solutions were analyzed using MALDI MS to determine product size 
distribution over the course of degradation.134 
Synthesized degradation products were dissolved in cell culture media composed of 
Dulbecco’s Modified Eagle Medium (DMEM; VWR, Radnor, PA), 10% newborn calf 
serum (NBCS; Sigma-Aldrich, St. Louis, MO), 1% penicillin/streptomycin (P/S; VWR, 
Radnor, PA), and 0.1% fungizone (VWR, Radnor, PA). Cytotoxicity assays were performed 
using dilutions of products in order to calculate the concentrations at which a 30% reduction 
in cell viability would be observed (IC30 threshold) for each product.  
50% H2O2 was allowed to sit for 10 minutes prior to use, and was then added to 
vials.20 1 g of SMP was placed into a vial with 50 mL of H2O2 solution. The vials were 
incubated at 37°C until the samples were completely degraded (no solid mass was visible). 
The resulting solutions were diluted 50X with DI water and 100 µg/mL catalase was added 
to quench residual H2O2. A final H2O2 concentration less than 1 ppm was confirmed for each 
sample using a ferric thiocyanate kit (CHEMetrics, Midland, VA). A sample of fresh 50% 
H2O2 and a sample of DI water, respectively, were diluted and treated with catalase to serve 
as controls for the cytotoxicity assay.  
Media samples for cell exposure were made using 10X DMEM diluted to 1X with 
each sample solution. These media samples were also supplemented with 10% NBCS, 1% 
P/S, 0.1% fungizone, 3.5 mg/mL glucose, 3.7 mg/mL sodium bicarbonate, 4 µg/mL folic 
acid, and 20 µL/mL L-glutamine solution to afford a final media composition similar to the 
cell media described in the previous section.  
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For each assay, 3T3 Fibroblasts (ATCC, Manassas, Virginia) were seeded in 96-well 
tissue culture plates at a concentration of 5,000 cells/well and incubated in a humidified 
incubator at 37°C with 5% CO2 for 24 hours. Cell morphology was observed in all wells 
using a Nikon Eclipse TE2000-S inverted microscope (Nikon, Melville, NY) and even cell 
distribution was confirmed before treatment. Cell culture media was aspirated and cells were 
incubated with degradation product samples to determine cytocompatibility. Varied 
concentrations of the products were prepared by adding fresh cell culture media of the 
appropriate volume. An untreated control (fresh cell culture media) was included in each 
assay to provide a reference for 100% cell viability. For degraded foam samples, fresh cell 
culture media controls were made from 10X DMEM, using sterile DI water as the diluent 
instead of a degraded foam solution. Cells were incubated with treatments for 48 hours at 
37°C with 5% CO2.  
Following incubation, cell morphology was observed to evaluate changes induced 
by addition of the product solutions. The solutions were removed and a Neutral Red (NR) 
Uptake Assay Kit (Sigma-Aldrich, St. Louis, MO) was utilized to quantify cell viability.  
After incubation with NR for 2.5 hours the cells were quickly fixed with the NR assay 
fixative solution containing 0.1% CaCl2 in 0.5% formaldehyde. The dye was solubilized in 
the NR assay solubilizing solution containing 1% acetic acid in 50% ethanol for 
measurement. The amount of dye in each well was quantified by measuring the optical 
density (OD) at 540 nm using a Tecan Infinite M200 Pro plate reader (Tecan, Morrisville, 
NC). Cell viability is expressed as a percentage using equation 1 (Eq 1). 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑋) =
𝑂𝐷540(𝑋)−𝑂𝐷540(𝐵𝑙𝑎𝑛𝑘)
𝑂𝐷540(𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑡𝑟𝑜𝑙)−𝑂𝐷540(𝐵𝑙𝑎𝑛𝑘)
    Eq. 1 
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X is any treatment group, blank is a well with no cells, and the untreated control is used as 
a standard that equals 100% viability. 
Gravimetric analysis results were used to determine a worst-case scenario for 
degradation product accumulation, as well as models for more accurate predictions of 
product accumulation or release from the bulk. Rates of mass loss were examined to 
determine the most appropriate method for assessing toxic risk using 3% H2O2. 
3.3 Results and Discussion 
SMPs were found to possess high porosity, good shape recovery at in vivo conditions, 
and spectroscopically were found to agree with previous studies (Figure 3.3).27,36-37,49,134 
Material characterizations of these SMPs is reported elsewhere in greater detail, but Tgs 
range from 0 to 80°C, depending on the diisocyanate species used, the ratio of TEA to HPED, 
and method of analysis.27,36-37,49,134 In general, increasing HPED results in higher thermo-
mechanical properties. Shape recovery was not altered by composition, but recovery rate 
and strain fixity is dependent on Tg and the effect of plastization.27  Morphology of the SMPs 
is controlled through both the chemical and physical blowing reactions.27 While the use of a 
low-boiling point solvent or non-reactive molecule is useful for achieving greater porosity 
and lower density, this is also tunable through alteration of catalysts (both amine and metal) 
used during synthesis of the alcohol premix.  
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Figure 3.3. Basic characterization of porous SMPs. SEM images before (A) and after 
(B) 90 days of real time oxidation (3% H2O2 at 37°C), shape recovery testing of the 
original materials at two relevant in vivo temperatures (37°C and 50°C) (C), and 
FTIR spectra of the before and after oxidized materials. 
 
 
 
Using FTIR, the carbonyl peak was found at ca 1689 cm-1, indicating the formation 
of a carbamate with strong hydrogen bonding.27 Further, FTIR indicates the formation of 
urea (1635 cm-1) and tertiary amine peak at ca 1030 cm-1. The tertiary amine was found to 
decrease upon oxidation of the material and a slight shoulder was found at 860 cm-1, both of 
which are expected with amine oxidation.134 The degradation of the amino alcohols occurs 
as the tertiary amine oxidizes, initially forming N-oxides, after which it may fragment to 
 52 
 
form secondary amines and aldehydes.134 The aldehydes may further oxidize to form 
carboxylic acids, and the secondary amines may further fragment to primary amines.134 This 
is displayed for idealized sections of the SMP in Figure 1, where general overviews of the 
fragmentations are presented for both TEA and HPED, individually.  
Over the course of real-time degradation testing, samples were taken and analyzed 
using MALDI-MS. Sample analysis indicates that the soluble components of the SMP are 
primarily fragments below 1 kDa, with most fragments occurring between 200 and 700 Da. 
This was found to be consistent over the course of in vitro oxidation, indicating that while 
larger products may be formed, they are at least not soluble in the in vitro test media. For the 
purposes of this analysis, it was assumed that these larger products will only have limited 
exposure upon implantation and were not considered further. 
Mass loss of the SMPs is dependent on the concentration of H2O2, and while many 
literature standards indicate that 3% H2O2 is appropriate for real time testing, previous 
studies indicate that 1% to 2% H2O2 is more appropriate in some applications for these 
SMPs.134 However, 3% H2O2 was selected as the rate of degradation for risk assessment to 
provide a safety factor (safety factor of 6, determined by calculated times to total SMP mass 
loss). To determine the rate used for the analysis, linear fitting was performed, with both the 
average fit across the mass loss profile as well as the greatest rate of change of mass 
determined from both the mass loss studies and gel fraction studies. The average rate of mass 
loss is 1.01 %/day, with an upper limit of 1.25 %/day and lower limit of 0.68% per day, all 
of which assume a constant mass loss and no change in degradation behavior as the material 
collapses and surface area changes.  
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Figure 3.4. Mass loss profiles based upon the concentration of H2O2 (left), and fitted 
linear approximations of degradation displaying the maximum rate of change and the 
fitted rate of change for both mass loss and gel fraction measurements of SMPs 
degraded in 3% H2O2 (right). All experiments were conducted at 37°C. 
 
 
 
The cytotoxicity thresholds (IC30) were determined from cell viabilities using 
dilutions of degradation products (Table 3.1, Figure 3.5), as well as those for the fully 
degraded SMP bulk. Thresholds ranged from 2.04 mg/mL (HDI lactic acid) to 0.031 mg/mL 
(glyoxal). The majority of the products had similar thresholds between 0.1 mg/mL to 0.4 
mg/mL. 
While there may be residual H2O2 in the bulk SMP degraded foam solutions, it 
appears that the addition of the catalase reduces its toxicity to marginal levels for this 
analysis. Additionally, the catalase in fresh cell culture media does not appear to alter cell 
viability at the examined concentrations.  
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For the examined products, IC30 values were established along with morphological 
changes to the fibroblasts after exposure (Figure 3.5, Figure 3.6). With an IC30 threshold 
of 0.115 mg/mL, HDI DEA Gly was exposed to cells at 0.05 mg/mL without changes in 
viability of morphology, relative to the controls. However, at concentrations of 0.15 
mg/mL, viability had decreased to 52.9% and a far greater number of cells are spherical, 
rather than extended. 
 
 
Table 3.1. Cytotoxicity threshold established for degradation products and degraded bulk 
material. 
Product IC30 
(mg/mL) 
HDI Bis Amino 0.276 
HDI Bis EA 0.219 
HDI DEA EA 0.488 
HDI DEA Amino 0.333 
HDI DEA Lac 0.626 
HDI Bis Gly 0.283 
HDI Bis Lac 0.103 
HDI DEA Gly 0.115 
HDI Amino 0.125 
HDI EA 0.355 
HDI Gly 0.292 
HDI Lac 2.04 
Oxalic acid 0.047 
Glyoxal 0.031 
HH20 Foam 0.30 
HH80 Foam 0.20 
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Despite the excellent healing and reduced inflammation of these SMPs when 
examined to 90 days in porcine aneurysms, there are still long-term risks associated with 
implanted materials that slowly degrade.33-34 In the case of SMP foams, examining the worst-
case scenario of 1.25 %/day is used for assessing toxicity risks over the SMP lifespan. A 
limitation of this experimentation is determining the distribution of products that will be 
produced and soluble in vivo. However, if it is assumed that only the smallest products are 
soluble and taken up by cells, or that only the small products are tested for toxicity, it is 
possible to establish theoretical thresholds based upon assumptions that include no deviation 
from the predicted degradation pathway, such as due to metabolism or excretion, and no 
toxicity changes due to interactions of the degradation products between themselves. Based 
upon this, calculations were made that established the product production per day (per kg 
body mass) for comparison to cytotoxic levels. 
The two products with the lowest IC30 thresholds were glyoxal and oxalic acid. 
Glyoxal has been found to be present in patient blood plasma levels up to 0.3 µmol/L (ca 
0.1 mg assuming 70 kg patient), which would constitute nearly 20% of the levels produced 
by 1 g of SMP, in the case of the HH20 composition.138  
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Figure 3.5. Cell viability curves for HPED degradation products (top left), TEA 
degradation products (top right), and bulk SMP foam (bottom) after complete 
degradation. All experiments were conducted at 37°C. 
 
 
 
More concerning are the oxalic acid levels, which could limit the maximum mass of 
implanted materials if the daily dose rate exceeded the human safe exposure limit of 0.54 
mg/kg body weight/day, determined from reproductive effects in animal studies; for an 
average 70 kg human this threshold is 37.8 mg/day for oxalic acid.139-140 The analysis of 
SMP degradation indicates that the levels of exposure for 1 g at 1.25 %/day (ca 63.8 mg total 
as a maximum possible dose) are well below what would be considered a patient protective 
safe exposure limit. 139-140  
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Figure 3.6. Brightfield microscopy images of cells exposed to HDI DEA Gly with 
concentrations at 0.15 mg/mL (top), 0.1 mg/mL (middle), and 0.05 mg/mL (bottom), 
displaying an increasing compatibility trend that increases from top to bottom. 
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For the other products, it appears that the HDI Bis Amino product may be concerning 
if it is released in large enough concentrations, most likely due to its structural similarity to 
polyamines.141 However, it does appear that the HPED will be the limiting starting material 
based upon the examined degradation behaviors, based upon the IC30 thresholds for both the 
starting materials and the degradation products. 
The 1.25 %/day mass loss rate determined from gravimetric analysis was used to 
approximate theoretical accumulation of degradation products, assuming 1 g of SMP foam 
(typical masses for peripheral occlusion applications will be ca 100 mg, while neurovascular 
applications will be ca 20 mg), a perfectly homogenous material, constant mass loss upon 
implantation or exposure, and that only the smallest fragments would be produced during 
degradation. These assumptions provide a total factor of safety of 60 (Table 3.2).  
 
 
 
Table 2.2. Factors of Safety use in analysis of toxicity risks for SMP degradation. 
 Assumed In vivo Factor of Safety 
Device Mass 1.0 g <0.1 g 10 
Rate of Mass Loss 1.25 %/day (80 days) ~0.2 %/day (500 days) 6 
Patient mass 70 kg 70 kg 1 
Total  60 
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This theoretical model was used to determine product accumulation for a 70-kg 
patient (average adult size) over the course of degradation, levels which were then compared 
to the IC30 values. The composition of the SMPs will alter both the production of products 
(due to changes in stoichiometric ratios of TEA to HPED) as well as the IC30 threshold value, 
although all examined compositions were found to below its respective limit using this 
analysis. As presented in Table 3.3 for the SMP compositions studied by Rodriguez et al 
and Horn et al, noted as HH60 (HDI-based SMPs containing 60:40 HPED to TEA as the 
alcohol moiety ratio), the product daily production rates (doses) are below the toxicity 
thresholds, a trend found for all of the examined SMP formulations.33-34 Furthermore, while 
the levels that are predicted for the products are below IC30, this model is limited by 
examining only the smallest products. Developing a more complex model would decrease 
these specific product values due to the lower doses of the smaller products, although these 
larger products might possess different synergistic effects as well as different IC30 
thresholds. Such analysis would also require a greater understanding of the solubility and 
material-cell interactions over the course of SMP degradation.  This limitation is partially 
addressed through the use of fully degraded SMPs, and previously examined SMPs that had 
undergone incubation in degradation solutions, all of which confirm cytocompatibility for 
the SMPs in the examined forms or at device-relevant degradation product dosages.134  
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Table 3.3. Cytocompatibility thresholds and approximated rates of production for select 
degradation products. A theoretical calculation is denoted by *. 
Product 
(HH60) 
IC30 
(mg/mL) 
1 g (1.25 %/day) 
(mg/kg body weight/day) 
HDI Amino 0.125 0.0807 
HDI EA 0.355 0.0327 
HDI Gly 0.292 0.0721 
HDI Lac 2.04 0.0883 
Oxalic acid 0.047 0.0114 
Glyoxal 0.031 0.0073 
HH60* 0.221 0.1332 
 
 
 
 
These results, combined the with utilized safety factors of accelerated mass loss 
based upon 3% H2O2 and maximum rate of change for determining material lifespan, 
indicate that these SMPs pose minimal risk for use in adult patients in vascular applications. 
Further work is needed to examine the roles of the aldehyde end group-containing 
degradation products, which were neglected here.  Recent studies of aldehyde-containing 
biomaterials have indicated that polymers with aldehyde end groups increase tissue-
adhesiveness, even in diseased tissue.132-133 While it is unknown what function the aldehydes 
will have for these SMPs in vascular applications, it is possible that some of the reduced 
inflammation found with these SMPs is due to superior tissue adhesion.33-34,132-133 It is also 
expected that while the amine degradation products may be taken up by cells and further 
metabolized, it is also possible that these products will be excreted due to both their size and 
potential charge Previous work with polyamines and cationic amines have demonstrated that 
 61 
 
these molecules, if sufficiently small, will be readily cleared via the renal system, which is 
the main method of clearance for cationic metabolites in healthy patients.142-144 In lieu of in 
vivo data to provide an understanding of degradation product excretion, metabolism, and 
migration, the use of toxicity risk assessment is useful for continuing to justify translation of 
the SMPs into vascular occlusion devices. 
3.4 Conclusions 
Despite the large number of medical devices available on the market for use in 
humans, there are many that are not well understood as material properties relate to 
degradation. Here we have demonstrated methods for further predicting the toxicological 
risk associated with the long-term implantation of polymeric materials. While the 
degradation mechanism was previously examined, here it is utilized to develop a series of 
degradation products for testing of the compatibility of the SMP material over long 
implantation times. For conformation of the method, bulk SMP was degraded, tested, and 
compared to theoretical levels. Theoretical calculations of degradation products were 
developed to reflect the worst-case levels of product formation for 1 g of material, indicating 
that even with these factors of safety and excessive amounts of material present the SMPs 
pose a minimal long term risk for patients. Most importantly, the methods of testing 
presented here may be tailored to any implantable material system for validating the 
cytotoxicity risk posed over the lifespan of an implant. 
 It is important to note that this study was performed to assess toxicity risk, but it does 
not fully confirm a lack of toxicity. True confirmation is only achieved through in vivo 
studies in the region of interest in appropriate animal models or human subjects. This testing, 
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however, provides important insight into the toxicity risks that may occur. Such information 
can be useful in developing such studies as well as for guiding the translation of these SMP 
biomaterials into certain device applications. However, despite some of the limitations of 
this approach, the use of several methods for assessing cytocompatibility limitations and 
toxicity risks (synthesized degradation products, partially degraded SMPs, fully degraded 
SMPs) does indicate that these SMPs, when used as vascular occlusion devices, will pose 
minimal risk for patients. 
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CHAPTER IV  
OXIDATION-RESISTANT SHAPE MEMORY POLYURETHANES CONTAINING 
ANTIOXIDANTS 
 4.1 Introduction 
Polyurethanes have been known to undergo degradation for decades, with notable 
failures including breast implants and pacemaker wires.1,5-8,16-17,22,114 While this has raised 
concerns about the long-term stability of these materials for in vivo applications, 
polyurethanes are still widely used in blood contacting applications due to their excellent 
biocompatibility.1,5-8,16-17,22 When porous, polyurethane-based shape memory polymers 
(SMPs) were first developed, one application suggested for these materials was aneurysm 
occlusion.26-30 Due to the SMP’s ability to undergo shape change from a compressed shape 
to the original shape when exposed to a stimulus, these SMPs are ideally suited for minimally 
invasive medical devices.26-30,36  
Failures of polyurethanes have had notable impact on devices in both polyurethane 
breast implants and pacemake wire coatings.1,5-7,16-17,114 The breast implant coatings 
demonstrated variable failures, with many patients never experiencing failure, pain, or 
adverse effects from long term implantation.6,17,114 However, in vitro analysis indicated that 
hydrolysis of the urethane bond, as well as from the reaction of residual diisocyanate starting 
materials with water, produced aromatic diamines.1,5,7 These degradation products are 
known to be carcinogenic, and so the failure of these systems posed some risk to patients if 
urethane hydrolysis was occurring.1,5-7,16-17,114  
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Due to the limitations of aromatic, thermoplastic polyurethanes, a new series of 
polyurethanes was needed for long-term implantable medical devices. Wilson et al 
developed a series of thermoset polyurethane SMPs from symmetric, aliphatic monomers in 
an effort to produce more stable polyurethanes that possess high strain recoveries and 
improved biocompatible if hydrolysis were to occur.36 While the hydrolytic stability of these 
SMPs was found to be improved, the use of amino alcohols results in a rapid oxidation 
mechanism in these materials.116,134,117-121 The tertiary amine oxidizes to a N-oxide (amine 
oxide) in the presence of a hydroxyl radical, followed by the eventual formation of a 
secondary amine and corresponding aldehyde; further oxidation-reduction fragmentations 
results in the formation of a primary amine, a second aldehyde, and a carboxylic acid as a 
result of aldehyde oxidation.116,134,117-121 The primary amine may oxidize to form ammonia, 
as an eventual end product.116,135,117-121 The diisocyanate and urethane linkage were also 
examined in oxidative solution, revealing minimal changes to both.134 The tetra functional 
alcohol used in the SMPs, N,N,N’,N’ tetrakis (2-hydroxypropyl) ethylenediamine (HPED), 
may also produce oxalic acid as an eventual fragment, which has been linked to the necrosis 
of renal tubule cells and the formation of oxalate crystals.131,134,182 Prevention of N-oxide 
formation will reduce the onset of fragmentation and mass loss of the bulk SMP, ultimately 
reducing the rate of formation of oxalic acid and other potentially harmful oxidation 
products. A radical scavenger included in the polymer offers an avenue to reduce the rate of 
oxidation, and eventual mass loss, and potentially could be translated into other systems that 
have oxidatively-induced degradation.74,213  
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Numerous antioxidant systems have been studied in polymer systems. Hindered 
amine light scavengers (HALS) antioxidants have found success in polyurethanes for 
coatings applications.75-81 HALS systems are successful due to their scavenging efficiency 
as well as the ability to reform the antioxidant after scavenging.75-81 Phenol and phenol-
derived antioxidants have also been used with varying degrees of success, as well as 
phosphite antioxidants.82-83 Butylated hydroxytoluene (BHT) has been used successfully in 
other polymer systems, with specific applications in medicine and medical materials.84-87 
BHT and its derivatives has high scavenging efficiencies and good solubility, unlike other 
efficient scavengers such as tannic acid.84-85 While many other methods exist for 
incorporating or utilizing antioxidants in polymer systems, directly incorporating the 
antioxidant into the polymer chain and physical addition of the antioxidant as small 
molecular weight additives are used frequently, and so the use of physical additives and 
chemically bound small molecules was selected.88-93 It is expected that these antioxidants 
will scavenge radicals preferentially to the tertiary amines, in order to reduce mass loss of 
the SMP without compromising the bulk integrity of the polymer, as is the case when 
synthesizing composite SMPs, and without requiring the initial polymer chain degradation 
that is utilized by in-chain antioxidants or antioxidant degradation products.90-93 
SMPs can undergo shape change when exposed to a variety of stimuli, including 
thermal, electric and magnetic fields, solvent, and light.36 Many SMPs slated for medical 
applications use thermal, solvent, or a combination of the two.36,40 The mechanism for shape 
recovery is controlled by the entropy of the molecule, with the SMP assuming a maximum 
entropic-configuration during synthesis.29 The secondary, or temporary, shape of the 
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polymer is set by raising the temperature of the polymer above the transition temperature 
(glass transition temperature Tg in the case of amorphous polymers) and mechanically 
deforming it until has cooled into the new configuration (which has reduced entropy relative 
to the original configuration).29,36 Application of the heat again drives the recovery of the 
original shape, as the polymer again assumes the original, maximum entropy configuration. 
29,36 The shape fixation may be temporary as the polymer relaxes, but polymers with strong 
intramolecular interactions such as hydrogen bonding may have improved fixity, and not 
undergo spontaneous shape recovery with a stimulus being applied. 29,36 For thermally-drive 
actuations, the Tg is the point at polymer chain mobility is sufficient to allow it to return to 
the configuration of maximum entropy.29 Solvent-actuations are similar, but the solvent 
interrupts the intramolecular interactions, allowing for shape recovery to occur at lower 
temperatures, also known as a wet Tg.40 Polyurethanes, polyamides, polyesters, among 
others, possess both a dry and wet Tg. For medical applications, this change in Tg 
(plasticization of the bonds) allows for the shape recovery of an implanted SMP when it 
reaches ambient moisture and temperature of the body, rather than an elevated temperature 
that may damage native tissue or proteins.211-212 
However, for SMPs that utilize a thermal actuation mechanism for shape recovery, 
the use of chemical methods for changing the oxidative degradation profile may compromise 
functionality of the biomaterial. Examination of chemical crosslinked (covalently bound) 
and physically added/absorbed antioxidants in porous SMP scaffolds (foams) were 
performed to determine the effects on thermal, mechanical, and shape memory properties. 
The utility of antioxidants for controlling degradation was then examined using accelerated 
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oxidative degradation testing and extraction testing in the form of cleaning the SMPs. 
Degradation products analysis was to access the risk of the SMPs overall for use in vascular 
occlusion applications. 
4.2 Methods and Materials 
All chemicals were purchased from Sigma Aldrich and used without modification or 
cleaning, unless otherwise stated. HPED (99%), triethanolamine (TEA, 98%, Alfa Aesar), 
hexamethylene diisocyanate (HDI, TCI America) and trimethyl hexamethylene diisocyanate 
(TMHDI, TCI America, a mixture of 2,2,4 and 2,4,4 monomers) were used as monomers. 
BHT, triphenyl phosphite (Triphen), 1,2,2,6,6 tetramethyl piperidinol (Piper), didodcyl 3, 3 
thiodipropionate (Thio), L-ascorbic (Vit C), and 2,2’-methylenebis(6-tert-butyl-
methylphenol) (Methyl) were chosen as antioxidants. Antioxidant structures are displayed 
in Figure 4.1. 
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Figure 4.1. Antioxidant structures used to produce oxidatively stable porous SMPs. 
(A) butylated hydroxytoluene, (B) 1,2,2,6,6 tetramethyl piperidinol, (C) 2,2’-
methylenebis(6-tert-butyl-methylphenol), (D) didodecyl 3,3 thiodipropionate, (E) 
triphenyl phosphite. 
 
 
 
Deuterated dimethyl sulfoxide (DMSO, 99.99%, Sigma Aldrich), ethanol (97%, 
Sigma Aldrich), and isopropyl alcohol (99.5%, Sigma Aldrich) were used as solvents. Ethyl 
isocyanate (98%, Sigma Aldrich) was used without purification. Cobalt chloride (CoCl2), 
hydrogen peroxide (H2O2, 50%, Sigma Aldrich), acetone (99%, Sigma) were used for 
degradation solutions. 
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Acetonitrile (99.93%, HPLC grade, Sigma), methanol (50% in H20 with 0.1% v/v 
formic acid, LCMS grade, Sigma), methanol (99.9%, LCMS grade, Sigma), and water 
solution (0.5 % v/v formic acid, HPLC grade, Sigma) were used with liquid chromatography. 
Porous SMP scaffolds were synthesized using a traditional two-step polyurethane 
foam synthesis process.20,35 First, an isocyanate premix was made by adding 35-40% of the 
desired alcohol moieties (molar %, with percentage varied to control premix viscosity and 
thus scaffold pore size) to the full measure of diisocyanates. This premix was cured over 36 
hours at 50°C to achieve the desired viscosity. The second step was the production of the 
alcohol premix, consisting of the remaining alcohols, antioxidants (added at 5 % and 10 % 
by wt), surfactants and catalysts.20,35 The premix was homogenously mixed using high shear 
mixing, which also dissolved the antioxidants into the solution, and was then mixed to the 
isocyanate premix using a high speed shear mixer, followed by the addition of a physical 
blowing agent. The scaffold was cured at 90°C for 20 minutes, followed by cold curing over 
night at ambient conditions.27,37,71 
Foam cell structure was determined by cutting axial and transverse samples that were 
examined using scanning electron microscopy (SEM). Samples were mounted onto a stage 
and sputter coated with gold using a Cressington Sputter Coater (Ted Pella, Inc., Redding, 
CA) for 60 seconds at 20 mA. Samples were then examined using a Joel NeoScope JCM-
5000 SEM (Nikon Instruments Inc., Melville, NY) at 11X magnification and 15 kV under 
high vacuum. 
Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
spectroscopy was used to determine any spectroscopic changes to the bulk material. ATR-
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FTIR spectra were taken using a Bruker ALPHA infrared spectrometer (Bruker, Billerica, 
MA) using 48 scans per spectra for both background and samples. Spectra data was collected 
in absorption mode with a resolution of 4 cm-1. OPUS software was used to examine spectra, 
identify peaks, and perform baseline and atmospheric corrections. 1H and 13C NMR were 
performed using a Mercury 300 MHz NMR in deuterated d6-DMSO.  
Extractions were performed using isopropyl alcohol at 50°C for 1 hour, extracted 
with sonication. 4 g of SMP were used for the extractions, and the final mass and 
concentration of the extracted antioxidants was determined for the entire 16 g of starting 
SMP.  Gas chromatography mass spectrometry (GCMS, positive mode) was used to 
determine the extracted concentration using a Thermo Scientific DSQ II Series Single 
Quadrupole GCMS (ThermoFisher Scientific, Waltham, MA), as well as the degradation 
products from the model compounds. A 10 uL sample volume was injected, with a dwell 
time of 4 seconds. The initial temperature was 50°C, heated to 320°C at a rate of 20°C/min. 
The flow rate was 50 mL/min with a surge pressure of 0.44 psi using methanol.  
Product determination was confirmed using liquid chromatography mass 
spectrometry (LCMS). Samples were diluted 100-fold in a 50% methanol (49.95% water, 
0.05% formic acid) solution, and injected into a normal phase C18 silica column. The 
injection volume was 10µL, and the mass flow rate was varied from 0% acetonitrile to 95% 
acetonitrile over a 6-minute gradient. An Exactive Plus OrbiTrap Mass Spectrometer 
(ThermoFisher Scientific, Waltham, MA) was used to perform MS. The capillary 
temperature was 100 °C. Spectral data was collected over a 30 second integration, and 
Xactive software (ThermoFisher Scientific, Waltham, MA) was used for analysis. 
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Degradation products of select antioxidants were determined using model compound 
studies and literature reviews. The behavior of TMHDI and HPED in the urethane network 
was examined by Weems et al, and is not repeated here.134 Model studies of antioxidant 
behavior were performed using unmodified antioxidants in 50% H2O2, heated to 60°C to aid 
in reactivity and solubility, and analyzed using both GCMS and LCMS. Additionally, model 
reactions of ethyl isocyanate with antioxidants were performed to examine urethane 
formation. 5 mmol of reagents were added (NCO:OH ratio), after which they were heated to 
50°C in a sealed vial overnight. The solution was then heated at 80°C under vacuum. 
Unreacted ethyl isocyanate would be removed from the solution, leaving primarily urethane, 
antioxidants, and ureas. The products were characterized for relative abundance using 
LCMS. 
Differential scanning calorimetry (DSC) was also used to measure both wet and dry 
Tg using a Q-200 DSC (TA Instruments, Inc., New Castle, DE). Samples of ca 5.0 mg ± 1.0 
mg were sealed in TZero aluminium pans and placed in the heating cell. The sample was 
cooled to equilibration at -40°C, heated to 120°C at 10°C/min, cooled 10°C/min to -40°C 
and heated to 120°C at 10°C/min. The half-height transition of the final heating cycle was 
the reported Tg. Wet samples were weighed and sealed in the same manner, and were then 
heated from -40°C to 80°C at 10°C/min. 
Thermogravimetric analysis (TGA) was used to assess any changes in thermal 
degradation temperatures. A TA Q50 TGA (TA Instruments, New Castle, DE) was used to 
heat samples to 500°C at 10°C/min under a mixed atmosphere of oxygen and nitrogen 
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(60mL/min to 40 mL/min respectively). Samples were examined for the onset of degradation 
temperature and major transitions in the mass loss profiles.  
Shape recovery of cylindrical foam samples (6 mm diameter, 10 mm length, six 
samples per series) crimped over a wire was examined at 50°C in RO water to determine the 
volume recovery behavior (strain recovery).214-215 Samples were crimped to a minimal 
diameter (ca 1.0 mm using a SC150-42 Stent Crimper (Machine Solutions, Flagstaff, AZ) 
by first being equilibrated at 100°C for ten minutes, and then radially compressed and cooled 
to room temperature. Samples relaxed for 12 hours and were tested over the course of 30 
minutes in 37°C H2O. Image J was used for analysis of the change in diameters over time. 
Uniaxial tensile testing was performed on ASTM d638 IV samples using an Instron 
Tensile Tester with 500 N load cell. The extension rate was set to 5 mm/min at room 
temperature, and seven samples were tested for each species. Elastic modulus, strain to 
failure, ultimate tensile strength calculated. 
For analysis of degradation rates, cleaned samples were completely immersed in 
respective solutions of 20% H2O2 with 0.1M CoCl2 at 37°C. Sample solutions were changed 
every 3 days to ensure a relatively stable ion concentration, and once per week samples were 
removed, cleaned in EtOH, and dried in at 50°C under vacuum (30 in Hg), after which 
sample mass was recorded and samples returned to fresh solution.135 
4.3 Results  
NMR confirmed the formation of urethane linkages for Methyl and Piper 
antioxidants only; other examined species contained original structures and small 
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concentrations of urea linkages. Proposed structures and mass spec are displayed in Figure 
4.2.  
The spectra of the SMP foams displayed the characteristic hydroxyl bands at ca 
3250-3500 cm-1, the methyl band at 2800-3000 cm-1, the carbonyl band at 1688 cm-1 that 
denotes the urethane bond and the corresponding should for the urea bond at ca 1640 cm-1, 
and the skeletal carbon peak at 1252 cm-1. The Methyl and Thio SMPs display shoulders on 
the carbonyl at ca 1710-1730 cm-1 that correspond to the ester bonds in the antioxidants 
(Thio) or the formation of a new urethane linkage (Methyl). The increase in the relative 
height of the urethane carbonyl of the Piper SMP compared with the control indicates the 
formation of the urethane linkage.   
Table 4.1 displays thermal analysis of the bulk SMPs. Tg for these materials was 
found to be ca 55C for the control, as well as for Piper. Methyl and BHT both displayed 
increased Tg (61.5°C and 57.2°C respectively). These same two antioxidants also resulted in 
increased onset of thermal degradation temperatures (control at ca 273°C, BHT at 303°C 
and Methyl at 299°C). All antioxidant SMPs, except for the Thio, displayed an increased 
onset of thermal degradation. 
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Figure 4.2.  Spectroscopic analysis of the antioxidant reactions with isocyanates using 
model compounds BHT, Methyl and Piper, and FTIR-ATR of the antioxidant-
containing SMPs. 
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Table 4.1. Thermal characterizations of antioxidant SMPs. 
Species Tg (°C) Wet Tg (°C) Td (onset temp) (°C) Td (derivative peak) (°C) 
Control 55.3 ± 0.3 10.4 ± 1.0 239 ± 2 273 ± 3 
Piper 55.0 ± 0.3 11.5 ± 1.1 250 ± 1 279 ± 1 
Methyl 61.5 ± 0.2 14.2 ± 1.4 260 ± 3 299 ± 4 
BHT 57.2 ± 0.8 10.2 ± 1.9 261 ± 1 303 ± 2 
Thio 41.0 ± 3.0 5.2 ± 0.5 236 ± 1 267 ± 1 
Triphen 38.9 ± 0.3 12.3 ± 1.3 247 ± 3 279 ± 4 
 
 
 
Mechanically, the Methyl again displayed enhanced properties relative to the control 
and the other examined species (Figure 4.3, Table 4.2). The elastic modulus of the control 
was 0.25 MPa, while Methyl displayed a 2.32 MPa; strain to failure for the control was 165% 
while Methyl’s was 128%, indicating that this increase in elastic modulus did not 
compromise the mechanical integrity of the material severely. Of the other examined 
antioxidants, Piper displayed slight increases in elastic modulus (0.28 MPa), and all species 
displayed increased strain to failure and tensile strength, except for Triphen. The Triphen 
SMP displayed nearly twice the strain to failure (283 %), while also possessing reduced 
tensile strength (0.35 MPa compared to 0.41 MPa for the control) and a lower elastic 
modulus (0.11 MPa).  
Unfortunately, the Methyl SMPs displayed little shape recovery(ca 35% recoverable 
strain) (Figure 4.3). This may be due to the increased rigidity of the polymer. The other 
covalently bound antioxidant, Piper, also had slightly reduced shape memory (ca 90% 
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recoverable strain. The other SMP species did not have significantly altered shape memory 
properties.  
Extractions of antioxidant SMPs displayed large amounts of extractable BHT and 
Triphen (Figure 4.4, Table 4.3). Relative peak heights were substantially greater for these 
antioxidants, although small peaks are noted for all SMPs. The identities of these peaks were 
confirmed from fitting the masses at these time points to the starting materials and thermo-
oxidative fragments. 
 
 
 
Figure 4.3. Shape memory behavior of porous SMPs (HH40) containing 10% 
antioxidants (left) and mechanical behavior for HH40 SMPs containing 10% 
antioxidants. 
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Table 4.2. Mechanical properties of antioxidant-SMPs. 
Foam 
Composition 
Elastic 
Modulus 
(MPa) 
Strain to 
Failure (%) 
Tensile 
Strength 
(MPa) 
Toughness 
(J*m3) 
Control 0.25 ± 0.06 165 ± 21 0.41 ± 0.08 333 
BHT 0.24 ± 0.06 207 ± 39 0.97 ± 0.14 940 
Piper 0.28 ± 0.19 219 ± 27 0.61 ± 0.23 787 
Thio 0.24 ± 0.06 283 ± 49 0.81 ± 0.21 722 
Triphen 0.11 ± 0.02 170 ± 21 0.35 ± 0.06 204 
Methyl 2.32 ± 0.44 128 ± 27 1.77 ± 0.46 1264 
 
 
 
The incorporation of the antioxidants into the SMPs resulted in the delay of 
oxidatively-induced mass loss from H2O2 in the Piper SMP only (Figure 4.5). Not displayed 
are mass loss profiles for TMHDI based SMPs, in which BHT was better retained; the mass 
loss of BHT SMPs was reduced to the same degree as the Piper SMPs. SEM images of the 
control SMP pores compared with the 10% Piper are displayed in Figure 4.6. Pore 
membranes are rapidly eroded, leading to the eventual collapse of the material in 7 days 
without antioxidants. By qualitative contrast, the Piper SMP at day 7 corresponds more 
closely with the control at day 3. 
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Figure 4.4. 10% antioxidant in HH40 (left) and 5% antioxidant in HH40 (right) 
degraded in 20% H2O2 with 0.1M CoCl2, at 37°C. 
 
 
 
 
 
Figure 4.5. Control SEM and 12 Piper at day 0 (A,D), day 3 (B,E), and  day 7 (C,F). 
A B C 
D E F 
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Figure 4.6.  GCMS chromatographs for extracted antioxidants from SMPs. 
 
 
 
 
Table 4.3. Mass and concentration of antioxidants added during synthesis and extracted 
during cleaning, determined using GC/MS. 
 Additive Mass 
(g) 
Additive 
Concentration 
(mol) 
Extract Mass 
(g) 
Extract 
Concentration 
(mol) 
Piper 2.000 0.012 0.080 0.000 
Methyl 2.000 0.006 0.155 0.000 
Thio 2.000 0.004 0.149 0.000 
Triphen 2.000 0.007 1.928 0.006 
BHT 2.000 0.009 1.629 0.007 
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Figure 4.7. Predicted real time oxidative mass loss of antioxidant (Piper) containing 
HDI-based SMPs. (equivalent of 2% H2O2 at 37°C) 
 
 
 
BHT, Triphen, Thio, and Methyl were either removed prior to testing during cleaning 
or were ineffectual for reducing oxidative mass loss with HDI-based SMPs. Figure 4.7 
displays the GCMS curves of the extracted antioxidants. The concentrations of the 
antioxidants were calculated and compared with the starting concentrations and masses used 
during synthesis (Table 4.3).  
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4.4 Discussion 
From the spectroscopic results, Piper and Methyl was expected to form urethane 
bonds. BHT does not form these bonds due to the steric hindrance of the hydroxyl group as 
a result of the surrounding methyl groups. The rotation of the phenol group relative to the 
second phenol group of the Methyl antioxidant provides a less sterically hindered 
antioxidant, allowing for more readily reactive hydroxyl groups. These results were 
determined from both LCMS and NMR. The control group (EtOH reaction with ethyl 
isocyanate) was used to determine the relative peak shifts for urethane and urea linkages, 
and these were then compared with obtain spectra for antioxidant model studies.  
Subtraction FTIR was used to confirm the presence of antioxidants in the SMPs after 
synthesis. Triphen displayed a sharp, medium peak at ca 2355 cm-1, indicative of phosphines, 
as well as bands ca 1600 cm-1 and 906 cm-1, corresponding to the aromatic ring and the 
phosphite ester, respectively.218  
The Piper displayed methyl groups at 2800-2900 cm-1 and a urethane bond 
corresponding to the reaction of the hydroxyl group and the isocyanates. BHT had a sharp 
peak at ca 3600 cm-1, methyl peaks from 2800-3000 cm-1, and peaks at ca 1615cm-1, 1550 
cm-1 and 1480cm-1.219-220 The Methyl spectra displayed a larger peak at ca 3550 cm-1 and a 
smaller peak at ca 3625 cm-1, as well as the methyl peaks from 2800-3000cm-1, a peak at ca 
1480 cm-1 and the two peaks at 1200 cm-1 and 1240 cm-1. 
Methyl-containing SMPs’ higher Tgs may be attributed to the formation of crosslinks 
at the phenol groups, which increases backbone rigidity and therefore the Tg. This may be 
why the Methyl SMP was found to have reduced shape memory, as a result of the covalent 
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crosslinks formed, and the BHT, which possesses a slightly raised Tg but does not form 
covalent crosslinks, does not have altered shape memory.  
Mechanically, the Triphen antioxidant may have acted as a plasticizer for the SMP, 
allowing for increased strain before failure at the expense of the other mechanical properties. 
Again, the presence of crosslinked Methyl in the SMP backbone would also result in the 
increased elastic modulus, tensile strength, and toughness, as well as the decreased strain to 
failure. 
For the HDI-based SMPs, it was found the physically added antioxidants were 
extracted during cleaning, and this may be what prevented the antioxidants from reducing 
the mass loss, at least for BHT. Methyl SMP would not be able to scavenge radicals due to 
the formation of covalent crosslinks, leaving only the Piper as an efficient antioxidant.  
A lack of solubility could be a reason for the limited efficiency of the other antioxidants. 
DSC indicated the presence of Thio in the SMP after cleaning (crystallization peak) as did 
FTIR and GCMS extractions, but model testing was suggested limited solubility and 
interactions with H2O2, even at elevated temperatures. This lack of reactivity could explain 
the presence of the Thio even while degradation of the SMP was occurring.  
Based upon the obtained degradation results, Piper and BHT are the most suitable 
candidates for controlling oxidatively-induced mass loss for certain medical device 
applications. A review of literature was performed to determine if either of these antioxidants 
is known to be cytotoxic.75-87,217-223 BHT and its derivatives are widely used in cosmetics, 
foods, and medical devices, providing a means of adsorption and distribution into the body, 
and these oxidation products are known to occur in vivo for these applications.82-87 Overall 
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BHT and similar structures are known to be non-genotoxic, non-carcinogenic, and may even 
reduce the incidences of some related conditions, such as atheroscleorosis.83-86 BHT may be 
metabolized into the carboxylic acid analog and excreted from the body, as will the oxidation 
products, indicating its utility in medical applications provided low dosing is ensured.83-86 
Piper and its derivatives have been proposed for a variety of antibiotic, antimicrobial 
and similar applications, and similar structures have been found to be non-mutagenic and 
non-genotoxic.75-78,224-225 Provided that the Piper is covalently bound to the polymer 
backbone during synthesis and free Piper does not rapidly diffuse out, this antioxidant may 
also be appropriate for preventing mass loss in medical devices, although cytotoxicity 
studies are needed to further confirm this. 
Future work would include expanding the range of examined antioxidants to include 
vitamin E derivative α-tocopherol as a future additive for testing, as well as other polymeric 
antioxidants, in addition to examining the covalent bonding of the antioxidants to the 
polymer bulk.226 These larger antioxidants will not diffuse out as rapidly, but will have to be 
examined for the impact on thermo-mechanical and shape memory properties.  
A synergistic approach may also be beneficial, where the polymeric, physically 
added antioxidants are selected to be reactive with the free radicals during the initial stages 
of degradation after the implantation of the material, and a covalently bound antioxidant 
acting as a long-term radical scavenger to further tune the rates of degradation and 
degradation product formation. 
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4.5 Conclusions 
We demonstrate the utility of covalently added and physically added small molecule 
antioxidants in highly porous shape memory polymers. The use of antioxidants in SMPs was 
intended to control the oxidative degradation and mass loss in these materials, which was 
accomplished through the use of the covalently added Piper antioxidant. Other antioxidants 
were shown to be removed through extraction in processes similar to the cleaning of medical 
materials prior to implantation, but changes in the polymer backbone (increasing 
hydrophobicity) were found to increase the retention of BHT in the SMPs. The degradation 
products of the most efficient antioxidants, BHT and Piper, were identified from literature 
as well as spectroscopic methods, and the proposed structures are presented. The 
toxicological risk associated with these additives is addressed from a literature review of 
antioxidant cytotoxicity, proposed uses, and known metabolic outcomes, with the Piper and 
BHT SMPs showing promise for translation into materials for reduced or tuned degradation 
in medical, particularly vascular, device applications. 
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CHAPTER V  
POLYURETHANE MICROPARTICLE COMPOSITE SHAPE MEMORY 
POLYMER POROUS SCAFFOLDS CONTAINING ANTIOXIDANTS FRO 
ENHANCED OXIDATIVE BIOSTABILITY 
5.1 Introduction 
The use of amino alcohols in thermoset shape memory polymers (SMPs) has been a 
source of oxidation, which results in rapid mass loss dependent on the concentration of 
oxidizing species.134 For medical devices and materials that incorporate SMPs, the rate of 
mass loss is directly related with the toxicological risk for the patient, as the rate of mass 
loss is the inverse of the rate of degradation product formation.227-229 While these SMPs have 
been demonstrated to be cyto- and biocompatible, long term risk may be reduced through 
reduction of mass loss rates, and there are device applications that require long-term 
presence of implants.26,227-229 Obtaining the ability to tune the rate of mass loss is a necessary 
step towards developing a material platform of SMPs for vascular implants. Previous work 
has demonstrated that common, small molecule antioxidants may be incorporated directly 
into the SMPs during synthesis as a method of tuning morphological, thermal, shape 
recovery, and in some cases the degradation-resistant properties.230 This study found that 
retention of the antioxidants was dependent on method of incorporation and SMP 
composition, as many small molecules are removed during the necessary cleaning process 
required for medical materials intended for implantation.230 Here the use of poly(urethane 
urea) microparticles is demonstrated as an alternative method of incorporating the 
antioxidants into SMP, allowing for enhanced oxidative resistance by utilizing a wider 
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variety of antioxidants compared with the previously used incorporation of small molecule 
antioxidants, without the thermo-mechanical and shape memory property changes. 
Particle systems have been proposed and tested for a variety of fields, and in medical 
applications microparticles have been proposed for drug releasing systems, chemical 
sensors, and visualization.231-235 A series of antioxidant microparticles, produced from a 
hydrolytically degradable vanillyl alcohol-containing copolyoxalate, were produced and 
tested in conjunction with dexamethasone. However, these particles would release ca 80% 
of the drug payload within 12 hours, and had sizes ranging from ca 10-15 µm. While the 
authors did not examine the degradation products, this polymer will also degrade into oxalic 
acid, which be cytotoxic.130,236 The same particles were previously studied for their 
interaction with hydrogen peroxide (H2O2) as radical scavengers.237 Polyketal microparticles 
were tested for radical scavenging by delivering superoxide dismutase to a model of lung 
fibrosis, with the ketals displaying no inflammation response compared with the 
inflammation found using the standard PLGA particles. This method also inhibited lung 
fibrosis.238   
Previous work with shape memory polymers (SMP) synthesized from amino 
alcohols and aliphatic diisocyanates indicates an oxidative degradation mechanism, where 
the rate of mass loss is directly related with the concentration of H2O2, which is used as a 
model for immune response to the implanted biomaterial.50,134,230 While the use of small 
molecule antioxidants has been demonstrated to be useful in delaying the oxidative mass 
loss of these materials, several of these examined species were found to be unsuitable or to 
yield less-than-ideal SMP materials due to thermo-mechanical property changes.230 While 
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some of these changes occurred as a result of the antioxidants acting as plasticizers, the 
butylated hydroxy toluene (BHT) was not well retained in the SMP matrix, and BHT 
derivatives were found to covalently react with the diisocyanates to produce more 
mechanically rigid SMPs without increasing oxidative biostability.230 The SMP matrix 
material has displayed excellent biocompatibility in previous studies and is anticipated to 
have minimal degradation toxicity.27,33 A method of incorporating the antioxidants into this 
matrix without covalent bonding, rather than changing the matrix, may be more suitable for 
increasing oxidative biostability.27,33 Previous work with composite SMPs has indicated that 
metal and metal oxides will result in thermo-mechanical property changes and that loading 
thresholds are dependent of stability of the porous matrix during synthesis.37,239 The use of 
a more compatible particle (polymeric particle) may allow for incorporation of the 
antioxidants without sacrificing the thermo-mechanical properties of the matrix SMP; 
poly(urethane urea) chemistries were selected due to the similarities with current synthesis 
methods, the well understood degradation products that would be produced for such 
formulations, and for the body of literature surrounding molecule-eluting applications.134,239-
240  
Formation of porous polyurethane microspheres through solution templating using 
calcium carbonate solution has been attempted, resulting in particles with ca 7.5 µm 
diameters.241 A solution of dimethyl sulfoxide (DMSO) and water (H2O) was used to 
produce porous polyurethane microparticles in a one-pot reaction that included the use of 
polyvinyl alcohol and isophorone diisocyanate.243 Castor oil and methylene-di-phenyl 
diisocyanate were reacted to form thermoplastic polyurethane microparticles, with water 
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added to produce the polyurea.244 Acetone/water mixtures have been used with a variety of 
amines to produce polyurea microspheres and particles with a range of sizes.245-246 
 Here we present a method for producing hollow, shell poly(urethane urea) 
microparticles with average diameters ranging from 2 to 8 µm, depending on the reaction 
conditions and starting reagents used. These particles were synthesized with or loaded with 
antioxidants and incorporated into SMPs as a method of reducing the rate of oxidative mass 
loss. Characterization of these materials indicates that this method for including antioxidants 
is superior as there are no thermo-mechanical property changes or shape recovery kinetic 
differences. 
5.2 Experimental 
Hexamethylene diisocyanate (98%, HDI, Sigma), isophorone diisocyanate (98%, 
IPDI, Sigma), triethanolamine (99%, TEA, Sigma), N,N,N’,N’ tetrakis (hydroxypropyl) 
ethylenediamine (98%, HPED, Sigma) were used without modification. Butylated 
hydroxytoluene (BHT), 1,2,2,6,6 tetramethyl piperidinol (piper), and 2,2’-methylenebis(6-
tert-butyl-methylphenol (methyl) were chosen as antioxidants and purchased from Sigma 
Aldrich. Ethanol (97%, EtOH, Sigma Aldrich), acetone (99%, VWR) and isopropyl alcohol 
(99.5%, Sigma Aldrich) were used as solvents. Cobalt chloride (CoCl2), hydrogen peroxide 
(H2O2, 50%, Sigma Aldrich) were used for degradation solutions. Phloxine B (PhB, Sigma) 
and Nile blue chloride (Nile, Sigma) were used without modification. 
Fourier transform infrared spectroscopy (FTIR) attenuated total reflectance (ATR) 
was performed using a Bruker ALPHA infrared spectrometer (Bruker, Billerica, MA); 48 
scans per spectra for both background and samples were used. Spectra data was collected in 
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absorption mode with a resolution of 4 cm-1. OPUS software was used to examine spectra, 
identify peaks, and perform baseline and atmospheric corrections. Examinations were 
performed in triplicate to confirm results. The obtained spectra were compared to previously 
reported spectra and a control without antioxidant additives. was used to confirm the 
formation of urethane and urea linkages. Previous work has confirmed the reactions of 
antioxidants with isocyanates using NMR. X-ray photoelectron spectroscopy (XPS) 
(Omicron XPS with Argus detector) using a Mg/Al x-ray source was used to characterize 
particles and SMPs.  
IPDI (5 g, 22.5 mmol) was added to a water/acetone solution (95 g) and mixed for 1 
hour at room temperature.24 Reaction temperature and solvent ratio were varied to optimize 
synthetic outcomes. TEA (29.97 mmol), DEA, or HPED were dissolved while stirring at 30 
rpm in the mixture. 5 g IPDI (22.5 mmol) was added over 10 minutes at a constant rate. The 
reaction was allowed to proceed overnight, yielding a viscous white solution. The solution 
was centrifuged for 5 min at 4000 rpm, and the particles were rinsed in H2O-acetone (30/70 
ratio) three times before drying at 70°C overnight. Particles were dried and characterized 
(Yield 54%). 
The thermoplastic core was extracted using IPA/acetone mixtures at 50°C for 12 
hours with a one-hour sonication every 4 hours. Particles were then centrifuged and 
separated from the effluent, and removal of the core was confirmed using differential 
scanning calorimetry and x-ray diffraction experiments. Loading of the particles was 
performed by dissolving 20g of antioxidant or fluorescent dye into solution and adding 20 g 
of particles. The mixture was stirred and heated to 50°C overnight. Particle solutions were 
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then centrifuged, separated, washed three times using H2O/acetone, and dried overnight at 
50°C. 
Synthesis of antioxidant containing particles was repeated with 50% wt of 
antioxidants added immediately after the alcohol, prior to the additional IPDI. Particles were 
collected and washed the same way as described previously. Particles produced this way are 
labeled Synth (i.e. B-Synth).  
Porous SMP scaffolds were synthesized using a traditional two-step polyurethane 
foam synthesis process. An isocyanate premix was first made by adding 42% of the desired 
alcohols (molar %, with percentage varied to control premix viscosity and thus scaffold pore 
size) to the entire amount of diisocyanate, with a ratio of NCO:OH of ca 2:1. This premix 
was cured at 50°C for 36 hours. The alcohol premix was then synthesized, consisting of the 
remaining alcohols, particles (10% wt), surfactants and catalysts. The premix was 
homogenously mixed, and was then mixed to the isocyanate premix along with 
microparticles using a high speed shear mixer, followed by the addition of a physical 
blowing agent. The scaffold was cured at 90°C for 20 minutes, followed by cold curing over 
night at ambient conditions. 
SMP samples were imaged using an Olympus Fluoview 1000 laser scanning 
confocal microscope (LSCM) (Olympus America Inc, Center Valley, PA), and were excited 
at 543 nm utilizing <1% maximum intensity.27 Foam cell structure was determined by 
cutting axial and transverse samples that were examined using scanning electron microscopy 
(SEM). Samples were mounted onto a stage and sputter coated with gold using a Cressington 
Sputter Coater (Ted Pella, Inc., Redding, CA) for 60 seconds at 20 mA. Samples were then 
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examined using a Joel NeoScope JCM-5000 SEM (Nikon Instruments Inc., Melville, NY) 
at 11X magnification and 15 kV under high vacuum. 
Differential scanning calorimetry (DSC) was also used to measure both wet and dry 
Tg using a Q-200 DSC (TA Instruments, Inc., New Castle, DE). Samples of ca 5.0 mg ± 1.0 
mg were sealed in TZero aluminium pans and placed in the heating cell. The sample was 
cooled to equilibration at -40 °C, heated to 120 °C at 10 °C/min, cooled 10 °C/min to -40 °C 
and heated to 120 °C at 10 °C/min. The half-height transition of the final heating cycle was 
the reported Tg. Wet samples were weighed and sealed in the same manner, and were then 
heated from -40°C to 80°C at 10°C/min.  
Shape recovery of cylindrical foam samples (6 mm diameter, 10 mm length, six 
samples per series) crimped over a wire was examined at 50 °C in RO water to determine 
the volume recovery behavior (strain recovery). Samples were crimped to a minimal 
diameter (ca 1.0 mm using a SC150-42 Stent Crimper (Machine Solutions, Flagstaff, AZ). 
To crimp, samples were equilibrated at 100 °C for ten minutes and then radially compressed 
and cooled to room temperature. Samples relaxed for 12 hours and were tested over the 
course of 30 minutes. Image J was used for analysis of the change in diameters over time. 
Uniaxial tensile testing was performed on ASTM d638 IV samples using an Instron 
Tensile Tester with 500 N load cell. The extension rate was set to 5 mm/min at room 
temperature, and seven samples were tested for each species. Elastic modulus, strain to 
failure, ultimate tensile strength calculated. 
Release of antioxidants was studied at 1 hr and 1 wk using 2.0 g SMPs in 50 mL of 
IPA at 50 °C. Samples were withdrawn and the solution was examined using gas 
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chromatography mass spectrometry (GCMS). Solution was injected into the column (C18 
silica, normal phase) and heated at 20 °C/min to 300 °C. 
For analysis of degradation rates, cleaned samples were completely immersed in 
respective solutions of 20% H2O2 with 0.1M CoCl2 at 37 °C. Sample solutions were 
changed every 3 days to ensure a relatively stable ion concentration, and once per week 
samples were removed, cleaned in EtOH, and dried in at 50 °C under vacuum (30 in Hg), 
after which sample mass was recorded and samples returned to fresh solution.  
5.3 Results and Discussion 
An overview of the synthetic method is displayed in Figure 5.1. The three amino 
alcohols examined for synthesis with IPDI were characterized for size, shown in Table 5.1. 
While the smallest particles are achieved with HPED, the small distribution was achieved 
with TEA or DEA. HPED resulted in two sizes of particles with a larger standard deviation 
than with the DEA and TEA monomers. TEA was selected for further examination due to 
the Dn. Table 5.2 shows the effect of temperature conditions on the synthesis of TEA-IPDI 
particles, and Table 5.3 displays the effect of solvent ratios. 
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Figure 5.1. Synthesis of polyurethane particles, as first thermoplastic chains that are 
the core of the crosslinked shell. The particles are then cleaned, the thermoplastic 
core extracted, and then loaded with antioxidants. The particles are then combined 
with the displayed monomers to synthesize shape memory polymer foam (SMP). 
 
 
Once the cores were removed, the particles were loaded with the antioxidants or the 
fluorescent molecules. Particle loading was analyzed using XPS to determine the 
composition (Table 5.4), which was related to the elemental composition of PhB as a model, 
using the presence of chlorine as a reference. Loading during synthesis was viable only for 
BHT and Piper, as Methyl is not soluble in the polymer solution sufficiently. Loading 
percentages of up to 45% were attempted during synthesis, and did not appear to alter 
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particle composition or morphology, but removal of BHT was a possibility during particle 
cleaning and so was not further examined. Loadings of ca 45% (wt) were achieved using 
physical means after synthesis. 
 
 
Table 5.1. Morphological properties of IPDI microparticles synthesized from three alcohol 
monomers. 
Temperature Monomer Diameter 
(µm) 
Number ave 
Distribution 
(Dn) 
Weight ave 
Distribution 
(Dw) 
Dw/Dn 
50° TEA 6.15 ± 2.06 6.791 10.690 1.574 
50° DEA 6.85 ± 1.26 7.254 8.742 1.287 
50° HPED 5.61 ± 3.48 9.544 10.484 1.10 
 
 
 
Table 5.2. Morphological properties of IPDI-TEA microparticles. 
Temperature Diameter (µm) Number ave 
Distribution 
(Dn) 
Weight ave 
Distribution 
(Dw) 
Dw/Dn 
0 °C 6.17 ± 0.78 6.662 9.122 1.369 
20 °C 2.43 ± 0.91 2.799 4.176 1.491 
50 °C 6.15 ± 2.06 6.791 10.690 1.574 
80 °C 5.16 ± 1.93 6.419 9.125 1.421 
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Table 5.3. Morphological properties of IPDI-TEA microparticles synthesized using varied 
concentrations of acetone and water. 
Temperature Acetone % Diameter 
(µm) 
Number ave 
Distribution 
(Dn) 
Weight ave 
Distribution 
(Dw) 
Dw/Dn 
20° 30 6.26 ± 1.88 6.657 9.723 1.461 
20° 50 4.09 ± 1.21 4.526 7.051 1.558 
20° 60 5.20 ± 2.13 4.695 8.295 1.767 
20° 70 2.43 ± 0.91 2.799 4.176 1.491 
 
 
 
 
 
Figure 5.2. Size distribution of IPDI TEA particles synthesized at varied 
temperatures. 
 
 
 
The size distributions of the TEA-IPDI microparticles determined through microscopy are 
shown for solvent conditions and temperature in Figure 5.2, and the morphology of 
individual particles at 20°C are shown in Figure 5.3. 
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Figure 5.3. Particles synthesized from IPDI and TEA at 20°C. 
 
 
 
There particles contain a thermoplastic polyurea core with the poly(urethane urea) 
crosslinked shell surrounding it. Removal of the core was achieved through sonication in 
solvent, confirmed using DSC and XRD (Figure 5.4).244 
The formation of urethane and urea linkages was confirmed through the presence of 
carbonyl peaks at 1689 cm-1 and 1640 cm-1, respectively. The lower wavenumbers for the 
urethane peak are due to the increased hydrogen bonding achieved using aliphatic 
monomers. XPS confirmed the incorporation of greater amounts of free hydroxyls (286.4 
eV) associated with the leftover end groups from the synthesis (Table 5.4), as wells are a 
should peak at 288.7 eV associated with carbonyls.28 Further analysis of the SMPS 
confirmed the residual presence of tin, which is used as a catalyst. Silicone is present due to 
the surfactants used, as well as chlorine in the examined PhB-containing species. The dual 
binding peak seen for the C1s scan at 286.6 eV may also indicate a greater presence of C-N 
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bonds as well as hydroxyls, as a result of greater incorporation of the alcohol into the SMP 
compared with in the microparticle, which possesses a thermoplastic core and linear shell 
components. The maximum intensities of the PU particle plain and PhB particles N1s peaks 
were ca 37000 counts/sec 31000 counts/sec, while the SMP composite nearly 53000 
counts/sec. This is supported by the relative area of the N1s peak displayed for the SMP 
compared with the particles in the survey scan.249  
 
 
 
Figure 5.4. A comparison of the areas of the original microspheres (PU with core) and 
those that have undergone extraction reveals a relative crystallinity of 3.3% for the 
starting material, which can be attributed to the thermoplastic polyurea core. 
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Table 5.4. XPS determined elemental composition of selected particles and composite 
SMPs. 
Species Elemental Composition  
 C% O% N% Additional 
elements 
Pu particle 75.43 11.89 12.69  
BHT 76.6 9.88 13.52  
Methyl 75.49 10.67 13.84  
Piper 77.28 8.58 14.14  
PhB  73.66 13.57 11.54 Cl, Br 
SMP Composite 57.40 20.57 2.99 Sn, Cl, Si, 
Br 
 
 
 
Determined from SEM, the average strut diameter is ca 20.7 ± 3.6 µm. The average 
aggregate diameter was 13.4 ± 10.1 µm, as displayed in Figure 5.4, determined through 
optical microscopy of fluorescent-tagged particles. Dry Tg of the examined species was 
found to be ca 65°C, regardless of additive species. Wet Tg was ca 28°C. 
Shape recovery characterization demonstrates that all composite SMPs examined 
have similar shape recovery profiles (Figure 5.5), a trait that is not reproducible with metal 
or metal oxide-based additives.37,239 Previous work with antioxidants added into SMPs as 
small molecules resulted in changes in the shape recovery behavior, notably in the Methyl 
and Piper antioxidants due to covalent bond formations.230 However, the Methyl-loaded 
particles do not impact shape recovery compared with small molecules, and the Piper-loaded 
particles have superior shape recovery behavior compared with the small molecules. Piper-
loaded composite SMPs are capable of 100% strain recovery over 15 minutes (with full 
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recovery occurring at ca 10 minutes) with similar recovery kinetics to the control material. 
Piper added as a small molecule results in delayed recovery and a final recoverable strain of 
ca 90%. By 10 minutes only ca 75-85% strain is recovered.  
Further comparison of the composite SMPs and small-molecule containing SMPs 
can be made using tensile testing (Table 5.5). Previously, the incorporation of covalently 
bonding antioxidants (Methyl and Piper) resulted in the reduction of strain to failure, 
increased tensile strength and elastic moduli. In the case of Methyl small molecule 
antioxidants, the elastic moduli were ca 8 times greater and the tensile strength was 4 times 
greater. Using microparticles, the mechanical properties do not significantly change. The 
changes that are displayed may be result of this are not statistically significant and may be 
attributable to the slight change in SMP morphology that is obtained through inclusion of 
physical additives.230 
Release of additives from the composite SMP was measured using GCMS (Table 
5.6). At 1 hr, which would be the equivalent of cleaning the SMP prior to device packaging 
and sterilization, the particle synthesized with the antioxidants appeared to have released the 
majority of the release-able payload. BHT-synth released more than 80% of the available 
antioxidant, by 1 hr. By 1 wk, 91% of the available BHT had been released from the BHT-
synth. By comparison, BHT/BHT (containing both microparticles and small molecule 
antioxidants) released nearly 50% of the available antioxidant, and BHT-load had released 
ca 75%. These release studies were further confirmed using UV-vis experiments. 
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Figure 5.5. SMP foam with TEA-hollow microparticles (A), BHT loaded with BHT-
hollow microparticles (B). The agglomeration of microparticles can be seen to occur 
along the edges of pore membranes (C, D). Aggregate diameters (E) and pore sizes 
(F) determined using microscopy. 
 
 
 
The degradation products of these SMPs have been previously characterized. The 
amino alcohols are known to oxidize to lower amines and corresponding aldehydes, which 
may further oxidize to carboxylic acids or are part of the tissue integration process, 
depending on location and foreign body response.135 The use of TEA is designed to increase 
long-term cytocompatibility of the particles and particle degradation products, as TEA will 
not form oxalic acid as a potential by-product, unlike HPED; particle morphology and size 
dispersity were other considerations.135  
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Figure 5.6. Shape recovery characterization over 15 minutes in 37°C RO H2O 
displaying the various compositions and their shape recovery behavior. 
 
 
 
Table 5.5. Mechanical properties of microparticle composite SMPs. 
Species Elastic Modulus Strain to Failure Ultimate 
Strength 
Control (HH60) 1.45 ± 0.19 45.2 ± 11.6 % 0.21 ± 0.1 
Piper 1.32 ± 0.26 52.9 ± 8.2 % 0.27 ± 0.1 
Methyl 1.19 ± 0.18 61.2 ± 26.1 % 0.26 ± 0.1 
BHT 1.52 ± 0.29 51.2 ± 5.8 % 0.27 ± 0.1 
 
 
 
From the loading calculations, it appears that these microparticles may be suitable 
for increasing the oxidative resistance of the matrix SMP, as 10% loading of these particles 
would provide ca 0.85 g of antioxidant (5% wt of the SMP matrix) (Figure 5.7). In 
comparison with the direct addition of these antioxidants to the bulk material, the use of 
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microparticles may be used to better retain BHT and Methyl antioxidant species for 
enhancing SMP biostability. Previously, the BHT was not retained in the SMP and the 
Methyl crosslinked, resulting in increased elastic modulus at the cost of its strain recovery 
that degraded at the same rate as the control.215 Utilizing the microparticles, SMPs were 
developed that had similar thermo-mechanical and shape recovery properties with increased 
degradation resistance for all examined antioxidants. However, while this method enhances 
the utility of same antioxidants, for the Piper series it was found to be no more effective than 
the addition of small molecules into the bulk.  
Approximations of real time oxidative mass loss were calculated using the 
accelerated data. For the control materials, in 2% H2O2 the lifespan of the materials is 
predicted to be ca 500 days. For Methyl SMP composites, the lifespan of the material is ca 
600 days. Piper and BHT had predicted lifespans of ca 650 days. From a toxicological risk 
perspective of the degradation products, increasing the time to total mass loss (decreasing 
the rate of degradation) achieves a lower production rate of degradation products and a 
reduced risk. 
For the SMP matrix, toxicity assessments have been performed using completely 
degraded materials, synthesized degradation products, and corresponding literature review 
of available products. From the cytocompatibility studies, it appears the oxalic acid is the 
most concerning degradation product. In selecting TEA as the alcohol monomer of the 
particles, complete particle degradation is not limited by generation of oxalic acid or glyoxal.  
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Table 5.6. Released concentrations of antioxidants determined from GCMS. 
Species Initial 
Mass 
Initial 
Concentration 
(mol) 
1 Hr 
release 
Mass 
1 Hr release 
Concentration 
(mol) 
1 Wk 
release 
Mass 
1 Wk release 
Concentration 
(mol) 
BHT 
and 
BHT 
2.4000 0.0109 1.1220 0.0051 1.1480 0.0052 
BHT 
Synth 
0.8000 0.0036 0.6515 0.0030 0.7312 0.0033 
BHT 
Load 
0.8000 0.0036 0.3218 0.0015 0.6008 0.0027 
Methyl 
Synth 
0.8000 0.0024 0.0159 0.0001 0.1496 0.0004 
Methyl 
Load 
0.8000 0.0024 0.0143 0.0001 0.02117 0.0001 
Piper 
Synth 
0.8000 0.0051 0.0243 0.0002 0.0243 0.0002 
Piper 
Load 
0.8000 0.0051 0.0143 0.0001 0.0151 0.0001 
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Figure 5.7. Degradation of composite SMPs compared to control and selected small 
molecule antioxidant containing SMPs over the course of 20 days in accelerated 
conditions (left, 20% H2O2 with 0.1 M CoCl2 at 37°C), and the predicted real time 
degradation behavior of the SMP composites (right, equivalent of 2% H2O2 at 37°C). 
 
 
 
5.4 Conclusions 
Previous work with inclusion of antioxidants revealed that many species will result 
in altered thermo-mechanical properties, decrease shape memory, or will be removed from 
the bulk SMP during cleaning for device preparation. Through the use of microparticles as 
antioxidant reservoirs, these changes are minimized and oxidative resistance is improved. 
Microparticles were produced for diisocyanates and amino alcohols, with synthetic 
conditions and starting reagents examined for particle physical characteristics prior, and 
antioxidants loaded prior to synthesis of composite SMPs. The materials were characterized 
and found to exhibit similar mechanical, shape memory, thermal, and morphological 
properties when compared with control samples, indicating that the particles are compatible 
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with the SMPs and that the presence of antioxidants will not influence material properties. 
Oxidative resistance was found to be enhanced with all examined antioxidants. 
 Comparisons of the Piper small molecule antioxidant and the Piper-containing 
microparticles indicates similar times to complete mass loss, for real time oxidation. The 
BHT and Methyl antioxidants, previously incompatible with the HDI-based SMPs, are found 
to increase oxidative resistance when incorporated into the microparticle-composite SMPs. 
With this method, the lifespan of the SMP is increased from 500 days to nearly 700 days 
(Figure 5.8). While in some cases the use of the Piper antioxidant may be superior to the 
microparticles, this method allows for a greater variety of antioxidants and may also increase 
the functionality of the SMPs, as demonstrated through the brief examination of 
environmental responsiveness. 
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Figure 5.8. Comparison of the predicted mass loss profiles for antioxidant-containing 
SMPs, with Piper incorporated as both a small molecule antioxidant as well as in the 
microparticles. The predictions are for 2% H2O2, or the equivalent of real time for 
the HH60 composition being examined. 
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CHAPTER VI  
HIGHLY POROUS THERMOSET SHAPE MEMORY POLYURETHANE TISSUE 
SCAFFOLD FROM THE RENEWABLE RESOURCE GLYCEROL, AND ITS 
OXIDATIVE DEGRADATION PATHWAY 
6.1 Introduction 
Shape memory polymers (SMPs) have been proposed for a variety of medical 
applications, such as vascular occlusion devices, due their ability to recover their original 
shapes upon thermal equilibration or the introduction of solvent.30,32-34,42,180-181 Of these 
stimuli-responding polymers, polyurethanes (PU) are some of the best candidates for 
medical devices due to their biocompatibility and wide variety of formulations available, 
despite the reported cases of PU failures.1,5-6,18,30,32,42,73 SMP PU compositions may be tuned 
to allow for shape recovery to take place upon equilibrating with body temperature, or due 
to the influx of water once the material is placed in vivo.182-184  
Thermoplastic PU have demonstrated a lack of biostability, classically as a result of 
chain extenders containing hydrolytically labile groups or due to urethane hydrolysis.18,33,73 
However, the developed thermoset SMP PUs based upon aliphatic amino alcohols and 
diisocyanates, despite possessing improved hydrolytic stability, were still susceptible to 
degradation.134 The cause of the oxidative susceptibility was found to be the tertiary amines, 
which may fragment to form lower amines, aldehydes and acids, and eventually ammonia.37 
The replacement of these amino-alcohols with a less susceptible monomer will result in 
increased oxidative stability and further reduce patient risk. Glycerol was selected to replace 
triethanolamine (TEA), the more oxidatively susceptible monomer.134,185-191 In addition to 
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the tri-functionality of glycerol, which will theoretically not reduce the crosslink density and 
strain recovery of the bulk material, it is also renewable and inexpensive. 134,185-191 
Degradable polymers have been synthesized utilizing glycerol, but the degradable linkages 
have been determined to be from the copolymer component, such as dsulfide, ester or ether 
linkages.1,5-8,192-194 To our knowledge, no work has been done to characterize what, if any, 
degradation occurs for “biostable glycerol-based urethanes. 
Figure 6.1. Accelerated mass loss (left, 20% H2O2 with 0.1 M CoCl2) examined over 
35 days, and real time mass loss (right, 2% H2O2) examined over the course of real 
time oxidation out to eight months. All experiments were conducted at 37°C. 
Stoichiometric amounts of the amino-alcohol hydroxypropyl ethylene diamine 
(HPED) and glycerol were varied for characterization of degradation behavior, as well as 
basic material properties to produce SMPs with 20% glycerol (20 Gly, containing 10% by 
endgroups glycerol, 40% HPED, and 50% TMHDI), 40% glycerol (40 Gly), and 80% 
glycerol (80 Gly).  The Tgs of the SMPs were found to be ca 74°C when dry, although the 
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plasticized Tg ranges from 42 to 48°C. After real-time oxidative testing, the Tg was found to 
have decreased by 7° to 20 °C, depending on the extent of degradation. SEM images confirm 
the gravimetric results, with the control and 20 Gly losing all morphological features by the 
end of the degradation studies. The 80 Gly was found to have minimal, if any, changes in 
the pore morphology and membranes. 
13C NMR confirms that despite the reactivity differences between primary and 
secondary alcohols in isocyanate reactions, there will be low concentrations of free 
secondary alcohols remaining when stoichiometry is balanced. It is expected that with high 
concentrations of free secondary alcohols that shape recovery may be inhibited, but in all 
examined cases, strain fixity and strain recovery were found to be greater than 99%  when 
immersed in 50 °C H2O, with most materials fully recovering within 15 minutes. 
Gravimetric analysis of the samples in accelerated oxidative solution (20% H2O2 
with 0.1 M CoCl2) indicates that the control will undergo complete mass loss by ca 18 days, 
while lower concentrations of glycerol will be extended out to 25 or 35 days (20 and 40 Gly) 
(Figure 6.1). At 35 days, 80 Gly had ca 40% of mass remaining, and while the rate of mass 
loss is similar to 40 Gly, the time to initial mass loss is substantially improved from ca. 2 
days to 12 days. In real time testing (2% H2O2), 80 Gly had ca. 96% mass remaining at 8 
months, compared to less than 50% remaining for the control samples – an expected result 
due to the decrease in the tertiary amine concentration. The gel fraction of 80 Gly for real 
time oxidation conditions reduces from 98% to 88% over the course of testing, but the 
control and 20% Gly reduce to ca 5% and 15%, respectively. With ca identical Tgs for 
control and Gly SMPs, the mass loss from oxidative degradation is dependent on the amines. 
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While the crosslink density is theoretically the same (excluding reaction kinetic differences 
between the monomers), the network should be less fragmented at the glycerol units 
compared with the control TEA units at early time points. 
Tensile testing (ASTM Type IV D dogbones, 5 mm/min strain rate) over the course 
of degradation demonstrated a distinct increase in modulus over time, along with a decrease 
in strain to failure and tensile strength (Figure 6.2).  The 20 Gly samples were not robust 
enough to test after three months; 80 Gly SMPs had elastic moduli 133% of the original at 
eight months. The strain to failure decreased by ca 18%, and tensile strength decreased by 
33%. For evaluation of materials in an environment that most closely simulates in vivo 
conditions, the mechanical samples provide the shortest time for performance testing, but 
without degradation mechanism information. 
Liquid chromatography mass spectrometry (LCMS) was used to determine relative 
abundances and species of 2G (containing 2 urethane linkages and a free secondary alcohol) 
and 3G (3 urethane linkages) oxidation in 50% H2O2 solution (at 37°C over 4 weeks). Figure 
6.3 details the proposed degradation pathway for 2G. The 2G may be consumed to form the 
ketone (2), then a 1,2 diketone (3), which may undergo further fragmentation to aldehydes 
(4,7) and carboxylic acids (5,6). The aldehydes may further form carboxylic acids (7 to 5) 
or an anhydride that will decarboxylate to carbamic acids (4 to 6 to 8). It appears that the 
majority of the 2G does not undergo fragmentation until ca.weeks 2-3, as noted by the 
increase in ketones prior to increases in carboxylic acids. It appears that by week 4 most of 
the fragmentation has occurred. The degradation of the 3G molecule indicates minimal 
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fragmentation will occur under these conditions, as the starting material (15) was found to 
form ketones (16) and 1,3 diketones (17) over the course of examination (Figure 6.4).  
 
 
 
Figure 6.2. Representative stress-strain curve for 20 Gly SMPs at each examined 
degradation time point in 2% H2O2 at 37°C. 
 
 
 
As can be determined from the comparison of the model degradation studies, the 3G 
molecular segments will be much more stable compared with the 2G segments. By 4 weeks, 
2G will have formed more than 4 times the number of fragments than the 3G will have, and 
will be completely consumed in ca 2-3 weeks, while 3G starting material is still present 
(Figure 6.5). 
The degradation products that were found for the 2G molecule are similar to 
compounds reported for oxidation of a single glycerol molecule.185 While mesoxalic acid 
(ketomalonic acid) is an oxidation product of glycerol, presence of water and peroxide will 
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shift the equilibrium toward dihydroxymalonic acid.185 Continued oxidation is also possible, 
leading to fragmentation. However, spectroscopic analysis of the bulk SMPs revealed a 
similar carbamate carbonyl peak shift (FTIR) after degradation due to the formation of 
carboxylic acids, as has been found previously with the degradation of the amino alcohols.134 
This shift was found in the 20 and 40 Gly, but not the 80 Gly, due to the reduced oxidation 
and lack of COOH formation. Solid state 13C NMR supports these findings. This indicates a 
lack of 2G linkages in the SMPs, supported by the increase in oxidative stability with 
sufficiently high concentrations of glycerol, which is expected due to the excess isocyanate 
used during synthesis (1.05 NCO: 1.0 OH final ratio, 1.05: 0.40 for prepolymer synthesis). 
Photooxidation experiments of polyglycerol by S Morlat et al, where the proposed 
mechanisms include formation of ester and formate as a result of hydrogen abstraction from 
the CH2 atom of the glycerol molecule, followed by peroxy radical formation.195 However, 
it was suggested that in this case no aldehyde or carboxylic acids would form.195 This 
contrasts with oxidation studies of mono-glycerol, which indicates that selective oxidation 
may result in fragmentation at many points or a fully oxidized molecule, mesoxalic 
acid.35,185-191 These are more in agreement with the results that we have presented. 
6.2 Conclusions 
Overall, we believe that the amines present in the SMP will oxidize preferentially 
and will be the initial cause of mass loss, as demonstrated with the lower glycerol 
concentrations in gravimetric studies, such as with the control samples. As the concentration 
of glycerol increases in the SMP, the fragmentation of amines will have less impact on the 
initial mass loss, which is demonstrated by the 80 Gly gravimetric results. After the amines 
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are consumed, which has been demonstrated to occur within the first two weeks of 
accelerated testing using 50% H2O2, then the glycerol will be oxidizing and fragmenting. At 
this point, the glycerol oxidation will be the primary cause of mass loss from the bulk SMP, 
albeit at a much slower rate compared with the amines. However, as we demonstrate, 
unreacted secondary alcohols will be the site of more rapid oxidation and therefore polymer 
fragmentation. With increasing glycerol concentration in the SMP, there may be more 
secondary alcohol sites; while optimization of the SMP synthesis process to reduce the 
secondary alcohol concentration is expected to ultimately yield SMPs with greater oxidative 
stability compared with their counterparts, spectroscopic analysis presented here does not 
reveal an abundance of secondary alcohols in the compositions, which may limit the extent 
to which glycerol may be used to achieve perfect oxidative stability. 
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Figure 6.3. Proposed oxidative degradation pathway of the 2G molecule, examined at 
37°C in 50% H2O2 using LCMS. 
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Figure 6.4. Proposed oxidative pathway for the 3G molecular segments. 
 
 
 
 
Figure 6.5. Relative rate of product formation from 2G model compounds (top). 3G 
relative abundances of products are displayed (right). Model compounds were 
degraded in 50% H2O2 at 37°C. 
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This is further confirmed by the remaining 95.7% mass of the 80 Gly (87.1% gel 
fraction) in real time oxidative solutions at 8 months, as opposed to the 20 Gly (51.6% mass 
remaining and 15.3 ± 9.8 % gel fraction) and control (49.1% mass remaining and ca 5% gel 
fraction). For rapidly testing the relative biostabilitly of multiple compositions prior to 
devoting resources to long-term studies, a model compound study coupled with mechanical 
testing seems to provide the fastest insight for bulk SMPs. However, based upon the known 
biocompatibility of glycerol-based polymers, and the presented attributes with regard to 
degradation, these SMPs do have excellent potential for improving the stability from the 
current iterations of poly (amino urethane) SMPs. While previous methods of enhancing 
biostability (antioxidant and antioxidant-containing microparticles) were found to increase 
the biostability to from ca 500 days to ca 1350 days (for TMHDI-based SMPs; HDI-based 
SMPs with antioxidants had lifespans of ca 700 days), the use of high concentrations of 
glycerol was found to produce SMPs with lifespans of ca 2250 days (Figure 6.6). 
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Figure 6.6. Comparison of the predicted real time (2% H2O2, 37°C) mass loss profiles 
for TMHDI-based SMPs, comparing control samples, 5% BHT (antioxidant) SMPs, 
and various concentrations of glycerol. 
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CHAPTER VII  
ISOCYANURATE TRIOL AS A MORE OXIDATIVELY STABLE STARTING 
MATERIAL FOR SHAPE MEMORY POLYMERS BASED UPON ALIPHATIC, 
SYMMETRIC DIISOCYANATES AND AMINO ALCOHOLS 
 7.1 Introduction 
Polyurethane materials have been a gold standard for blood contacting medical 
devices, particularly for cardiovascular and similar long-term implants.1,5-7 While there are 
many studies presented in literature that attempt to develop polyurethanes with tunable rates 
of degradation, production of more biostable polyurethanes is not widely studied, despite the 
growing need.1,5-8 In fact, polyurethane failures, associated with either hydrolytic or 
oxidative degradation mechanisms, are approximated at resulting in billions of dollars in 
damages for pacemaker lead coating alone.13-16 Greater biostability in polyurethanes will 
result in fewer failures and reduced patient risk due to decreased degradation product 
exposure, both of which ultimately lead to improved clinical outcomes.1,9 
Previous work with aliphatic, thermoset polyurethanes possessing shape memory 
revealed superior hydrolytic stability compared with aromatic polyurethanes.134 This work 
indicated that for highly porous systems (densities of 0.01 g/cm3 or less) in 0.1 M NaOH at 
250 days only ca 1% of mass has been lost.134 Unfortunately, these materials were found to 
have a susceptibility to oxidation due to the presence of tertiary amines, and when exposed 
to in vivo oxidative conditions it is anticipated that complete degradation could occur within 
one year.134 While toxic risk from these materials was found to be minimal, further risk 
reduction could be accomplished through increasing oxidative stability (reducing the rate of 
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mass loss). To achieve this, several multifunctional alcohol monomers have been examined, 
notably glycerol as the most successful in increasing biostability.196 However, these 
glycerol-based shape memory polymers (SMPs) still were found to degrade oxidatively, 
indicating that substitution of the amino-alcohols for alternative starting monomers may 
yield superior biostability.196 Also, the glycerol monomer was incompatible with HDI 
without introducing other starting materials limiting its use.196 
Beginning in the 1980s, it was found that polyurethane materials did not possess 
sufficient thermal stability.197-201 Modifications during synthesis could be used to achieve 
materials with greater thermal stability due to the isocyanate, in the presence of appropriate 
catalysts, undergoing a cyclization reaction with additional isocyanates to form a six-
membered ring structure, an isocynaurate, that has greater thermal stability and imbues the 
bulk material with more robust mechanical properties.198-199 While these isocyanurates have 
been investigated for several applications, including coatings and thermally stable foams, 
very little work has been pursued in biomedical applications.200 More recently, these 
structures have been used as crosslinkers in self-healing, shape memory, and other functional 
or advanced materials.201-205  
This cyclic structure is compatible with previously examined starting material, 
allowing for incorporation into the SMP bulk using established protocols, allowing for 
production of bulk scale materials for biocompatibility and biostability testing.27,36-37,43 Here 
we present the effects of utilizing the isocyanaurate functionality in aliphatic polyurethane 
SMPs, with the intent of improving biostability, by using tris(2-hydroxyethyl) isocyanurate 
(Iso) as a starting triol. The SMPs are produced as both porous and non-porous materials, 
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and thermo-mechanical properties are examined based upon using one of two aliphatic 
diisocyanates, hexamethylene diisocyanate (HDI) and trimethyl hexamethylene 
diisocyanate (TMHDI), along with amino alcohols triethanolamine (TEA) and tetrakis 
(hydroxypropyl) ethylenediamine (HPED) with the Iso (nomenclature is based upon 
diisocyanate used, amino alcohol used, isocyanurate percentage; i.e HDI TEA Iso 30). It was 
found that while the more rigid TMHDI reduced toughness, HDI TEA Iso 30 could be used 
to improve the toughness of both porous and non-porous materials compared with the control 
SMP (HDI and TEA only). Additionally, the mechanical properties of the non-porous and 
dry porous SMPs are greater than the controls, but in water the elastic modulus, strain to 
failure and ultimate tensile strength are similar. Interestingly, while the thermal transitions 
of the SMP are greatly increased with the addition of the isocyanurate, shape memory is still 
present at body temperature. Most importantly, the biostability of both porous and non-
porous materials is presented using accelerated testing, displaying great improvements over 
previous compositions, and model compound studies are used to predict the degradation 
products that will eventually form. 
7.2 Methods and Materials 
Hexamethylene diisocyanate (98%, HDI, Sigma), isophorone diisocyanate (98%, 
IPDI, Sigma), triethanolamine (99%, TEA, Sigma), N,N,N’,N’ tetrakis (hydroxypropyl) 
ethylenediamine (98%, HPED, Sigma), and tris-(2-hydroxyethyl)-isocyanurate (Sigma) 
were used without modification. Deuterated dimethyl sulfoxide (d6-DMSO, 99.99%, Sigma 
Aldrich), ethanol (97%, Sigma Aldrich), dimethyl formamide (DMF, 99.5%, Sigma), 
acetone (99.5%, VWR) and isopropyl alcohol (99.5%, Sigma Aldrich) were used as solvents. 
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Ethyl isocyanate (98%, Sigma Aldrich) was used without purification. Cobalt chloride 
(CoCl2) and hydrogen peroxide (H2O2, 50%, Sigma Aldrich) were used for degradation 
solutions. 
Matrix assisted laser desorption/ionization (MALDI) time of flight mass 
spectrometry (MS) was used to characterization the prepolymer network.  
Fourier transform infrared spectroscopy (FTIR) attenuated total reflectance (ATR) 
was performed using a Bruker ALPHA infrared spectrometer (Bruker, Billerica, MA); 48 
scans per spectra for both background and samples were used. Spectra data was collected in 
absorption mode with a resolution of 4 cm-1. OPUS software was used to examine spectra, 
identify peaks, and perform baseline and atmospheric corrections.  
Liquid chromatography mass spectrometry (LCMS) was performed using a single 
quad OrbiTrap (ThermoFisher) with Exactive software and a C18 normal phase silica 
column. The capillary and heater temperatures were set for 50 °C to prevent thermal-induced 
fragmentation. 
Nuclear magnetic resonance (NMR) (13C 125 MHz and 1H 300 MHz) was performed 
on a Mercury 300 MHz spectrometer operating in the Fourier transform mode with d6-
DMSO as the solvent. 
Iso (15.78 g, 0.060 mol) was added at room temperature toin a flask containing DMF 
(6 mL) and acetone (15 mL). HDI (4.2 g, 0.025 mol) was then added dropwise over the 
course of 10 minutes while stirring. The flask was then heated with stirring to 180°C over 
the course of 1 hour and held for another hour before being allowed to cool to room 
temperature. The clear, viscous polymer product (Iso prepolymer) was then characterized 
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and used in subsequent syntheses. 1HNMR (d6-DMSO): 4.38 (2H, d, NCH2CH2OCO), 4.05 
(2H, d, NCH2CH2OCO), 4.04 (2H, d HOCH2CH2N), 3.51 (2H, d, HOCH2CH2N), 3.21 (2H, 
d, OCONHCH2CH2CH2), 1.66 (2H, d, OCONHCH2CH2CH2) 1.21 (2H, d, 
OCONHCH2CH2CH2); 
13C NMR (d6-DMSO): 157.18, 150.13, 61.38, 58.75, 46.47, 42.98, 
37.31, 36.40, 26.27;  Mn= 2490 g/mol, PDI (2.05). 
Films were produced by reacting stoichiometric amounts of alcohols and isocyanates 
(105:100 NCO:OH) in solvent. Iso prepolymer (7.649 g, 3.07 mmol, 30% alcohols) and TEA 
(7.129 g, 47.85 mmol, 70% alcohols) were dissolved in DMF, followed by the addition of 
HDI (17.22 g, 102.44 mmol, 100% isocyanates). The solution was mixed and cast into films. 
This protocol was repeated for films containing TMHDI and HPED.  
SMP porous scaffolds were synthesized using a traditional two-step process for 
porous scaffolds. Iso prepolymer (4.208 g, 1.69 mmol) was dissolved in 6 mL DMF, and 
TEA (3.922 g, 26.32 mmol) was added. HDI (27.07 g, 161.04 mmol) was added over 2 
minutes and mixed for 5 minutes until the solution (premix) turned clear. The premix was 
heated to 50°C and held isothermally under vacuum for 48 hours.  
An alcohol premix was then synthesized. The control samples substituted HPED for 
the Iso prepolymer. Iso prepolymer (2.186 g, 0.88 mmol, 30% Iso), TEA (2.038 g, 13.68 
mmol), water (1.081, 59.99 mmol), surfactant DC 5943 (2.8 g), tin catalyst (0.3.g) and amine 
catalyst (0.75 g) were mixed for 2 minutes and added to the isocyanate premix with a low 
boiling point blowing agent. The mixture was immediately placed in a 90 °C oven and held 
for 20 minutes, with the primary foam blowing occurring within the initial 5 minutes. This 
protocol was followed for varied ratios of TEA and Iso prepolymer (30%, 20%, 10%, and 
 123 
 
control compositions were investigated). The SMPs were then cut and washed. The cleaning 
process consisted of alternating washes in RO H2O and EtOH, at 50 °C with sonication for 
30 minutes, two cycles of each. The SMPs were dried for three days at 50 °C under vacuum 
(30 in Hg) and stored in a sealed box with dessicant. HDI TEA 30 Iso FTIR: 3321, 2926, 
2853, 1688, 1638, 1538, 1457, 1362, 1292, 1182, 1135, 1035 cm-1. The control samples 
substituted HPED for the Iso. 
Gel fraction was determined for selected compositions (n=3). Samples (ca  0.10 mg) 
were immersed in 30 mL of ethanol and heated to 50°C for 2 days. The samples were then 
removed, blotted dry, and placed in a vacuum oven at 50 °C (30 in Hg) for 2 days to remove 
any solvent before being weighed. Density was determined from porous SMP cubes (1 cm3, 
n=3). Porous SMP samples were removed from vacuum at room temperature, and stored in 
individual open containers at ambient conditions overnight. Sample mass was taken 
periodically. 
Dynamic mechanical analysis (DMA) of cylindrical samples (6 mm diameter, 5 mm 
length) was used to conduct thermomechanical analysis using a Q800 TA DMA (TA 
Instruments, New Castle, DE). Dry temperature sweep samples were equilibrated at 0°C for 
fifteen minutes and then ramped to 200 °C (films), 90 °C (dry foams), and 70 °C (wet foams) 
at a rate of 2 °C/min. The storage modulus (E’) and the loss modulus (E”) were used to 
determine the peak tan δ (E’/E”), with the maximum value recorded as the Tg.  
Differential scanning calorimetry (DSC) was also used to measure both wet and dry 
Tg using a Q-200 DSC (TA Instruments, Inc., New Castle, DE). Samples of ca 5.0 mg ± 1.0 
mg were sealed in TZero aluminum pans and placed in the heating cell. The test profile was 
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as follows: equilibration at -40 °C, heating to 180 °C at 10 °C/min, cooling 10 °C/min to -
40 °C and holding for 5 minutes, and a final heating to 180 °C at 10 °C/min. The half-height 
transition of the final heating cycle was the reported Tg. Wet samples were weighed and 
sealed in the same manner, and were then heated from -40 °C to 120 °C. 
Shape recovery of cylindrical foam samples (6 mm diameter, 10 mm length, six 
samples per series) crimped over a wire was examined at 37 °C in RO water to determine 
the volume recovery behavior (strain recovery). Samples were crimped to a minimal 
diameter (ca 1.0 mm using a SC150-42 Stent Crimper (Machine Solutions, Flagstaff, AZ). 
To crimp, samples were equilibrated at 100 °C for ten minutes and then radially compressed 
and cooled to room temperature. Samples relaxed for 12 hours in a sealed box with desiccant 
and were tested over the course of 20 minutes. Image J (NIH, Bethesda, MD) was used for 
analysis of the change in diameters over time.  
Foam cell structure was determined by cutting axial and transverse samples that were 
examined using scanning electron microscopy (SEM). Samples were mounted onto a stage 
and sputter coated with gold using a Cressington Sputter Coater (Ted Pella, Inc., Redding, 
CA) for 60 seconds at 20 mA. Samples were then examined using a Joel NeoScope JCM-
5000 SEM (Nikon Instruments Inc., Melville, NY) at 11X magnification and 15 kV under 
high vacuum.  
Mechanical testing of SMP dogbones was performed using tensile testing. An Instron 
5965 electromechanical screw driven test frame, equipped with a 500N load cell, was used 
to test the dogbones at 5 mm/min at room temperature. Both porous and non-porous samples 
were cut in Type IV D dogbones for testing. 
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Green fluorescent protein (GFP)-expressing fibroblasts (NIH3T3/GFP, Cell Biolabs 
Inc., USA) were expanded then seeded onto control (unmodified) and degraded films at a 
density of 20,000 cells/film in normal growth media, which contained high glucose 
Dulbecco’s Modified Eagle Medium (DMEM, GE Biosciences, USA) with 10% FBS 
(Atlanta Biologicals, USA), and 1% penicillin/streptomycin (100 U/µg/mL, Invitrogen, 
USA). For foam studies, foams were soaked overnight in cell-binding media, which 
contained normal growth media with 1% dissolved gelatin, prior to cell seeding. After initial 
cell seeding, films and foams were transferred to new well-plates to ensure cell growth was 
limited to the polymeric biomaterial.  
To investigate cell proliferation, an Alamar Blue assay (Thermo Fisher, USA) was 
utilized per the manufacturer’s instructions to calculate percent reduction of resazurin (blue) 
to resorufin (pink). Proliferation within foam samples was normalized to accessible surface 
area via considerations of foam volume and percent porosity. At the respective time points 
(Day 0, Day 1, Day 3, and Day 7), cell morphology was evaluated using fluorescence 
microscopy with an excitation of 488 nm (Nikon Ti-U Inverted Microscope, USA); at Day 
0, cells were allowed to adhere for three hours prior to imaging. Representative images were 
selected over the course of imaging three replicates for each film or foam. 
For analysis of degradation rates, cleaned samples were completely immersed in 
respective solutions of 3% H2O2 (real time oxidation) and 20% H2O2 with 0.1 M CoCl2 
(accelerated oxidation), both stored at 37 °C. Sample solutions were changed every 3 days 
to ensure a relatively stable ion concentration, and once per week samples were removed, 
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cleaned in EtOH, and dried in at 50 °C under vacuum (30 in Hg), after which sample mass 
was recorded and samples returned to fresh solution. 
Model compounds were dissolved in 50% H2O2 and placed in a 37°C oven for five 
weeks, with samples withdrawn for analysis on a weekly basis; peroxide was refreshed at 
the same time. Hydrolytic samples were added to 2 M NaOH and incubated for the same 
time. Samples were diluted 100-fold in a 50% methanol (49.95% water, 0.05% formic acid) 
solution, and injected into the LCMS column. The injection volume was 10 µL, and the flow 
gradient was varied from 0% acetonitrile to 95% acetonitrile over a 3-minute gradient. 
Exactive software (ThermoFischer) was used for analysis of the chromatography scan and 
the peaks. 
7.3 Results and Discussion 
Films displayed distinctly increased mechanical properties with the incorporation of 
the Iso compared with the control group consisting on only HDI and TEA monomers. While 
the Tg of the control was found at ca 1.3 °C (Table 7.1, Figure 7.1), the addition of the Iso 
served to increase the Tg by nearly 80 °C. Furthermore, the addition of HPED versus TEA 
increased the thermo-mechanical properties, as did using the methyl-containing TMHDI 
rather than the HDI.  
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Table 7.1. Tg determined by DMA and maximum complex modulus value. 
Species Tan δ (°C) E*max (MPa) 
Control (HDI TEA) 1.3 ± 2.1 9.2 
HDI TEA Iso 81.4 ± 3.9 1103.1 
HDI HPED Iso 86.8 ± 2.1 1036.2 
TM TEA Iso 104.5 ± 0.8 2075.6 
TM HPED Iso 125.2 ± 1.0 2786.1 
Figure 7.1. Thermomechanical properties of Iso films, displaying tan δ vs temp (left) 
and E’ (storage moduli) vs temp (right). 
Tensile testing at room temperature further confirmed the mechanical behavior from 
DMA testing (Figure 7.2). The inclusion of the Iso greatly improved the elastic modulus 
and ultimate strength, but at the cost of the strain to failure and toughness (Table 7.2). The 
exception to this is for the HDI TEA Iso composition. This also indicates that further 
increasing the Iso concentration in the SMP may reduce mechanical properties even more. 
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Results of the cellular compatibility study confirm that the TEA-containing films is 
a more compatible surface compared with the HPED-containing films, and that the presence 
of the Iso does not alter biocompatibility (Figure 7.3). 
 
 
 
Figure 7.2. Stress-strain behavior of non-porous SMPs, comparing the role of 
diisocyanate, amino alcohol monomers, and isocyanurate triol on mechanical 
properties under ambient conditions. 
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Table 7.2. Mechanical properties of SMP films at ambient conditions, incorporating 
isocyanurates and varied diisocyanate and amino alcohol monomer units. 
Species Elastic Modulus 
(MPa) 
Strain to 
Failure (%) 
Ultimate 
Strength (MPa) 
Toughness 
(J/m3) 
Control (HDI TEA) 8.99 ± 1.10 65.7 ± 25.1% 4.54 ± 1.22 792.18 
HDI TEA Iso 502.48 ± 22.7 22.7 ± 1.4 % 45.67 ± 0.74 815.35 
HDI HPED Iso 671.30 ± 2.38  20.7 ± 4.2 % 45.97 ± 3.61 724.04 
TM TEA Iso 826.24 ± 153.8 16.4 ± 4.9 % 47.02 ± 0.78 191.42 
TM HPED Iso 889.92 ± 92.2 7.5 ± 1.9 % 48.44 ± 6.67 178.33 
 
 
 
Figure 7.3. Fluorescent 3T3 fibroblasts seeded on films at 7 days incubation. 
 
 
 
 
 
 
 
 
 130 
 
 
 
 
Figure 7.4. SEM images of 10% (left), 20% (middle) and 30% (right) Iso SMPs. 
  
 
 
While the use of solvent for foam blowing of porous scaffolds is not common, the presented 
SMPs obviously are not morphologically hindered by this method (Figure 7.4). Pore sizes 
are shown to vary, with an average diameter of 1.1 mm ± 0.4 mm. The variation in pore sizes 
do not appear to be due to composition, but rather with premix viscosity and the mixing 
during synthesis.  
        As expected from previous work with porous SMPs, these crosslinked polymers may 
be produced with ultra-low density and a high gel fraction. With sufficient presence of the 
isocyanurate, the Tg is also high enough to be clinically relevant when dry (greater than 
room temperature), but will easily plasticize and undergo shape recovery in water (Table 
7.3). HDI TEA Iso 30 porous samples examined using tensile testing compared with the 
control SMPs in both ambient and wet, 37 °C conditions. While there were significant 
mechanical differences when the samples were dry, upon exposure to moisture both series 
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of SMPs possessed similar elastic moduli (0.05 MPa), strain to failure (ca 60%), and 
ultimate strength (0.02 MPa). The Iso series displayed slightly improved toughness as well 
(Table 7.4). 
Table 7.3. Physical and thermal properties of porous Iso SMPs (HDI TEA Iso). 
Composition Gel fraction 
(%) 
Density (g/cc) Wet DSC (°C) Dry DSC 
(°C) 
Control 98.1 ±0.02 0.022 ± 0.001 -5.0 55.3 
10% Iso 98.0 ±0.04 0.032 ± 0.002 -1.2 34.6 
20% Iso 96.4 ±0.01 0.025 ± 0.003 -2.1 37.2 
30% Iso 97.5 ±0.04 0.032 ± 0.004 -1.1 57.6 
Table 7.4. Mechanical properties of control and HDI TEA Iso 30 porous SMPs at ambient 
conditions and submerged in 37°C water. 
Species Elastic Modulus 
(MPa) 
Strain to 
Failure (%) 
Ultimate 
Strength 
(MPa) 
Toughness 
(J/m3) 
Control Dry 0.04 ± 0.01 130.0 ± 13.1 0.05 ± 0.01 32.5 
Iso 30 1.12 ± 0.25 39.4 ± 11.4 0.19 ± 0.06 41.2 
Control Wet 0.05 ± 0.01 64.7 ± 12.4 0.02 ± 0.01 5.0 
Iso 30 0.05 ± 0.04 57.6 ± 19.4 0.02 ± 0.00 5.2 
Despite the changes in dry mechanical properties, the Iso-SMPs possessed full strain 
recovery and strain fixity (Figure 7.5). However, the presence of the isocyanurate also 
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causes distinct uptake in water, determined both through a change in mass and a brief 
examination of mechanical properties using samples that were allowed to equilibrate with 
the room’s conditions over the course of hours. The SMPs displayed increased masses by ca 
3% over the course of hours, and mechanical properties qualitatively changed within 2 hours 
(less than a full standard deviation tested over the course of this experiment) (Figure 7.6). 
 
 
 
 
Figure 7.5. Shape recovery behavior of porous SMPs. 
 
 
 
Degradation testing using gravimetric analysis indicates that while the control SMPs 
will undergo rapid oxidative mass loss, depending on the porosity of the SMP, within days 
or weeks. With the addition of the isocyanurate, oxidative stability is greatly increased in 
both films and porous SMPs (Figure 7.7). At day 110, films possessed ca 70% of the original 
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mass (HDI TEA Iso 30) or up to 90% (TM HPED Iso 30). For the porous SMPs (HDI TEA 
Iso composition), while the control samples had undergone total mass loss by 15 days, the 
Iso series retained greater than 90% mass loss at this point. Only after did any significant 
mass loss begin to occur.  
Model compound studies were used to propose the mechanisms of degradation, and 
to predict if any toxic by- products would be produced. Hydrolytic degradation studies using 
model compounds indicates that the most likely route to polymer fragmentation is due to the 
urethane (carbamate) hydrolysis rather than a ring opening of the isocyanurate, determined 
by MS (Figure 7.8). While some ring opening product was obtained, the primary route of 
degradation will be cleavage of the urethane to produce a primary amine and an alcohol. 
 
 
 
Figure 7.6. (Left) Water uptake studies is gravimetric analysis and (right) plots of 
elastic modulus and strain to failure for 30 Iso SMPs allowed to equilibrate with the 
room over the course of 2.5 hrs (n=2 at each time point for tensile testing). 
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Figure 7.7. Oxidative degradation of non-porous SMP containing isocyanurate (left) 
and of porous SMPs (HDI TEA Iso) containing (right). Samples were degraded in 
20% H2O2 catalyzed by 0.1 M CoCl2 at 37°C. 
 
 
 
 
Figure 7.8. Proposed main hydrolysis steps for isocyanurate-urethane linkages as 
determined using model compound studies and MS, determined from model 
compounds in 2M NaOH at 37°C. 
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Oxidatively, the SMPs are stable compared with previous compositions, but 
degradation may occur in the bulk SMP due to the continued presence of the tertiary amine 
crosslinkers. The isocyanurate model compound may undergo fragmentation to produce 
disubstituted isocyanurates as a result of oxidative degradation (Figure 7.10).  
 
 
 
 
Figure 7.9. Proposed main oxidative step for isocyanurate-urethane linkages as 
determined using model compound studies and MS over 5 weeks in 50% H2O2 at 
37°C. 
 
 
The hydrolysis of isocyanurates has been reported for disubstituted structures 
resulting in the formation of linear biuret structures.206-207 The model compound study shows 
degradation occurring over the course of weeks, in conditions that extremely accelerated 
compared with physiological environments, as demonstrated by the bulk degradation 
studies. Previous work with the degradation of polyurethane foams in non-physiological 
conditions was the source of regulatory discussion, substantial research, and the recalling of 
many implanted devices; these studies inaccurately claimed that carcinogenic byproducts 
would form from the polyurethane degradation in vivo.1,5-8,16-17 In this case, the model studies 
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are not meant to demonstrate the rates of formation of toxic products, but rather to examine 
possible hydrolysis pathways. For the Iso-containing SMPs, the pathway to degradation is 
still likely oxidative, as the primary hydrolysis degradation pathway is through carbamate 
hydrolysis. Previous studies of aliphatic carbamates have indicated that there is hydrolytic 
stability in 0.1 M NaOH out to at least 250 days (1% mass loss of the bulk material in this 
time); the presented experiment utilized 2 M NaOH, with carbamate hydrolysis still 
appearing to be the favored degradation pathway.135 The oxidative pathway for these SMPs 
is again due to the amino alcohols used as starting materials. 
In the control films, total mass loss in accelerated oxidative solution occurs by ca 40 
days. In the TM HPED Iso 30 (30% isocyanurate and 70% HPED), ca 95% of the original 
mass is retained at this point. At 110 days in accelerated oxidative solution, TM HPED Iso 
30 has lost only 5.8% of the original mass. HDI TEA Iso 30, 82.1% of the original non-
porous films’ mass is retained at 110 days. In porous SMPs, the controls are completely 
degraded within approximate 25 days; HDI TEA Iso 30 97.7% of the original mass at the 
same time point. It appears that tuning the rate of oxidation can be achieved through 
incorporation of varying concentrations of the Iso prepolymer to achieve higher oxidative 
stability compared with the control SMPs. This is useful for ultimately allowing native tissue 
to replace the SMP, but the longer degradation times ensure less toxic risk associated with 
the released degradation products. 
Oxidatively, the degradation that is demonstrated for these materials is due to the 
amino alcohol TEA used in synthesis. It is apparent that the presence of the Iso group 
increases oxidative stability. The end groups that will preferentially form are most likely 
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primary amines, aldehydes and carboxylic acids as a result of fragmentation of the tertiary 
amine to a secondary amine and corresponding aldehyde, followed by further fragmentation 
to a primary amine. The oxidation of the Iso structure is unlikely, but if it occurs may yield 
a disubstituted isocyanurate. This ring structure may undergo hydrolysis in the presence of 
hydroxyl ions due to the possible resonance structures between the surrounding carbonyls 
and the amine (equilibrium results in the partially charged species and water), possibly 
resulting in a 1,6 ring opening to form disubstituted biurets.206  
Both degradation schemes, as well as accelerated degradation studies, indicate that 
the isocyanurate ring is not likely to undergo fragmentation in the in vivo environment. In 
studies of similar molecules, in this case small molecule isocyanurates with substituted end 
groups, clearance occurred via the renal system without change to the ring structure in 
similar concentrations for what may be produced from oxidative degradation of the 
SMPs.208-210 Reports of toxic effects are associated with end groups rather than the cyclic 
structure (epoxides from triglycidyl isocyanurate, for example).209-210 
Based upon the degradation profiles of the control SMPs, it appears that ca 100% 
mass loss will occur within 1.5 years; 30 Iso will have lost ca 2.5%. For decreasing the 
degradation cytotoxicity risk associated with the degradation, the 30 Iso is 26 times less 
(0.0001 %/day) than the control (0.23 %/day). While these SMPs are not as biostable as non-
porous polyurethanes used in alternative applications, the use of the isocyanurate does 
provide a means to improve biostability for these porous materials. 
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7.4 Conclusions 
While the oxidative degradation of porous SMPs is rapid in oxidative environments, 
reduction in the mass loss may be achieved through the incorporation of isocyanurate triols 
into the SMP. With some SMP systems, this will increase mechanical toughness and other 
properties without sacrificing shape memory and biocompatibility, both of which are 
necessary for translating a material system out of the lab and into the clinic. It found that 
these new SMPs do possess reduced rates of oxidative degradation, and it is predicted that 
they will possess high hydrolytic stability, as well, due to the main path of hydrolytic 
degradation being hydrolysis of the urethane bonds. Overall, this seems like a valid method 
for pursuing more biostable SMPs for vascular devices. 
 Predictions of real-time degradation indicate that inclusion of the Iso prepolymer 
results in greater overall biostability compared with the previously examined methods, 
including antioxidants and glycerol. The HDI TEA Iso 30 (Figure 7.10) is predicted to be 
completely degraded after ca 7520 days, or 20 years. While it is not possible to achieve true 
biostability with polyurethanes, the inclusion of isocyanurates does allow for significant 
reduction in the rate of oxidative mass loss, and is useful for producing SMPs with greater 
biostability compared with previous iterations, including those containing glycerol and 
antioxidants. 
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Figure 7.10. Mass loss profiles of SMPs in real time oxidative solution (2% H2O2), 
predicted from real time data and accelerated testing (20% H2O2 in 0.1 M CoCl2). 
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CHAPTER VIII         
CONCLUSIONS 
8.1 Summary 
Shape memory polymers (SMPs) synthesized from aliphatic, symmetric amino 
alcohols and diisocyanate monomers were characterized for their degradation behavior. The 
SMPs and the starting materials were tested through examination of the bulk and model 
compounds, in order to determine that the mechanism of degradation was a result of tertiary 
amine oxidation. The degraded SMPs and the degradation mechanism was then used to 
examine the cytocompatibility over the course of implantation. Degradation products were 
synthesized and tested simultaneously to the degraded bulk SMPs examine the toxic risk to 
patients over the lifespan of the SMP. Results indicated that these SMPs may pose minimal 
risk to patients, and that translation of this technology into clinical devices is possible. 
Antioxidants were examined as alternative methods for controlling oxidation. 
Results varied due to reactions with the isocyanates during synthesis or poor compatibility 
with the SMP bulk that resulted in removal of the antioxidants during polymer cleaning. 
Thermo-mechanical properties were found to be widely variable based upon this, as well as 
shape memory properties. When the antioxidants were loaded into synthesized polyurethane 
microparticles and added to the SMPs, the thermo-mechanical property changes found when 
using small molecule antioxidants were minimized; mechanical properties and shape 
recovery kinetics were improved for the examined antioxidants. While SMPs containing 
Piper as a small molecule were not improved upon through the use of microparticles, the use 
of BHT and Methyl antioxidants did improve oxidative stability. These methods are 
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predicted to expand the life-span of these SMP compositions from 500 days out to nearly 
900 days (ca 1.5 years to ca 2.5 years), and may also be useful for expanding the 
functionalities of the SMPs. 
Glycerol and isocyanurate triol were examined to improve oxidative stability, with 
both monomers decreasing the rate of oxidative mass loss without sacrificing shape memory 
or thermal properties. While the glycerol was used primarily with the more hydrophobic 
SMPs based upon trimethyl hexamethylene diisocyanate (TMHDI), isocyanurate triol was 
found to be compatible with the hexamethylene diisocyante (HDI)-based SMPs and 
demonstrated greater oxidative stability than the glycerol SMPs, despite their greater Tgs. 
Glycerol is predicted to further extend the SMP life-span to ca 5 years, while sufficient 
concentration of isocyanurate may yield SMPs that degrade in 20 years. 
The amino-alcohol based SMPs are promising candidates for translation into the 
clinic. While the cytocompatibility of HDI-based SMPs has been confirmed, studies 
examining the use of alternative diisocyanates, such as TMHDI, are required for the 
translation of other SMP compositions into medical devices. These studies would also have 
bearing on the alterative compositions that were proposed here, including the use of glycerol, 
isocyanurate triol, antioxidants, and microparticles. 
For further tuning oxidative stability, alternative antioxidants, such as larger 
molecules or molecules that degrade into antioxidant products, could be examined. For 
increasing the degradation rates, the use of HPED-based esters, as well as other renewable 
monomers, could be examined to further tune the increased oxidation rates for degradable 
SMPs. Developing various starting monomer and macromers for these applications will 
 142 
 
require gaining an understanding of the limitations of the foaming process, as well as how 
to improve the compatibility of some starting materials with the currently utilized reagents. 
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